Compositions and methods for treating disease

By developing fusion proteins containing desmosome cadherin and immunoglobulin Fc region, targeting and depleting pathogenic B cells, the problem of poor efficacy in the treatment of autoimmune diseases in the prior art has been solved, and precise diseases have been achieved Targeted and safe therapeutic effects.

CN118922438APending Publication Date: 2024-11-08DANA FARBER CANCER INSTITUTE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280088500.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-11
Filing Date
2022-12-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat and prevent autoimmune diseases, especially difficult to target and deplete pathogenic B cells, resulting in limited therapeutic effects and greater side effects.

Method used

A fusion protein, which contains the extracellular domain of desmosome cadherin and the Fc region of immunoglobulin, has been developed to achieve targeted killing of B cells, including Fc-mediated Therapeutic agents and BCR-T cell conjugate methods.

Benefits of technology

Accelerated targeted treatment for autoimmune diseases, reduces the side effects of immunosuppression, improves the therapeutic effect, avoids the risks of off-target immunosuppression and cytokine release syndrome, and provides a universal treatment platform suitable for a variety of self-organizations. Immune blister disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922438A_ABST
    Figure CN118922438A_ABST
Patent Text Reader

Abstract

Aspects of the present invention relate to compositions and methods for treating and preventing autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to U.S. Provisional Application No. 63 / 289,595 filed on December 14, 2021 and U.S. Provisional Application No. 63 / 368,119 filed on July 11, 2022, the entire contents of which are incorporated herein by reference.

[0002] All patents, patent applications, and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications are hereby incorporated by reference in their entirety into this application in order to more fully describe the state of the art as known to those skilled in the art as of the date of the invention described and claimed herein.

[0003] This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent files and records, but otherwise reserves any and all copyrights whatsoever. Technical Field

[0004] Aspects of the invention relate to compositions and methods for treating and preventing disease. In embodiments, the disease is an autoimmune disease.

[0005] Sequence Listing

[0006] This application contains a sequence listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on [], is named [] and is [] bytes in size. Background Art

[0007] A variety of autoimmune diseases exist in animals, including humans. Agents and methods for treating autoimmune diseases are of interest. Summary of the invention

[0008] The present invention discloses agents and methods for treating autoimmune diseases in animals, including autoimmune blistering diseases. In some embodiments, the agent comprises a fusion protein having a domain comprising an autoreactive antigen from a diseased animal and a domain capable of binding to an effector cell. In some embodiments, the effector cell binding domain can be the Fc portion of an antibody capable of binding to an Fc receptor on an effector cell. In some embodiments, the effector cell binding domain can be an antibody capable of binding to an effector cell.

[0009] Aspects of the invention relate to a fusion protein comprising a desmosomal cadherin or a fragment thereof, such as desmoglein (encoded by genes DSG1, 2, 3 or 4) or desmoglein (encoded by genes DSC1, 2 or 3). In some embodiments, SEQ ID NOs. 5 to 28 (found in Example 4 and Fig.13 The amino acid sequences are all or part of them.

[0010] In some embodiments, the fusion protein comprises a desmosomal cadherin such as the extracellular (EC) domain of desmoglein 3 (Dsg3) or the EC domain of desmoglein 1 (Dsg1) and an isolated immunoglobulin Fc region or a fragment thereof. In embodiments, the fusion protein comprises any one or more of SEQ ID NOs.: 1 to 4, 29 to 32, or a fragment thereof. In embodiments, the fusion protein comprises an amino acid sequence at least 80% identical to SEQ ID Nos 1 to 4 or 29 to 32. In embodiments, the fusion protein targets one or more B cells through its desmosomal cadherin portion. In another embodiment, the targeted B cells include autoreactive anti-Dsg3 B cells or autoreactive anti-DSG1 B cells. In embodiments, the fusion protein also targets effector cells (e.g., NK cells, macrophages) through its Fc region. In an embodiment, the Fc region of the fusion protein comprises an amino acid sequence that is at least 80% identical to the Fc region of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 29, SEQ ID NO 30, SEQ ID NO 31, or SEQ ID NO 32. In an embodiment, the Fc region comprises an IgG Fc region. In an embodiment, the EC domain comprises Fig.13 In one or more of the various sequence IDs provided in . In another embodiment, the EC domain includes EC1, EC2 and EC3. In an embodiment, the fusion protein further comprises a therapeutic portion, an imaging portion, a capture portion, or a combination thereof. In another embodiment, the capture portion includes a hydrophilic protein, a bacterial transpeptidase, a GST tag, a His tag, polyethylene glycol (PEG), or a combination thereof. In another further embodiment, the imaging portion includes a fluorophore, a radioisotope, or a combination thereof. In another further embodiment, the therapeutic portion includes a cytokine, a toxin, a radiotherapeutic agent, a T cell engaging portion, a natural killer cell engaging portion, or a combination thereof.

[0011] In some embodiments, the fusion protein may comprise desmosomal cadherin or a fragment thereof and an antibody or fragment that can bind to an effector cell. In some embodiments, the effector cell may be a T cell.

[0012] In some embodiments, the fusion protein may comprise Desmosomal cadherin or a fragment thereof and a radioactive isotope.

[0013] Aspects of the present invention relate to a pharmaceutical combination comprising the fusion protein described herein and a pharmaceutically acceptable carrier.

[0014] Aspects of the invention relate to a method of depleting autoreactive anti-Dsg or anti-Dsc B cells, the method comprising administering to a subject a therapeutically effective amount of a fusion protein as described herein or a pharmaceutical composition as described herein. In one embodiment, the effective amount is positively correlated with the level of anti-Dsg or Dsc antibodies circulating in the subject.

[0015] Aspects of the present invention relate to a method for treating an autoimmune disease, the method comprising administering to a subject a therapeutically effective amount of a fusion protein as described herein or a pharmaceutical composition as described herein, wherein the subject is suffering from an autoimmune disease. In one embodiment, the disease is selected from the group consisting of: autoimmune blistering disease, lupus, scleroderma, Goodpasture's disease, Graves' disease, and immune-mediated vasculitis. In embodiments, autoimmune blistering diseases include pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, acquired bullous epidermolysis bullosa, linear IgA bullous dermatosis, muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG), PLA2R membranous nephropathy, or hemophilia A with FVIII alloantibodies. In embodiments, the amount of fusion protein or pharmaceutical composition administered to a subject triggers an immune response to an autoimmune disease.

[0016] Aspects of the invention relate to a nucleic acid encoding a fusion protein described herein.

[0017] Aspects of the invention relate to a vector comprising a nucleic acid encoding a fusion protein described herein.

[0018] Aspects of the invention relate to a cell comprising a vector comprising a nucleic acid encoding a fusion protein described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Certain illustrations, diagrams or flow charts are provided to allow a better understanding of the present invention. However, it is to be noted that the drawings illustrate only selected embodiments of the present invention and therefore should not be considered limiting of the scope. There are additional and equally effective embodiments and applications of the present invention.

[0020] Figure 1 An image of pemphigus vulgaris, which can cause painful and severe blistering of the skin and mucous membranes, in a patient is shown.

[0021] Figure 2A representation of the desmosome architecture between corneocytes is shown (Panel A). Panel B shows a schematic diagram of the structure of the Dsg3 protein; anti-Dsg3 antibodies cause detachment of corneocytes (acantholysis). Five domains in the extracellular portion of the protein show different levels of immunogenicity. The percentage shown next to each domain is the percentage of PV patients with antibodies specific for that domain. Patients may have antibodies to multiple domains.

[0022] Figure 3 Schematic diagrams of (panel A) Fc-mediated fusion proteins (e.g., Dsg is bound by B cell receptors; NK cells / macrophages are bound by Fc receptors), (panel B) antibody-mediated fusion proteins (e.g., Dsg is bound by B cell receptors; T cells are bound by antibodies; this method may be referred to as a "B cell receptor (BCR)-effector cell engager" method, or in the case where the effector cell is a T cell, a "BCR-T cell engager method") and (panel C) radiotherapy methods are shown. Each of these methods is designed for targeted killing of pathogenic B cells.

[0023] Figure 4 A schematic sortase reaction is shown. Proteins equipped with the LPETG sortase tag can be labeled with a sortase substrate containing triglycine. "R" can be any biomolecule of interest. The His tag (H6) is used to purify proteins.

[0024] Figure 5Images of a passive transfer disease model are shown. Adult B6 mice were injected with AK23 hybridoma cells. Peripheral hair loss Panel A. Mouth Panel B. Eye Panel C. Back Panel D. Loss of keratinocyte adhesion Panels H and E. Active immunization model. Immunized Dsg3- / - splenocytes transferred to Rag-2- / - mice. Panel E. Significant size difference in mice that received Dsg3- / - splenocytes (bottom) compared to mice that received Dsg3+ / - splenocytes (top) 25 to 35 days after splenocyte transfer. Panel F. Crusted erosions around the snout and cheeks of mice that received Dsg3- / - splenocytes immunized with Dsg3. Panel G. Intraepithelial blebs in the upper esophagus of mice that received Dsg3- / - splenocytes immunized with Dsg3 compared to mice that received Dsg3+ / - splenocytes immunized with Dsg3 (Panel H). According to Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest. 2000 Mar;105(5):625-631. PMCID: PMC292455.

[0025] Figure 6 Shown (Panel A) Labeling of mDsg3-IgG2a with Alexa647 by sortase. (Panel B) SDS-PAGE, in-gel fluorescence and western blot characterization of mDsg3(EC1-3)-IgG2a (expected MW approximately 80 kDa). (Panel C) Flow cytometric analysis of anti-Dsg3 F779 and AK23 hybridoma cells with mDsg3-IgG2a-Alexa647 and Nalm6 as a negative control. (Panel D) ELISA analysis confirms the binding of mDsg3-EC1-3-IgG2a to patient-derived P3F3 and mouse-derived AK23 anti-Dsg3 Ab. (Panel E) Mouse RAW264.7 macrophages were stained with mDsg3-IgG2a-Alexa647; Nalm6 cells were used as a negative control, as shown in C: purple bar graph).

[0026] Figure 7In vitro Fc-mediated cytotoxicity assays for evaluating mDsg3-mFc chimeric proteins are shown. Anti-Dsg3AK23 (panel A) and F779 (panel B) cells and irrelevant hybridoma or Nalm6 control cells were co-cultured with mouse RAW264.7 macrophages with 10 nM of the mDsg3-IgG2a construct. After the indicated time points, killing efficacy was measured via a standard live-dead assay. Results were normalized to 0 nM experiments; ***p<0.001.

[0027] Figure 8 Shown is (panel A) a schematic diagram of the use of click reaction to fuse Dsg3 and anti-CD3 scFv. (panel B) Direct preparation of Dsg3-anti-CD3 fusion protein using sortase. (panel C) SDS-PAGE (Coomassie stain) characterization of anti-CD19 and anti-CD3 scFv and fusion protein after direct sortase reaction (each scFv size is about 35kDa); arrows show fusion (expected mass about 70kDa). (panel D) Flow cytometry staining of CD19-expressing Nalm6 and human CD3-expressing Jurkat cells with anti-CD19-anti-CD3 fusion protein prepared via direct sortase method. Click chemistry fusion provides similar results. Results are representative (n=3 to 5 for each).

[0028] Fig. 9 Shown (Panel A) Data for labeling mDsg3-EC1-3 with Alexa647 using sortase. (Panel B) SDS-PAGE, in-gel fluorescence and western blot characterization of mDsg3 (EC1-3) and Alexa-labeled products (expected MW: approximately 40 kDa). (Panel C) Flow cytometric analysis of anti-Dsg3-expressing F779, PVB-28 and AK23 hybridoma cells with mDsg3-Alexa647; Nalm6 cells were used as negative controls. Results are representative (n=3 to 5 for each).

[0029] Fig.10Shown (Panel A) Site-specific labeling of mDsg3-EC1-3 with DOTA using sortase. It will be radiolabeled using 225-Ac radioisotope as shown. (Panel B) SDS-PAGE (Coomassie stain) characterization of mDsg3(EC1-3) (lower band; lane 2) and DOTA-labeled mDsg3(EC1-3) (slightly higher band; lane 3); lane #1 is marker. (Panel C) LC-MS mass spectrophotometric analysis of mDsg3(EC1-3) (upper) and DOTA-labeled mDsg3(EC1-3) (lower) and expected and observed masses. (Panel D) DOTA labeling does not affect binding affinity. Flow cytometric staining of anti-Dsg3 expressing F779 cells with mDsg3(EC1-3) (positive control) and DOTA-tagged mDsg3(EC1-3) (lower) using secondary anti-FLAG antibody.

[0030] Fig.11 Schematic diagrams of (Panel A) Fc-mediated approach and (Panel B) BCR-T cell engager approach are shown. Each of these approaches is designed for targeted killing of pathogenic B cells.

[0031] Fig.12 Shown (Panel A) Schematic diagram of the Fc-mediated approach for targeting and killing autoreactive pathogenic B cells. (Panel B) In vitro characterization of Dsg3-Fc constructs. F779 (Nalm6-leukemia cells engineered with patient-derived anti-Dsg3 antibodies) were incubated with varying concentrations of mDsg3-mFc (IgG2a) (top) or hDsg3-hFc (IgG1) (bottom) and analyzed by flow cytometry to calculate EC50 values. (Panel C) Schematic diagram of the in vivo experimental timeline. (Panel D) Kaplan-Meier survival curves. Log-rank survival analysis of treated and control mice showed improved survival of treated mice. Comparison of control to treated (**p<0.005) (Panel E) Blood was collected from treated or control at BSC<2 and the blood flow was analyzed for human-CD19 escaping treatment. + GFP + Presence of anti-Dsg3 expression on the surface of F779 cells. The treated group showed almost complete antigen loss. The data represent 5 mice.

[0032] Fig.13A multiple sequence alignment of the extracellular domain of desmosomal cadherins is shown (SEQ ID NOs. 8 to 28). Human, mouse and bovine Dsg1-4 (blue) and Dsc1-3 (orange) amino acid sequences are aligned for each EC domain. Residues conserved across the two families are highlighted in gray; those conserved only within Dsg or Dsc are highlighted in blue and orange, respectively. The secondary structures corresponding to the human Dsg2 structure and the human Dsc 1 structure are shown above (blue) and below (orange) the alignment. O-linked glycans are shown as purple hexagons; N-linked glycans are shown as wheat-colored hexagons, and individual glycosylated residues are additionally framed in the absence of conservation. Disulfide bonds are shown by yellow lines above the alignment for Dsg and below the alignment for Dsc. Interface residues for which >10% of the solvent accessible surface area is buried in the homodimers after chain exchange are indicated by blue (Dsg2), orange (Dsc1) and light orange (Dsc2) bars. Dsg1, which lacks the EC5 domain, was excluded from the EC5 comparison (see Harrison et al., Structural basis of desmosomal cadherin adhesion, Proceedings of the National Academy of Sciences 2016 June, 113(26)7160-7165).

[0033] Fig.14 A non-limiting exemplary clinical presentation of mucosal predominant pemphigus vulgaris causing painful and severe erosions in the mucosa is shown.

[0034] Fig.15 Schematic diagrams of (Panel A) Fc-mediated approach and (Panel B) BCR-T cell engager approach are shown. Each of these approaches is designed for targeted killing of pathogenic B cells.

[0035] Figure 16 shows (Panel A) Site-specific labeling of Dsg3-(EC1-3)-Fc constructs via sortase. (Panel B) SDS-PAGE, in-gel fluorescence and Western blot characterization of mDsg3-mFc, as indicated on the right side of the gel. (Panel C) Flow cytometric analysis of anti-Dsg3+F779, PVB28 and AK23 hybridoma cells with mouse and human Dsg3-Fc labeled with Alexa Fluor 647; Nalm6 was used as a control. (Panels D and E to G and H) EC1-3 was determined for mDsg3-mFc and hDsg3-hFc constructs via flow cytometric analysis using F779 (for the Dsg3 portion) and using Raw cells and human PBMCs (for the Fc portion). 50Values. Note that only about 50% of the hPBMCs are Fc-R+ cells, further demonstrating the specificity of the construct. (Panel F) ELISA analysis further confirms the specificity of the construct. Results are representative of multiple experiments (at least n=3 for each experiment).

[0036] Fig.17 An in vitro cytotoxicity assay for assessing the efficacy of Dsg3-Fc engineered proteins is shown. The assay was initiated with 200,000 pre-coated effector cells in a 48-well plate. Approximately 4 to 6 hours after coating, 20,000 target cells, Dsg3-Fc treatment (at various concentrations as indicated), and 1 mM calcium were added. Live GFP+ cells were counted via flow cytometry analysis after 24 and 48 hours (all target cells were GFP+). At least n=3 were used for each condition. Significant specific killing was observed for all conditions tested compared to control cells (***p<0.001).

[0037] Fig.18 It was shown that the presence of anti-Dsg3 autoantibodies did not neutralize the efficacy of the treatment in vitro. Fig.17 Fc-mediated cytotoxicity assays were performed with the same settings explained in but in the presence of AK23 antibody as indicated. No differences in killing efficacy were detected when AK23 antibody was added to the mixture. Results represent at least n=3 for each experiment.

[0038] Fig.19 It is shown that the hDsg3-anti-CD3e scFv construct specifically stains F779 and Jurkat cells (human T cells), but not control Nalm-6 cells.

[0039] Fig. 20 This shows that the presence of autoantibodies does not inhibit the efficacy of the treatment. Mice received 3 doses of IVIG (day -3, day -2, day -1; 16 mg / kg), allowing luciferase +Faster engraftment of PVB28 cells (1 million cells injected on day 0). mDsg3-EC14-mFc was used as treatment (three times a week for two weeks starting from day 4, and then once a week). Control mice received isotype IgG2a. The auto-Ab group received a mixture of AK23, AK19, and AK18 (150 μg in total), starting the day before treatment started, twice a week for two weeks. (Panel A) BLI imaging showed slower signal enhancement in treated recipient mice even in the presence of autoantibodies. (Panel B) Survival rates were significantly higher in both treated recipient groups compared to the control group (P value = 0.0023). In addition, the median survival for the autoantibody + treatment (auto-Ab + Tx) group was 38 days, which was higher than the treatment group (median survival = 35 days; P value = 0.048)). (Panel C) Flow cytometric analysis at the endpoints showed complete depletion of PVB28 cells in the spleen of treated recipient mice and anti-Dsg3 on PVB28 cells in the bone marrow + (data represent n=5 for each group).

[0040] Fig.21 Shown are (Panels A to D) Passive transfer model. Adult RAG2- / - mice were injected with AK23 hybridoma cells. Hair loss around the mouth (Panel A), hair loss around the eyes (Panel B), and hair loss around the back (Panel C). (Panel D) H and E of loss of keratinocyte adhesion. (Panels E to H) Active immunization model. Immunized Dsg3- / - splenocytes transferred to Rag-2- / - mice. (Panel E) Significant size difference in Rag-2- / - mice that received immunized Dsg3- / - splenocytes (bottom) compared to mice that received Dsg3+ / - splenocytes (top) 25 to 35 days after splenocyte transfer. (Panel F) Crusted erosions around the snout and cheeks of mice that received Dsg3- / - splenocytes immunized with Dsg3. (Panel G) Intraepithelial blebs in the upper esophagus of mice that received Dsg3- / - splenocytes immunized with Dsg3 compared to mice that received Dsg3+ / - splenocytes immunized with Dsg3. (Panel H) The same is true for the skin around the snout.

[0041] Fig. 22It is shown that even in the presence of autoantibodies, treatment does not cause cytokine storm and toxicity in immunocompetent mice. (Panel A) Schedule for injection of mice with treatment (mDsg3-EC14-mFc) and / or autoantibody cocktail (AK23, AK19, AK18). (Panel B and Panel C) Treatment recipient mice with or without autoantibodies continue to gain normal weight without observed toxicity (n=6 for each group; 3 males and 3 females). (Panel D) ELISA analysis shows that there is no cytokine storm in any of the three groups that received only treatment, only autoantibodies, or both autoantibodies and treatment (using ELISA MAX TM Standard Set Mouse (BioLegend). Serum from 6 mice that did not receive anything was used as a healthy control in each sex. Samples from 3 mice that received 2 mg / kg of lipopolysaccharide (LPS) were used to simulate cytokine storm in each sex. Unpaired t-test was used to test for significant differences between groups. (ns, P>0.05; *, P≤0.05; **, P≤0.01; ***, P≤0.001; ****, P≤0.0001).

[0042] Fig.23 It is shown that treatment (mDsg3-EC1-4-mFc) inhibits the pathogenic effects of the AK23 antibody. All animals received AK23 (12 mg / kg; subcutaneous); the AK23+ treated cohort received mDsg3-mFc (15 mg / kg, ip) 1 hour later. Panels A and B show that the AK23 group showed significant hair loss by tape stripping performed after 72 hours (Panel A) and showed a severe PV phenotype (i.e., hair loss and mucosal erosions (not shown)) on day 5 (Panel B); however, the "AK23+ treated" group was similar to control healthy mice (Panels A and B); data represent n=3 for each cohort. (Panel C) The AK23 cohort showed weight loss; however, weight gain was normal in mice that received AK23 and treatment. (Panel D) ELISA analysis of IL6 performed on serum collected at 72 hours showed high levels of the cytokine in the AK23 cohort, but similar to healthy controls in the "AK23+ treated" group. (Panel E) Survival analysis of the experiment. All AK23 mice developed severe PV and had to be euthanized within 7 days. All treated mice appeared normal. The experiment was terminated at day 60 (n=3 for each cohort). DETAILED DESCRIPTION

[0043] Disclosed herein are reagents and methods for treating a disease or illness, wherein autoreactive B cells produce autoantibodies in affected animals (e.g., humans, dogs, cats, horses). The reagent and the method are designed to target and exhaust autoreactive B cells. In some embodiments, the reagent and the method are used to treat autoimmune blistering diseases, such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, acquired epidermolysis bullosa, linear IgA bullous dermatosis, pemphigus foliaceus, intraepidermal neutrophilic IgA dermatosis, paraneoplastic pemphigus, etc. In some embodiments, the reagent may contain autoreactive B cell epitopes that bind to B cell receptors on autoreactive B cells. In some embodiments, autoreactive B cell epitopes may be from the extracellular domain of desmoglein (Dsg) or desmoglein (Dsc) molecules. In various embodiments, in addition to the autoreactive B cell epitopes, the agent may also contain an effector cell binding region that can bind to various effector cells (e.g., NK cells, macrophages, and T cells). When the autoreactive epitopes of the agent bind to autoreactive B cells, the effector cells bound to the effector cell binding region of the agent are located close to the B cells and can deplete the B cells.

[0044] In some embodiments, agents having autoreactive B cell epitopes that bind to B cell receptors on autoreactive B cells may have an effector cell binding region that includes the Fc portion of an antibody. The Fc portion of an antibody may bind to cells (including effector cells, such as macrophages, natural killer (NK) cells, etc.) that have Fc receptors (FcRs). These effector cells may deplete autoreactive B cells. These therapeutic agents may be referred to as Fc-mediated therapeutic agents.

[0045] In some embodiments, the reagent having an autoreactive B cell epitope that binds to a B cell receptor on an autoreactive B cell may have an effector cell binding region comprising an antibody that can bind to an effector cell. In some embodiments, the antibody may be specific for T cells (anti-CD3 antibodies). The antibody may be specific for cytotoxic T cells. T cells may deplete autoreactive B cells. These therapeutic agents may be referred to as B cell receptor (BCR)-effector cell conjugates. The therapeutic agent that binds to an effector cell that is a T cell may be referred to as a BCR-T cell conjugate.

[0046] In some embodiments, the reagent molecules as described above may have a spacer between or connecting the autoreactive B cell epitope and the effector cell binding region. In some embodiments, the spacer may be an amino acid spacer. The spacer may be a flexible spacer. The flexible spacer may contain glycine and serine amino acid residues. In some embodiments, the spacer connecting the autoreactive B cell epitope and the effector cell binding region may be made using "click" chemistry. In some embodiments, the spacer may comprise a CC bond made using copper-mediated azide-alkyne cycloaddition chemistry. In some embodiments, the spacer may comprise a NC bond made using a sortase.

[0047] The specific implementation of one or more embodiments is provided herein. However, it should be understood that the present invention can be embodied in various forms. Therefore, the specific details disclosed herein should not be interpreted as limiting, but as the basis of the claims and as a representative basis for teaching those skilled in the art to adopt the present invention in any appropriate manner.

[0048] Unless the context clearly dictates otherwise, the singular forms "a," "an," and "the" include plural referents. In the claims and / or specification, when used in conjunction with the term "comprising," the use of the word "a" or "an" may mean "one," but is also consistent with "one or more," "at least one," and "one or more than one."

[0049] Wherever the phrases "for example," "such as," "including," etc. are used herein, unless expressly stated otherwise, they should be understood to be followed by the phrase "and but not limited to." Similarly, "example," "exemplary," etc. should be understood to be non-limiting.

[0050] The term "substantially" allows deviations from the descriptor that do not adversely affect the intended purpose. Even if the term "substantially" is not explicitly recited, the descriptive term should be understood to be modified by the term "substantially".

[0051] The terms "comprising" and "including" and "having" and "involving" (and similarly "comprises," "includes," "has," and "involves") and the like are used interchangeably and have the same meaning. Specifically, each of these terms is defined to be consistent with the common U.S. Patent law definition of "comprising," and thus should be interpreted as open terms meaning "at least the following," and should also be interpreted as not excluding additional features, limitations, aspects, etc. Thus, for example, "a process involving steps a, b, and c" means a process that includes at least steps a, b, and c. Whenever the term "a" or "an" is used, it should be understood to mean "one or more" unless such interpretation does not make sense in the context.

[0052] As used herein, the term "about" may mean approximately, roughly, around, or in the region thereof. When the term "about" is used in conjunction with a numerical range, the term modifies the range by extending the boundaries above and below the numerical values ​​set forth. Typically, the term "about" is used herein to modify numerical values ​​above and below the stated value by a change above or below (higher or lower), such as 20%.

[0053] The term "subject" or "patient" may refer to any organism to which aspects of the present invention may be performed, e.g., for experimental, diagnostic, preventive and / or therapeutic purposes. Subjects to which the methods described herein are performed include mammals, such as primates, e.g., humans. For veterinary applications, a wide variety of subjects are suitable, e.g., livestock, such as cattle, sheep, goats, cows, pigs, etc.; poultry, such as chickens, ducks, geese, turkeys, etc.; and domesticated animals and pets, such as dogs and cats. For diagnostic or research applications, a wide variety of mammals are suitable subjects, including rodents (e.g., mice, rats, hamsters), rabbits, primates, and pigs (such as inbred pigs), etc. The term "living subject" may refer to a subject mentioned herein or another living organism. The term "living subject" may refer to a whole subject or organism, not just a portion removed from a living subject (e.g., a liver or other organ). The term "normal subject" may refer to a subject not afflicted with a disease or disorder, such as a subject not afflicted with cancer.

[0054] As used herein, the phrase "therapeutic agent" may refer to any agent that causes a desired pharmacological effect when administered to a subject. In some embodiments, an agent is considered a therapeutic agent when it exhibits a statistically significant effect across an appropriate population. In some embodiments, an appropriate population may be a population of a model organism. In some embodiments, an appropriate population may be defined by various criteria, such as a specific age group, sex, genetic background, pre-existing clinical conditions, etc. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, mitigate, inhibit, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a disease, illness, and / or condition.

[0055] As used herein, the term "therapeutically effective amount" may refer to the amount of a therapeutic agent whose administration is associated with or reasonably expected to be associated with the realization of a specific therapeutic effect when viewed in a relevant population. The therapeutic effect can be objective (i.e., measurable by some tests or markers) or subjective (i.e., the subject gives an indication of the effect or feels the effect). In some embodiments, the therapeutically effective amount of a substance is an amount sufficient to treat, diagnose, prevent and / or delay and / or alleviate one or more symptoms of a disease, illness and / or condition when administered to a subject who is suffering from or susceptible to a disease, illness and / or condition. Disease progression can be monitored by clinical observations, laboratories and imaging studies that are obvious to those skilled in the art. A therapeutically effective amount is administered with a dosing regimen that can include multiple unit doses. For therapeutic agents, a therapeutically effective amount (and / or an appropriate unit dose within an effective dosing regimen) can be variable, for example, based on the route of administration, based on a combination with other agents. In addition, the specific therapeutically effective amount (and / or unit dose) for a patient may be based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific agent being used; the specific composition being used; the age, weight, general health, sex and diet of the patient; the time of administration, the route of administration and / or the rate of excretion or metabolism of the specific fusion protein being used; the duration of treatment; and similar factors as are well known in the medical field. In addition, within the treatment regimen, an effective amount may be administered via a single dose or via multiple doses. In some embodiments, a separate dose or composition is considered to contain a "therapeutically effective amount" when it contains an amount that is effective as a dose in the context of a treatment regimen. Those of ordinary skill in the art will understand that a dose or amount can be considered effective when it is proven or has been proven to show statistically significant effectiveness when administered to a group of patients; it is not necessary to achieve a specific result in a specific individual patient in order to be considered as a therapeutically effective amount as described herein.

[0056] The word "treatment" may refer to medical management of a subject (e.g., an animal, including a human) that is intended to prevent, cure, stabilize, or improve symptoms or conditions. The term includes active treatment, i.e., treatment specifically directed to the improvement of a condition; palliative treatment, i.e., treatment designed to alleviate symptoms rather than cure a condition; preventive treatment, i.e., treatment directed to the prevention of a condition; and supportive treatment, i.e., treatment that supplements another specific therapy directed to the improvement of a condition. The term "treatment" also includes symptomatic treatment, i.e., treatment directed to systemic symptoms of a condition. The term "treat" or "treatment" may also refer to both therapeutic treatment and prophylactic or preventive measures, wherein the purpose is to prevent or slow down (mitigate) undesirable physiological changes or conditions. "Treatment" may also refer to prolonged survival compared to the expected survival in the absence of treatment. Those in need of treatment include those who already have a condition or condition, and those who are prone to a condition or condition, or those in which a condition or condition is to be prevented.

[0057] "Treating" a condition with a compound of the invention involves administering such compounds to a patient, alone or in combination, and by any appropriate means. Treatment may be administered to a subject who does not exhibit signs of the disease, disorder, and / or condition (e.g., before the disease, disorder, and / or condition is identifiable) and / or to a subject who exhibits only early signs of the disease, disorder, and / or condition for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition.

[0058] The term "administering" may refer to introducing a pharmaceutical composition or formulation as described herein into a subject. One route of administration of the composition is intravenous administration. However, any route of administration may be used, such as oral, topical, subcutaneous, peritoneal, intra-arterial, inhalation, vaginal, rectal, nasal, introduction into the cerebrospinal fluid, or instillation into a body compartment.

[0059] As used herein, "allergen" may refer to a substance that can cause an allergic reaction. For example, an allergen may produce an abnormally strong or violent immune response (e.g., a hypersensitivity reaction of the immune system). In some embodiments, the hypersensitivity reaction may be a type I hypersensitivity reaction. In some embodiments, the hypersensitivity reaction may be mediated by IgE.

[0060] Herein, "antibody" may refer to one or more molecules that bind to an antigen. Herein, "antibody" may refer to all types of antibodies, fragments and / or derivatives. Antibodies include polyclonal antibodies and monoclonal antibodies of any suitable isotype or isotype subclass. Herein, antibodies may refer to, but are not limited to, Fab, F(ab')2, Fab' single-chain antibodies, Fv, single chains, monospecific antibodies, bispecific antibodies, trispecific antibodies, multivalent antibodies, chimeric antibodies, canine-human chimeric antibodies, chimeric antibodies, humanized antibodies, human antibodies, antibodies transplanted with CDRs, shark antibodies, nanobodies (e.g., antibodies composed of a single monomer variable domain), camelid antibodies (e.g., from the Camelidae family), microbodies, intrabodies (e.g., intracellular antibodies) and / or defucosylated antibodies and / or their derivatives. Antibody mimetics are also provided. In some embodiments, the antibodies disclosed herein are active agents as part of the compounds disclosed herein that can cross the blood-brain barrier.

[0061] "Antibody" or "antigen-binding polypeptide" may refer to a polypeptide or polypeptide complex that specifically recognizes and binds to an antigen. An antibody may be a complete antibody and any antigen-binding fragment or single chain thereof. For example, an "antibody" may include any protein or peptide containing such a molecule that contains at least a portion of an immunoglobulin molecule having a biological activity of binding to an antigen. Non-limiting examples of a heavy or light chain complementary determining region (CDR) or a ligand binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework (FR) region, or any portion thereof, or at least a portion of a binding protein. As used herein, the term "antibody" may refer to an immunoglobulin molecule and an immunologically active portion of an immunoglobulin (Ig) molecule, i.e., a molecule containing an antigen binding site that specifically binds to (immunoreacts with) an antigen. By "specifically binds" or "immunoreacts with..." is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides.

[0062] As used herein, the term "antibody fragment" or "antigen-binding fragment" is a portion of an antibody, such as an F (ab′)2 、F (ab)2 、F ab′ 、Fa b, Fv, scFv, etc. Regardless of the structure, antibody fragments bind to the same antigen recognized by the complete antibody. The term "antibody fragment" may include aptamers (such as spiegelmers), miniantibodies and diabodies. The term "antibody fragment" may also include any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. Antibodies, antigen-binding polypeptides, variants or derivatives described herein include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single-chain antibodies, epitope binding fragments such as Fab, Fab' and F(ab')2, Fd, Fv, single-chain Fv (scFv), single-chain antibodies, dAb (domain antibodies), miniantibodies, disulfide-linked Fv (sdFv), fragments comprising VL or VH domains, fragments produced by Faab expression libraries, and anti-idiotype (anti-Id) antibodies.

[0063] "Single-chain variable fragment" or "scFv" refers to the heavy chain (V H ) and light chain (V L ) fusion protein of the variable region of the single-chain Fv ("scFv") polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed by a gene fusion comprising a VH encoding gene and a VL encoding gene connected by a peptide encoding linker. (See Huston et al. (1988) Proc Nat Acad Sci USA 85(16):5879-5883). In some aspects, the regions are connected with a short linker peptide of 10 to about 25 amino acids. The linker can be rich in glycine for flexibility, and can be rich in serine or threonine for solubility, and the VH and VL regions can be connected. H The N-terminus of L The C-terminus of the antibody is connected to the C-terminus of the antibody, or vice versa. The protein retains the specificity of the original immunoglobulin, despite the removal of the constant region and the introduction of the linker. Many methods have been described to identify the chemical structure for converting the naturally aggregated but chemically separated light and heavy polypeptide chains from the antibody V region into scFv molecules, which will fold into a three-dimensional structure that is substantially similar to the structure of the antigen binding site. See, for example, U.S. Patent Nos. 5,091,513; 5,892,019; 5,132,405; and 4,946,778, each of which is incorporated herein by reference in its entirety.

[0064] Antibody molecules obtained from humans fall into five classes of immunoglobulins: IgG, IgM, IgA, IgE and IgD, which differ from each other by the nature of the heavy chains present in the molecule. It will be appreciated by those skilled in the art that heavy chains are classified as gamma, mu, alpha, delta or epsilon (γ, μ, α, δ, ε), with some subclasses (e.g., γ1 to γ4) among them. Certain classes also have subclasses, such as IgG1, IgG2, IgG3 and IgG4, etc. Immunoglobulin subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgG5, etc.) are well characterized and known to confer functional specialization. With regard to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of approximately 23,000 daltons and two identical heavy chain polypeptides of 53,000 to 70,000 daltons. The four chains are usually connected in a "Y" configuration by disulfide bonds, wherein the light chain begins at the opening of the "Y" and continues to support the heavy chain through the variable region. The immunoglobulin or antibody molecules described herein can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.

[0065] Light chain is classified as kappa or lambda (κ, λ). Every kind of heavy chain classification can be combined with κ or λ light chain. Generally speaking, light chain and heavy chain are covalently bound to each other, and when immunoglobulin is generated by hybridoma, B cell or genetically engineered host cell, the " tail " part of two heavy chains is bound to each other by covalent disulfide bond or non-covalent bond. In heavy chain, amino acid sequence extends from the N-terminal at the forked end of Y configuration to the C-terminal at the bottom of each chain.

[0066] Both light and heavy chains are divided into regions with structural and functional homology. The terms "constant" and "variable" are used in terms of functional significance. The variable domains of both the light chain (VL) and heavy chain (VH) portions determine antigen recognition and specificity. In contrast, the constant domains of the light chain (CL) and heavy chain (CH1, CH2 or CH3) confer important biological properties, such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. The term "antigen binding site" or "binding portion" may refer to the portion of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by the amino acid residues of the N-terminal variable ("V") region of the heavy chain ("H") and the light chain ("L") . The three highly different segments in the V region of the heavy and light chains, called "hypervariable regions", are inserted between the more conservative flanking segments called "framework regions" or "FR". Therefore, the term "FR" may refer to the amino acid sequence that naturally occurs between the hypervariable regions of immunoglobulins and adjacent to the hypervariable regions. In an antibody molecule, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are arranged relative to each other in three-dimensional space to form an antigen binding surface. The antigen binding surface is complementary to the three-dimensional surface of the bound antigen, and the three hypervariable regions of the heavy chain and the light chain are each called "complementarity determining region" or "CDR". VH region and VL region, they contain CDR.

[0067] As used herein, the term "monoclonal antibody" or "mAb" or "Mab" or "monoclonal antibody composition" may refer to a population of antibody molecules containing only one molecular species of antibody molecules, which antibody molecules are composed of a unique light chain gene product and a unique heavy chain gene product. Specifically, the complementarity determining regions (CDRs) of the monoclonal antibodies are identical in all molecules of the population. MAbs contain an antigen binding site that is capable of immunoreacting with a specific epitope of an antigen, which is characterized by having a unique binding affinity for the antigen binding site.

[0068] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256: 495 (1975). In the hybridoma method, mice, hamsters or other suitable host animals are generally immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.

[0069] As used herein, "autoantibodies" may refer to antibodies produced by an animal that bind or react to an antigen from the animal (e.g., a self-antigen rather than a "foreign" antigen). Generally (e.g., in the absence of a disease or disorder), animals are tolerant to self-antigens and do not produce autoantibodies.

[0070] As used herein, "autoimmunity" may refer to an immune response (eg, antibody production) to self-antigens. "Autoimmune disease" may refer to a disease or disorder caused by an immune response to self-antigens.

[0071] As used herein, "autoreactivity" may refer to a component of an autoimmune response. For example, a B cell that produces an antibody reactive against a self-antigen may be referred to as an autoreactive B cell. The antibody may be referred to as an autoreactive antibody. The self-antigen with which the autoantibody is reactive may be referred to as an autoreactive antigen.

[0072] As used herein, "B cells" may refer to a type of lymphocyte that plays a role in the humoral immune response of an animal. B cells produce antibodies that are displayed on the surface of the B cells. Plasma cells, which are a more differentiated form of B cells, may secrete antibodies.

[0073] As used herein, "B cell receptor" or "BCR" may refer to an antibody produced by a B cell that is displayed on the surface together with a signal transduction moiety.

[0074] As used herein, "depletion" may refer to removal or elimination. As used herein, depletion may refer to the removal of autoreactive B cells. Depletion may refer to the killing of autoreactive B cells.

[0075] As used herein, "desmoglein" and "desmoglein" may refer to a family of cadherins involved in desmosome formation.

[0076] Herein, "effector cells" may refer to cells that can deplete autoreactive B cells. In some embodiments, the effector cells may be macrophages, NK cells, T cells, and the like.

[0077] As used herein, "epitope" may refer to the portion of an antigen that binds to an antibody (eg, to a B cell receptor). This epitope may be referred to as a B cell epitope, which may be distinguished from a T cell epitope.

[0078] The term "epitope" may include any protein determinant that can be specifically bound to an immunoglobulin, scFv or T cell receptor. The variable region allows an antibody to selectively recognize and specifically bind to an epitope on an antigen. For example, a subset of the VL domain and VH domain or complementary determining region (CDR) of an antibody is combined to form a variable region that defines a three-dimensional antigen binding site. This four-level antibody structure forms an antigen binding site present at the end of each arm of the Y. The epitope determinant can be composed of a chemically active surface grouping of a molecule (such as an amino acid or sugar side chain), and generally has a specific three-dimensional structural feature and a specific charge feature. For example, an antibody can be produced against the N-terminal or C-terminal peptide of a polypeptide. More specifically, the antigen binding site is defined by three CDRs on each of the VH chain and the VL chain (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3).

[0079] Herein, "extracellular domain" may refer to the portion of a cell membrane protein extending from the outer surface of the cell membrane of a cell.

[0080] Herein, "Fc region" (fragment crystallizable region) may refer to the tail region of an antibody that binds to an Fc receptor. The Fc region can be restored when the antibody is digested with papain.

[0081] As used herein, "Fc receptor" or "FcR" may refer to a receptor that can bind to the Fc region of an antibody. Fc receptors are present on the surface of certain cells, including natural killer cells and macrophages.

[0082] As used herein, the terms "immunobinding" and "immunobinding properties" may refer to the type of non-covalent interaction that occurs between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. In some embodiments, these terms may describe the binding of an Fc domain to an Fc receptor. The strength or affinity of an immunobinding interaction may be measured using the dissociation constant (K) of the interaction. d ), where smaller Kd represents greater affinity. Methods well known in the art can be used to quantify the immunological binding properties of a selected polypeptide. One such method requires measuring the rates of formation and dissociation of antigen binding sites / antigen complexes, where these rates depend on the concentration of the complex partners, the affinity of the interaction, and geometric parameters that affect the rates equally in both directions. Thus, the "binding rate constant" (K on ) and the “dissociation rate constant” (K off ) can be determined by calculating the concentration and the actual binding and dissociation rates. (See Nature 361: 186-87 (1993)). off / K on The ratio of allows elimination of all parameters not related to affinity and is equal to the equilibrium binding constant KD (See generally, Davies et al. (1990) Annual Rev Biochem 59:439-473.) When the equilibrium binding constant (K) is measured by a kinetic assay such as a radioligand binding assay or similar assays known to those skilled in the art such as BIAcore or Octet (BLI), the equilibrium binding constant (K) is the binding constant of the ligand. D )≤1 μM, ≤10 μM, ≤10 nM, ≤10 pM, or ≤100 pM to about 1 pM, the antibodies of the present invention can specifically bind to the epitope. For example, in some embodiments, K D K between about 1E-12M and about 1E-11M D In some embodiments, K D K between about 1E-11M and about 1E-10M D In some embodiments, K D K between about 1E-10M and about 1E-9M D In some embodiments, K D K between about 1E-9M and about 1E-8M D In some embodiments, K D K between about 1E-8M and about 1E-7M D In some embodiments, K D K between about 1E-7M and about 1E-6M D For example, in some embodiments, K D is about 1E-12M, while in other embodiments, K D is about 1E-11 M. In some embodiments, K D is about 1E-10M, while in other embodiments, K D is about 1E-9 M. In some embodiments, K D is about 1E-8M, while in other embodiments, K D is about 1E-7M. In some embodiments, K D is about 1E-6M, while in other embodiments, K D is about 1E-5M. In some embodiments, for example, K D is about 3E-11M, while in other embodiments, K D In some embodiments, K DAbout 6E-11 M. "Specifically binds" or "has specificity for..." can refer to an antibody that binds to an epitope via its antigen binding domain, and that the binding requires some complementarity between the antigen binding domain and the epitope. For example, an antibody is said to "specifically bind" to an epitope when the antibody binds to the epitope via its antigen binding domain more readily than the antibody would bind to a random, unrelated epitope.

[0083] Herein, "fusion protein" may refer to a protein formed by connecting genes that were originally separate genes.

[0084] As used herein, "macrophage" may refer to a type of phagocytic white blood cell.

[0085] As used herein, "natural killer cells" or "NK cells" may refer to a type of cytotoxic lymphocyte.

[0086] As used herein, "polypeptide" may encompass the singular "polypeptide" as well as the plural "polypeptides", and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any one or more chains of two or more amino acids, and does not refer to a specific length of the product. Therefore, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to refer to one or more chains of two or more amino acids may refer to "polypeptides" herein, and the term "polypeptide" may be used in place of any of these terms or interchangeably with any of these terms. "Polypeptide" may also refer to the product of post-expression modification of a polypeptide (including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization, proteolytic cleavage or modification by non-naturally occurring amino acids through known protecting / blocking groups). A polypeptide may be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a specified nucleic acid sequence. It may be generated in any manner, including by chemical synthesis. "Recombinant" as it relates to polypeptides (such as antibodies) or polynucleotides refers to forms of the polypeptide or polynucleotide that do not occur naturally, by way of non-limiting example, can be formed by combining polynucleotides or polypeptides that do not normally occur together.

[0087] As used herein, "sortase" may refer to an enzyme from bacteria that recognizes and cleaves a carboxyl-terminal recognition signal (usually in a peptide, polypeptide or protein). In some embodiments, the recognition signal may include the amino acid motif Leu-Pro-X-Thr-Gly, where "X" may be any amino acid.

[0088] As used herein, "T cell" may refer to a type of lymphocyte that plays a role in the cellular immune response of an animal.

[0089] As used herein, "targeting" when used as a verb may refer to cells or molecules that specifically attack other substances (e.g., a fusion protein is attached to a B cell and carries an effector cell that depletes the B cell; the fusion protein and effector cell target the B cell). "Target" when used as a noun may refer to, for example, a depleted B cell.

[0090] Autoimmune diseases

[0091] The diseases or conditions that the agents and methods disclosed herein are designed to treat may be autoimmune conditions or diseases. The diseases or conditions treated may relate to those diseases or conditions in which autoreactive B cells produce autoreactive antibodies specific for self or autoreactive antigens. Diseases may include, for example, autoimmune blistering diseases, lupus, scleroderma, Goodpasture's disease, Graves' disease, immune-mediated vasculitis, and the like.

[0092] Diseases may include (MuSK) myasthenia gravis (MG), a rare and usually more severe subtype of MG with a different pathogenesis and unusual clinical features.

[0093] Diseases may include PLA2R membranous nephropathy. PLA2R is an autoantigen present in glomerular podocytes. Membranous nephropathy (MN) may occur when circulating antibodies penetrate the glomerular basement membrane and form immune complexes with epitopes on the podocyte membrane in the subepithelial space.

[0094] Diseases may include hemophilia A with FVIII alloantibodies.

[0095] In some embodiments, the disease or disorder may include an autoimmune blistering disease such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, linear IgA bullous dermatosis, pemphigus foliaceus, intraepidermal neutrophilic IgA dermatosis, and paraneoplastic pemphigus.

[0096] In some embodiments, the disease or disorder may be present in an animal, including a human, dog, cat, or horse.

[0097] In some embodiments, the autoreactive antibodies present in an animal suffering from a disease or disorder may be specific for autoreactive antigens, which include molecules such as desmoplakin, involucrin, parathrombolysin, plectin, bullous pemphigoid antigen 1, keratogranulin, microtubule-actin cross-linking factor, exothrombolysin, and cadherin.

[0098] In some embodiments, the autoreactive antigen can be a desmosomal cadherin, such as Desmoglein-1 (Dsg1), Desmoglein-2 (Dsg2), Desmoglein-3 (Dsg3), Desmoglein-4 (Dsg4), Desmoglein-1 (Dsc1), Desmoglein-2 (Dsc2), and Desmoglein-3 (Dsc3).

[0099] In some embodiments, the autoreactive antigenic region of interest in the agents and methods disclosed herein is a portion of an autoreactive antigen that is an extracellular (EC) domain, such as Figure 2 B and Fig.13 As shown in . At least in some embodiments, the autoreactive antibodies in the above diseases and disorders may be specific for the EC domains of the autoreactive antigens. The specific epitopes within the autoreactive antigens to which the autoreactive antibodies bind may be referred to as autoreactive epitopes. Generally speaking, because the interest here is in targeting autoreactive B cells, the relevant epitopes may be B cell epitopes. The B cell autoreactive epitopes of the autoreactive antigens may bind to the B cell receptors (BCRs) of the autoreactive B cells. In some embodiments, the reagents and methods disclosed herein are designed to target B cells that have BCRs that can bind to these epitopes (e.g., EC domains from molecules such as Dsg1, Dsg2, Dsg3, Dsg4, Dsc1, Dsc2, and Dsc3).

[0100] In general, as described above, autoreactive antigens stimulate the production of autoreactive antibodies. In some embodiments, the autoreactive antibodies produced can be "pathogenic". In some embodiments, the autoreactive antibodies produced can be "non-pathogenic". Pathogenic antibodies generally produce symptoms and / or pathology of autoimmune diseases (such as pemphigus). Without wishing to be bound by mechanism, pathogenic antibodies can inhibit the function of proteins to which they bind. In some embodiments, the therapies described herein can target B cells that produce pathogenic autoreactive antibodies.

[0101] In general, for some autoimmune blistering diseases, such as pemphigus, the extracellular (EC) domain of the autoreactive antigen (e.g., see Figure 2 B and Fig.13) can be pathogenic or non-pathogenic. In some embodiments, the EC domain of desmoglein and / or desmoglein can be pathogenic or non-pathogenic. In some embodiments, the EC1 domain, EC2 domain, and / or EC4 domain of Dsg1, Dsg2, Dsg3, and / or Dsg4 can be pathogenic. In some embodiments, the EC1 domain, EC2 domain, and / or EC4 domain of Dsg3 and Dsg1 can be pathogenic. Without wishing to be bound by theory, it is believed that the inclusion of non-pathogenic or less pathogenic EC domains and pathogenic EC domains in a therapeutic agent will not affect the efficacy of the therapeutic agents disclosed herein.

[0102] Without wishing to be bound by theory, the level of immunogenicity of the EC domain (see, e.g., Figure 2 The percentage of pemphigus patients with autoreactive antibodies to the EC domain in B) may or may not be highly correlated with pathogenicity.

[0103] Depletion of autoreactive B cells

[0104] The present disclosure describes various methods for therapy in animals, including humans, suffering from autoimmune diseases or disorders. The agents and methods disclosed herein can target and deplete autoreactive B cells in animals.

[0105] In some embodiments, the reagent for depleting autoreactive B cells can be a fusion protein. The fusion protein can have an independent domain or region. In some embodiments, the fusion protein can contain one or more autoreactive epitopes, which bind to a B cell receptor (BCR) on the surface of a B cell that is reactive with the autoreactive epitope. In some embodiments, the fusion protein can also contain a domain that can bind to an effector cell. In some embodiments, the domain that can bind to an effector cell can be an Fc region of an antibody. These therapeutic agents can be referred to as Fc-mediated therapeutic agents. In some embodiments, the domain that can bind to an effector cell can be an antibody that binds to an effector cell. These therapeutic agents can be referred to as BCR-effector cell conjugates. In embodiments in which an antibody can bind to a T cell, the therapeutic agent can be referred to as a BCR-T cell conjugate.

[0106] In some embodiments, the fusion protein may have a domain comprising one or more autoreactive B cell epitopes. The autoreactive B cell epitopes may be from any of the above-mentioned autoreactive antigens, and in some embodiments from the EC domain of the autoreactive antigen. In the context of the fusion protein, the autoreactive B cell epitopes are configured so that they can bind to the BCR of the target autoreactive B cell. In some embodiments, the autoreactive B cell epitopes may be located at the end of the fusion protein. In some examples, the B cell epitope may be located at the N-terminus of the fusion protein.

[0107] In some embodiments, the "knobs-in-holes" strategy can be used to generate Fc-mediated therapeutics containing multiple epitopes, including multiple autoreactive B cell epitopes. Knobs-in-holes is a method in which separate C-terminal fragments from, for example, two IgG heavy chains are joined together. H 3 domains (C H The 3 domain contains a portion of the Fc region) to contain a "knob" or a complementary "hole", so that the independent C H Heterodimerization of CH3 domains is advantageous (Ridgway, John BB, Leonard G. Presta and Paul Carter. "'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization." Protein Engineering, Design and Selection 9.7 (1996): 617-621). In some embodiments, two recombinant polypeptides are designed. The first polypeptide may contain: a first self-reactive antigen (e.g., one or more EC domains); and a "complementary" CH3 domain. H The second polypeptide may contain: a second self-reactive antigen; and a "complementary" C H When the first polypeptide contacts the second polypeptide, the two C H The 3 domains preferentially heterodimerize and form disulfide bonds between polypeptides. Homodimerization is not favorable. Heterodimerized molecules typically contain a functional Fc region and two independent self-reactive antigens. In some embodiments, heterodimerized molecules may contain more than two antigens.

[0108] In some embodiments, the independent antigens in the "knob-in-hole" molecule may be from different autoreactive antigens. In some embodiments, the independent antigens may contain different epitopes from the same autoreactive antigen. In some embodiments, the independent antigens may be from Dsg3 and / or Dsg1. In some embodiments, the independent antigens may be from different extracellular (EC) domains of desmoglein. In some embodiments, the independent antigens may be selected from EC1, EC2, EC3, EC4, and EC5 of the desmoglein molecule. For example, the independent antigens may be from EC1 and EC2.

[0109] In some embodiments, the autoreactive B cell epitopes may be derived from the EC1 domain, EC2 domain, and / or EC4 domain of desmosomal cadherin (see Cho, Alice et al. "Single-cell analysis suggests that ongoing affinity maturation drives the emergence of pemphigus vulgaris autoimmune disease." Cell reports″28.4(2019):909-922). In some embodiments, EC3 may be included. In some embodiments, the autoreactive B cell epitope is from the EC1 domain, EC2 domain and / or EC4 domain of Dsg3. In some embodiments, the autoreactive B cell epitope is from the EC1 domain and / or EC2 domain of Dsg3. In some embodiments, a single fusion protein may have multiple EC domains (e.g., two or more of EC1, EC2 and EC3; e.g., EC1 to EC4) from one or more desmoglein core glycoproteins. In some embodiments, independent fusion proteins, each containing one EC1 domain, EC2 domain, EC3 domain or EC4 domain of Dsg3, can be combined into a composition and used for therapy in a patient.

[0110] Without wishing to be bound by theory, therapeutic agents may be designed to contain EC domains corresponding to those that bind to autoreactive antibodies in a patient, as well as EC domains corresponding to those for which autoreactive antibodies are not currently detected in the patient. In a phenomenon known in the art as "epitope spreading," some patients have autoreactive antibodies that are reactive with one epitope on an antigen but not with other epitopes on the antigen. However, over time, patients may develop autoreactive antibodies to one or more of the epitopes that did not initially stimulate autoreactive antibodies. Inclusion of epitopes to which autoreactive antibodies subsequently arise in the therapeutic agents disclosed herein may prevent or alleviate symptoms of the disease caused by the antibodies that subsequently arise. In some embodiments, in a patient who initially has only autoreactive antibodies to EC5 of Dsg3 or Dsg1, administration of a therapeutic agent containing EC1, EC2, EC4, and EC5 may be beneficial to the patient.

[0111] In some embodiments, the autoreactive B cell epitope can be from a thrombolysin (e.g., involucrin, parathrombolysin, desmoplakin I, desmoplakin II, exothrombolysin, plectin, BP230), a cadherin ((Dsg3, Dsg1, Dsc1, Dsc2, Dsc3, α2-macroglobulin-like molecule), BP180 (e.g., NC16A, LABD97, LAD-1 domain or C-terminal epitope), laminin 332, α6β4 integrin, collagen VII, laminin γ1 (p200), type VII collagen, epidermal transglutaminase, tissue transglutaminase, endomysial or deamidated prolamins.

[0112] Generally, the autoreactive antibody can be any class of antibody (IgA, IgD, IgE, IgG, or IgM). In some cases, the autoreactive antibody can be IgA or IgG.

[0113] In some embodiments, instead of an autoreactive B cell epitope, an allergen, a portion of an allergen, or a molecule that can mimic an allergen can be a portion of an Fc-mediated therapeutic or BCR-T cell engager disclosed herein. There are many different allergens. Non-limiting examples of allergens can come from drugs, foods, insects (e.g., insect stings, dust mites), latex, mold, pets / animals (e.g., dander), and pollen. Allergens can include urushiol, such as found in plants (e.g., poison ivy, eastern poison oak, western poison oak, poison sumac, etc.). In some embodiments, the allergen can be a birch pollen allergen, such as Bet v 1. In some embodiments, the allergen / a portion of an allergen can be a protein, a polypeptide, or a polypeptide.

[0114] In some examples, allergies can be type I hypersensitivity reactions. For example, allergies can be mediated by IgE. B cells can produce IgE. Then, IgE can bind to IgE-specific receptors found, for example, on mast cells, basophils, etc., which can release regulators of allergies, such as cytokines, vasoactive amines (e.g., histamine), proteases, prostaglandins, leukotrienes, etc. In some embodiments, allergens as part of Fc-mediated therapeutic agents or BCR-T cell conjugates can bind to and deplete B cells that produce IgE. In some examples, allergies can be type II, type III, or type IV hypersensitivity reactions.

[0115] In some embodiments, the fusion protein may have a domain that binds to effector cells. In a fusion protein having an autoreactive B cell epitope and an effector cell binding domain, the fusion protein may be configured so that the binding of the autoreactive B cell epitope to the BCR on the B cell will co-localize the effector cell bound to the effector cell binding domain of the fusion protein to close to the B cell, so that the effector cell can act on the B cell and deplete the B cell. In some embodiments, the domain that binds to the effector cell can be the Fc portion of an antibody. In some embodiments, the domain that binds to the effector cell can be an antibody that is specific to the effector cell.

[0116] In some embodiments, the effector cell binding domain can be located on the end of the fusion protein. In some examples, the effector cell binding domain can be located at the C-terminus of the fusion protein.

[0117] In some embodiments, the effector cell to which the effector cell binding domain of the fusion protein can bind can be a phagocytic cell or a phagocytic cell. Phagocytic cells can include so-called "professional" phagocytic cells and "non-professional" phagocytic cells. In some embodiments, professional phagocytic cells can include monocytes, macrophages, neutrophils, dendritic cells, and mast cells. In some embodiments, non-professional phagocytic cells can include certain T cells (e.g., cytotoxic T cells) and natural killer (NK) cells.

[0118] In some embodiments, the fusion protein domain that binds to the effector cell can be the Fc part or domain of the antibody. Generally speaking, any Fc part can be used in the reagents and methods disclosed herein. In some embodiments, any Fc part that can bind to effector cells (e.g., NK cells, macrophages, etc.) can be used. In some embodiments, any Fc part that can mediate the exhaustion of target pathogenic B cells (e.g., autoreactive B cells) can be used. The Fc part can bind to cells with Fc receptors (FcR). The Fc part can bind to FcR on the cell. In some embodiments, FcR can be Fc-γ receptor (FcγR), Fc-α receptor (FcαR) or Fc-ε receptor (FcεR). In some embodiments, FcγR can be FcγRI, FcγRII or FcγRIII. In the context of fusion protein, the Fc part of the antibody is configured so that it can bind to Fc receptors (FcR) on the cell.

[0119] In some embodiments, the Fc part or domain of the antibody used herein can be modified. In some embodiments, one or more modifications can affect the binding of the Fc region to the Fc receptors on various cells. In some embodiments, the modification can affect the function of the cell to which the Fc region is bound. In some embodiments, the Fc part or domain can be heterogeneously modified at the conserved N-glycosylation sites on the Fc domain. In some embodiments, the composite biantennary glycan can be attached to the conserved N-glycosylation sites on the Fc domain (see Li, Tiezheng et al. "Modulating IgGeffector function by Fc glycan engineering." Proceedings of the NationalAcademy of Sciences 114.13 (2017): 3485-3490). Generally speaking, any type of Fc domain modification can be used, as long as the modified Fc domain can be combined with effector cells (e.g., NK cells, macrophages, etc.). Generally speaking, any type of Fc domain modification can be used so long as the modified Fc domain can mediate depletion of target pathogenic B cells (eg, autoreactive B cells).

[0120] Within the fusion protein, the Fc portion can also be configured such that the effector cell to which the Fc portion binds is co-localized proximal to the autoreactive B cell to which the autoreactive B cell epitope of the fusion protein binds. Effector cells that have FcRs and to which the Fc portion of the fusion protein can bind can include, for example, neutrophils, monocytes, macrophages, mast cells, and dendritic cells.

[0121] In some embodiments, the fusion protein domain combined with effector cells can be an antibody combined with effector cells.Herein, the fusion protein containing autoreactive antigens and antibodies combined with effector cells can be referred to as BCR-effector cell conjugates.In some embodiments, the antibody can be an antibody combined with T cells (e.g., anti-CD3 antibodies) or a specific type of T cells.In some embodiments, the antibody can be an antibody combined with cytotoxic T cells (e.g., anti-CD8 antibodies) or an antibody combined with helper T cells (e.g., anti-CD4 antibodies).In some embodiments, the antibody can be an antibody combined with, for example, macrophages, natural killer (NK) cells or other phagocytic cells.In some examples, antibodies or antibody combinations combined with NK cells can be used.In some examples, anti-CD56 antibodies can be used.In some embodiments, the antibody can be a single-chain variable fragment (scFv).

[0122] In the fusion protein, the antibody that binds to the effector cell is configured so that it can bind to the specific effector cell. In some embodiments, the antibody can bind to one or more desired effector cells, but not to other cells or to other cells with lower effectiveness. In the fusion protein, the antibody that binds to the effector cell is also configured so that the antibody and the effector cell that bind to it are co-located to the autoreactive B cell that is close to the autoreactive B cell epitope of the fusion protein and binds to it. This co-localization is conducive to the ability of the effector cell to interact with the autoreactive B cell / act on the autoreactive B cell.

[0123] The fusion proteins disclosed herein may additionally have a spacer or linker. Generally speaking, the spacer may be located between the autoreactive B cell epitope domain and the domain that binds to the effector cell in the fusion protein. The spacer may facilitate the independent domains within the fusion protein to each perform their desired functions. For example, a spacer located between a fusion protein domain comprising an autoreactive B cell epitope and a domain that binds to an effector cell may provide an autoreactive B cell epitope to bind to the BCR on the autoreactive B cell, while the effector cell binding domain may bind to the effector cell and co-localize the effector cell to be close to the autoreactive B cell. The spacer may provide co-localized effector cells to deplete the autoreactive B cells.

[0124] In some embodiments, the spacer can be an amino acid spacer. In some embodiments, the length of the spacer can be between about 2 and 50 amino acids. In some embodiments, the length of the spacer can be between about 5 and 45, 6 to 40, 7 to 35, 8 to 30, 9 to 25, or 10 to 20 amino acids. In some embodiments, the spacer can be a flexible spacer that can increase the flexibility of the fusion protein.

[0125] In some embodiments, the flexible peptide spacer may include small polar (e.g., Ser, Thr) or non-polar (e.g., Gly) amino acids. The flexible peptide spacer may have a sequence of Gly and Ser residues (e.g., a "GS" linker). An exemplary GS linker amino acid sequence may include (Gly-Gly-Gly-Gly-Ser) n . An exemplary peptide spacer may be (Gly-Gly-Gly-Gly-Ser)3. Other types of flexible spacers may include KESGSVSSEQLAQFRSLD, EGKSSGSGSESKST, (Gly)8, GSAGSAAGSGEF, and (GGGGS)4 (Chen, Xiaoying, Jennica L. Zaro, and Wei-Chiang Shen. "Fusion protein linkers: property, design and functionality." Advanced drug delivery reviews 65.10 (2013): 1357-1369.). Other exemplary types of spacers may be rigid spacers or cleavable spacers.

[0126] In some embodiments of the fusion protein, various chemistries can be used to link the domain comprising the autoreactive B cell epitope and the effector cell binding domain to each other. In some embodiments, so-called "click" chemistry can be used. In some embodiments, a sortase can be used.

[0127] In some embodiments, CC fusion chemistry can be used to connect the domains. For example, sortase can be used to install a click "handle" at the C-terminus of the autoreactive C-cell epitope domain and the effector cell binding domain. The two modified domains can be "clicked" together using, for example, azide-alkyne click chemistry to create a CC fusion ( Figure 8 A).

[0128] In some embodiments, NC fusion chemistry can be used to connect the domains. For example, using the reversibility of sortase, a triglycine molecule (Gly-Gly-Gly) can be used to catalyze the formation of a NC fusion of two domains. One of the domains (the first domain) can be modified to have Leu-Pro-Glu-Thr-Gly at its C-terminus. The other domain (the second domain) can be modified to have Leu-Pro-Glu-Thr-Gly-Gly-Gly at its N-terminus. By reacting the two modified domains in the presence of triglycine and sortase, the Leu-Pro-Glu-Thr segment is removed from the second modified domain and converted to Gly3. Then, the Gly3-second domain can be reacted with the modified first domain to form a fusion protein ( Figure 8 B).

[0129] In some embodiments, the fusion proteins disclosed herein may include additional parts / domains, such as therapeutic moieties, imaging moieties, capture moieties, and combinations thereof. In some embodiments, click chemistry and / or sorting enzymes may be used to add these parts to the fusion proteins. In some embodiments, the therapeutic moiety may include cytotoxins, toxins, radiotherapeutic agents, T cell engagement moieties, natural killer (NK) cell engagement moieties, or combinations thereof. In some embodiments, the therapeutic moiety may include IL-2 or molecules with IL-1 activity. In some embodiments, the imaging moiety may include fluorophores, radioisotopes, or combinations thereof. In some embodiments, the capture moiety may include hydrophilic proteins, bacterial transpeptidases, GST tags, His tags, polyethylene glycol (PEG), or combinations thereof.

[0130] With respect to the fusion proteins disclosed herein and the individual domains of those proteins (e.g., autoreactive epitopes that bind to effector cells, Fc regions, antibodies), those skilled in the art will readily recognize that individual amino acid substitutions, deletions or additions made to peptide, polypeptide or protein sequences or to nucleotides of nucleic acid sequences (which alter, add, delete or substitute a single amino acid or a small percentage of amino acids in the encoded sequence) are collectively referred to herein as "conservatively modified variants". In some embodiments, the change results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants of the Fc domains or antibodies disclosed herein may exhibit increased effector cell binding compared to the unmodified sequence.

[0131] For example, a "conservative amino acid substitution" is an amino acid substitution in which an amino acid residue is replaced by an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a non-essential amino acid residue in an immunoglobulin polypeptide is replaced by another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced by a structurally similar string that differs in the order and / or composition of the side chain family members.

[0132] In some embodiments, the autoreactive epitope, Fc region or antibody that binds to the effector cell may have a specified percentage identity or similarity to the amino acid sequence or nucleotide sequence of the autoreactive epitope, Fc region or effector cell binding antibody described herein. For example, "homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing the positions in each sequence, and each sequence can be compared for the purpose of comparison. When the position in the compared sequences is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. For example, when compared to a specified region or the entire length of any of the molecules described herein, the molecules described herein may have 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more amino acid sequence identity. For example, when compared to a specified region or the total length of any of the antibodies described herein, the molecules described herein may have 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher nucleic acid identity. The sequence identity or similarity to the nucleic acids and proteins of the present invention can be determined by sequence comparison and / or contrast by methods known in the art, for example, using software programs known in the art, such as those described in Ausubel et al., ed. (2007) Current Protocols in Molecular Biology. For example, sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual comparisons or visual inspections can be used to determine the percentage sequence identity or similarity to the nucleic acids and proteins of the present invention.

[0133] Therapeutic preparations

[0134] Aspects of the invention relate to therapeutic agents. As used herein, the term "therapeutic agent" may refer to any compound or composition that can be used or administered for a therapeutic effect. As used herein, the term "therapeutic effect" may refer to an effect sufficient to cause an improvement in symptoms, for example, the treatment, cure, prevention or improvement of a related medical condition, or an increase in the rate of treatment, cure, prevention or improvement of such a condition.

[0135] Embodiments as described herein can be applied to a subject in the form of a pharmaceutical composition or therapeutic preparation prepared for an expected route of administration. Such compositions and preparations may include, for example, active ingredients and pharmaceutically acceptable carriers. Such compositions and preparations may be in the form of being adapted for oral administration, subcutaneous administration, parenteral administration (such as, intravenous administration, intraperitoneal administration), intramuscular administration, rectal administration, epidural administration, intratracheal administration, intranasal administration, epidermal administration, vaginal administration, buccal administration, ocular administration or pulmonary administration, such as in the form suitable for administration by peripheral routes or suitable for oral administration or suitable for parenteral administration. Other routes of administration are subcutaneous, intraperitoneal and intravenous, and such compositions can be prepared in a manner well known to those skilled in the art, for example, as "Remington's Pharmaceutical Sciences", the 17th edition Alfonso R.Gennaro (editor), Mark Publishing Company, Easton, Pennsylvania, the United States, 1985 and recent versions and "Drugs and the Pharmaceutical Sciences" series, Marcel Dekker's monograph generally described. Compositions and preparations may appear in conventional forms, for example, solutions and suspensions for injection, in the form of enteric formulations (eg, as disclosed in US Pat. No. 5,350,741), and capsules and tablets for oral administration.

[0136] Solutions or suspensions for parenteral, intradermal or subcutaneous administration may contain the following components: a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for adjusting tonicity such as sodium chloride or dextrose. pH may be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be packaged in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.

[0137] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM TM(BASF, Parsippany, New Jersey) or phosphate buffered saline (PBS). In all cases, the composition can be sterile and can be a fluid to the extent of being easy to inject. In embodiments, it can be stable under manufacturing and storage conditions, and can be preserved to prevent the contamination of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, a pharmaceutically acceptable polyol (such as glycerol, propylene glycol, liquid polyethylene glycol) and a suitable mixture thereof. For example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion, and by using a surfactant, appropriate fluidity can be maintained. The effect of preventing microorganisms can be achieved by various antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol, ascorbic acid and thimerosal). In many cases, it can be useful to include isotonic agents in the composition, for example, sugars, polyols (such as mannitol, sorbitol), sodium chloride. The extended absorption of the injectable composition can be achieved by including an agent (such as aluminum monostearate and gelatin) that delays absorption in the composition.

[0138] Sterile injectable solutions can be prepared by mixing the desired amount of the compound with one of the ingredients listed herein or a combination of these ingredients (as required) in an appropriate solvent, followed by sterilization by filtration. Generally speaking, dispersions are prepared by mixing the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed herein. For sterile powders for the preparation of sterile injectable solutions, examples of available preparation methods are vacuum drying and freeze drying, which produce a powder of the active ingredient plus any additional desired ingredients from a previously sterile-filtered solution.

[0139] Oral compositions may include an inert diluent or an edible carrier. Oral compositions may be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound may be admixed with an excipient and then used in the form of tablets, lozenges or capsules. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is administered orally and spit out or swallowed after rinsing the mouth. For example, depending on the half-life of the drug, an oral formulation of the drug may be administered once a day, twice a day, three times a day, or four times a day.

[0140] Pharmaceutically compatible binding agents and / or adjuvant materials may be included as part of the composition for administration to a subject. Tablets, pills, capsules, lozenges, and the like may contain any of the following ingredients, or compounds of a similar nature: binders such as microcrystalline cellulose, tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, (sodium starch glycolate) or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as colloidal silicon dioxide; a sweetener such as sucrose or saccharin; or a flavoring such as peppermint, methyl salicylate, or orange flavoring.

[0141] Systemic administration can also be carried out through mucosal or transdermal means. For transmucosal or transdermal administration, penetrants suitable for permeation barriers are used in the formulation. Such penetrants are well known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel or cream as is well known in the art.

[0142] In embodiments, administering may include placing the pharmaceutical composition into a subject by a method or route that causes the composition to be at least partially localized at a desired site such that a desired effect is produced.

[0143] For example, the pharmaceutical composition may be administered by bolus injection or by infusion. Bolus injection may refer to a route of administration in which a syringe is connected to an IV access device and the drug is injected directly into the subject. The term "infusion" may refer to intravascular injection.

[0144] Embodiments as described herein may be administered to a subject once (e.g., as a single injection, bolus, or deposition). Alternatively, the subject may be administered once or twice daily for a period of time, such as from about 2 weeks to about 28 days. Administration may be continuous up to one year. In embodiments, administration may be continuous for the life of the subject. It may also be administered once or twice daily to a subject for a period of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof.

[0145] In embodiments, a composition as described herein may be chronically administered to a subject."Chronic administration" may refer to administration in a continuous manner, such as to maintain a therapeutic effect (activity) over an extended period of time.

[0146] The specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the specific antibody, variant or derivative thereof, the patient's age, weight, general health, sex and diet, as well as the time of administration, the rate of excretion, the drug combination and the severity of the specific disease being treated. The judgment of the medical staff on such factors is within the scope of those of ordinary skill in the art. The amount also depends on the individual patient to be treated, the route of administration, the type of preparation, the characteristics of the compound used, the severity of the disease and the desired effect. The amount used can be determined by pharmacological and pharmacokinetic principles well known in the art.

[0147] The therapeutically effective amount of the reagent or therapeutic composition of the present invention can be the amount required to achieve the therapeutic goal. As described herein, this can be the binding interaction between the reagent or therapeutic composition and its target, and in some cases, the binding interaction interferes with the function of the target. The amount to be applied will also depend on the binding affinity of the reagent or therapeutic composition for its specific target, and will also depend on the rate at which the free volume of other subjects to which the applied reagent or therapeutic composition is exhausted. The dosage of the binding polypeptide described herein to the subject (e.g., patient) is generally 0.1mg / kg to 100mg / kg patient weight, between 0.1mg / kg to 20mg / kg patient weight, or 1mg / kg to 10mg / kg patient weight. Due to the immune response to foreign polypeptides, human antibodies have a longer half-life in the human body than antibodies from other species. Therefore, it is generally possible to apply lower doses of human antibodies and lower frequency. In addition, the dosage and frequency of application of the reagent or therapeutic composition of the present disclosure can be reduced by enhancing the intake and tissue penetration (e.g., entering the brain) of antibodies via modification (such as, for example, lipidation). As a non-limiting example, a typical range for therapeutically effective dosing of an antibody or antibody fragment of the invention may be about 0.1 mg / kg body weight to about 50 mg / kg body weight. Typical dosing frequencies may range, for example, from twice a day to once a week.

[0148] Where fragments (e.g., antibody fragments) are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based on the variable region sequence of an antibody, a peptide molecule that retains the ability to bind to the target protein sequence can be designed. Such peptides can be chemically synthesized and / or produced by recombinant DNA technology. (See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)). The formulation may also contain more than one active compound (such as necessary for the specific indication being treated), for example, those with complementary activities that do not adversely affect each other. Alternatively or in addition, the composition may contain an agent that enhances its function, such as, for example, a cytotoxic agent, a cytokine (e.g., IL-15), a chemotherapeutic agent, or a growth inhibitor. Such molecules are appropriately combined in an amount that is effective to achieve the intended purpose.

[0149] The active ingredient can also be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions, respectively. Sustained release formulations can be prepared.

[0150] The medicine or treatment carrier or diluent adopted can be conventional solid or liquid carrier.The non-limitative example of solid carrier is the lower alkyl ether of lactose, carclazyte, sucrose, cyclodextrin, talcum, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid or cellulose.The non-limitative example of liquid carrier is syrup, peanut oil, olive oil, phospholipid, fatty acid, fatty acid amine, polyoxyethylene and water.Similarly, carrier or diluent can comprise any sustained-release material as known in the art, such as single or glyceryl monostearate or glyceryl distearate mixed with wax.

[0151] When a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form, or it may be in the form of a troche or lozenge.The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.

[0152] When a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

[0153] The composition and / or formulation may also be in a form suitable for local or systemic injection or infusion, and may therefore be formulated with sterile water or isotonic saline or glucose solution. The composition may be in a form suitable for peripheral administration only, except for a form that can be centrally administered. The composition and / or formulation may be in a form suitable for central administration.

[0154] The composition and / or formulation can be sterilized by conventional sterilization techniques well known in the art. The resulting aqueous solution can be packaged for use or filtered and lyophilized under clean conditions, and the lyophilized formulation is mixed with a sterile aqueous solution before administration. The composition and / or formulation may contain pharmaceutically and / or therapeutically acceptable auxiliary substances such as buffers, tension adjusters, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc. as required to approximate physiological conditions.

[0155] Patients with autoimmune diseases (including autoimmune blistering diseases such as pemphigus) have autoreactive antibodies circulating in their blood. The therapeutic agents described herein contain autoreactive epitopes to which the autoreactive antibodies in the patient may bind. One potential problem may be that the autoreactive antibodies may bind to and / or inactivate the therapeutic agent after it has been administered to the patient. However, the data presented herein (e.g., see Examples 7, Fig.17 and Fig.18 ) show that autoreactive antibodies do not reduce the effectiveness of these therapeutic agents. In some embodiments, the effectiveness of the therapeutic agents disclosed herein is not reduced or minimally reduced by the presence of autoreactive antibodies in the patient to whom the therapeutic agent is administered.

[0156] Nucleic acids, vectors and cells expressing fusion proteins

[0157] Also disclosed are nucleic acids encoding all or part of the fusion proteins described herein. Also disclosed are various vectors (e.g., plasmids, viruses, etc.) comprising nucleic acids. Also disclosed are various cells (e.g., prokaryotic cells, eukaryotic cells) containing nucleic acids or vectors and capable of expressing fusion proteins.

[0158] Example

[0159] Examples are provided herein to facilitate a more comprehensive understanding of the present invention. The following examples show exemplary modes of preparing and practicing the present invention. However, the scope of the present invention is not limited to the specific embodiments disclosed in these examples for illustrative purposes only, because similar results can be obtained using alternative methods.

[0160] Example 1

[0161] Development of non-immunosuppressive, immune-based therapeutics for the targeted treatment of autoimmune diseases

[0162] Pemphigus vulgaris (PV) is a devastating autoimmune blistering disease that can be characterized by painful blistering of the skin and mucous membranes. PV is caused by the production of autoantibodies to desmoglein 3 (Dsg3), with or without antibodies to Dsg1, causing epithelial detachment (acantholysis). There is no cure for PV; treatment strategies may include systemic steroids and immunosuppressive drugs. Although anti-CD20 antibodies (e.g., rituximab) have become the first option for moderate to severe disease, they can cause off-target immunosuppression, including an increased risk of infection (although lower than traditional immunosuppressants) and a high risk of relapse after treatment. Relapses in PV may be due to the expansion of the same autoreactive cells that were not depleted during initial treatment; therefore, complete depletion of autoreactive B cells may be a cure. Currently in clinical trials, neonatal Fc receptor and Bruton's tyrosine kinase inhibitors fail to circumvent off-target immunosuppression. Early cell-based therapies, such as autologous polyclonal regulatory T cells and chimeric autoantigen receptor (CAAR) T cells, were not generally immunosuppressive in the cases where they were proven to be effective. However, cell-based therapies must be personalized and have specific requirements for manufacturing, storage, and transportation, which are not feasible in resource-poor areas.

[0163] There is no cure for PV. The treatment described herein can be curative and can be precise because it exploits the specificity of existing adaptive immune mechanisms. The proposed treatment is not expected to be globally immunosuppressive, thus circumventing the significant side effects of existing treatments. In addition, it eliminates the need for personalization because the target for PV is universal. Importantly, the current project not only provides a platform for the treatment of PV, but can be modified for all antibody-driven autoimmune diseases with known antigens that are primarily treated with traditional non-specific immunosuppressive therapies.

[0164] Based on existing tumor therapies, we designed two approaches to precisely deplete autoreactive anti-Dsg3 B cells: 1) Fc-mediated, and 2) BCR-T cell engagement (see Fig.11 ).

[0165] Fc-mediated approach: This approach is similar to the use of rituximab in PV, with the major advantage of targeting anti-Dsg3 B cells.

[0166] BCR-T cell engager approach: Dsg3-anti-CD3e constructs can establish molecular clustering and formation of immune synapses between target anti-Dsg3 B cells and T cells, which will thus lead to proliferation and activation of T cells to specifically kill the targeted anti-Dsg3 B cells, leaving other B cells intact. Unlike in tumor applications, cytokine release syndrome is not expected in the treatment of autoimmune diseases, given that the load of autoreactive B cells is lower than that against malignant clones.

[0167] One strategy for preparing Dsg3-Fc may be safe and an alternative to the use of rituximab. Another approach provides an attractive alternative option for patients who fail to respond to available treatments. Thus, this project has the potential to not only transform PV treatment, but also open avenues for developing treatments for several autoantibody / immune complex-mediated diseases to known antigen targets, ranging from other autoimmune blistering diseases (e.g., bullous pemphigoid, mucous membrane pemphigoid, acquired epidermolysis bullosa, linear IgA bullous dermatosis), lupus subtypes, scleroderma, Goodpasture's disease, Graves' disease to immune-mediated vasculitis. Thus, without wishing to be bound by theory, the therapeutic agents disclosed herein may be considered a breakthrough addition to the therapeutic toolbox for autoimmune diseases.

[0168] Our therapeutic agents can be used concurrently with other drugs that reduce anti-Dsg3 titers. In addition, it is reassuring to find that monoclonal and polyclonal anti-Dsg3 IgGs have no significant effect on the killing capacity of CAAR T cells specific for B cells producing Dsg3 autoantibodies.

[0169] Example 2

[0170] Pemphigus vulgaris (PV) is an autoimmune blistering disease characterized by painful blistering of the skin and mucous membranes ( Figure 1 PV is caused by the production of autoantibodies against desmoglein 3 (Dsg3), with or without antibodies against Dsgl, leading to epithelial detachment (acantholysis) ( Figure 2 Panel A to Panel B). There is no cure for PV; treatment strategies may include systemic steroids and immunosuppressive drugs. Although anti-CD20 antibodies directed against B cells (e.g., rituximab) have become the first-line option for moderate to severe disease, they are associated with off-target immunosuppression, including an increased risk of infection (although lower than with traditional immunosuppressants) and a high risk of relapse after treatment. Currently in clinical trials, neonatal Fc receptor and Bruton's tyrosine kinase inhibitors are unable to circumvent off-target immunosuppression. Early cell-based therapies (such as autologous polyclonal regulatory T cells14 and chimeric autoantigen receptor (CAAR) T cells16) were not immunosuppressive in their entirety when proven effective. However, cell-based therapies can be personalized, with specific requirements for manufacturing, storage, and transportation, which may or may not be feasible in resource-poor areas. Relapses in PV are often due to the expansion of the same autoreactive cells that were not depleted during initial treatment; complete depletion of autoreactive B cells would provide a potential cure. Three approaches were designed to precisely deplete autoreactive anti-Dsg3 B cells: 1) Fc-mediated, 2) BCR-T cell engagement, and 3) radiotherapy approaches ( Figure 3 Panels A to C). The current project provides a platform for treating not only PV but potentially several antibody-driven autoimmune diseases with known antigens.

[0171] Fc-mediated: In the sense of targeting B cells, this approach is similar to the use of rituximab in PV, with the major advantage of targeting only anti-Dsg3 B cells.

[0172] BCR-T cell engagers: Dsg3-anti-CD3e constructs can establish molecular clustering and formation of immunological synapses between target anti-Dsg3 B cells and T cells, which can thus lead to proliferation and activation of T cells to specifically kill targeted anti-Dsg3 B cells, while leaving other B cells intact. Unlike in tumor applications, cytokine release syndrome is not expected in the treatment of autoimmune diseases, given that the load of autoreactive B cells is lower than that against malignant clones.

[0173] Radiation therapy: In clinical practice, the short range of alpha particles in tissues (<0.1 mm) allows selective killing of target cells without damaging adjacent tissues; this killing is independent of oxygenation status, cell cycle, cell internalization, and previous treatment. Therefore, radiation therapy may provide an attractive alternative for patients resistant to conventional therapy, rituximab, or our Dsg3-Fc and Dsg3-anti-CD3 approaches.

[0174] method.

[0175] Site-specific modification of proteins. Sortase is a bacterial transpeptidase that recognizes the "LPETG" motif and cleaves the bond between threonine and glycine to form a thioacyl intermediate, which is replaced by a probe containing triglycine (GGG-probe). Therefore, sortase can rapidly convert "protein-LPETG" to "protein-LPET-GGG-probe" products in near-complete yield, where the probe can be any biomolecule of interest ( Figure 4 ). We and others have used sortases to install fluorophores, polymers, radioisotopes, or secondary proteins onto biomolecules. We can use sortases to install chelators and fluorophores onto Dsg3 proteins and antibody fragments, and to make NC- and CC-fusion proteins that would otherwise be difficult or impossible to generate using traditional genetic methods.

[0176] Immunogenicity of the extracellular domain of Dsg3. Studies of PV patients have shown that 91%, 71%, 51%, 19% and 12% of patients have autoantibodies against the extracellular domains EC1, EC2, EC3, EC4 and EC5, respectively ( Figure 2 Small picture B, Fig.13 We used Dsg3-EC1-3 because it covers the majority of physiological anti-Dsg3 antibodies in PV patients and its generation is not as complicated as the full-size EC1-5 construct. We can also use EC1-4 and 1-5 constructs.

[0177] Plasmids and cell lines. We used three cell lines: 1) AK23 hybridoma cells, which produce anti-mouse Dsg3 antibodies that induce PV in mice. The AK23 antibody recognizes the EC1 domain and cross-reacts with human Dsg3-EC1; 2 and 3) Nalm-6 F779 and Nalm-6 PVB-28 cancer cell lines. Nalm-6 is a B-cell precursor leukemia cell line, and F779 and PVB-28 are cells engineered to express patient-derived anti-Dsg3 antibodies that recognize the Dsg3-EC1 and Dsg3-EC2 domains, respectively. In addition, we have obtained a plasmid for an anti-human Dsg3 antibody (P3F3) identified from a PV patient. The P3F3 antibody is an IgG1 antibody that specifically binds to the human Dsg3-EC1 domain and induces strong acantholysis when added to human keratinocytes.

[0178] Animal Studies. The efficacy of therapeutic agents can be tested in two validated PV mouse models:

[0179] Passive transfer model. In this model, we generated a passive monoclonal pemphigus mouse disease model by implanting an established hybridoma cell line (AK23; already available) that induces pemphigus. As previously described, we injected approximately 5 to 10 million AK23 hybridoma cells (which secrete anti-Dsg3 antibodies that cause a pemphigus phenotype) or unrelated hybridoma cells as controls into eight-week-old C57BL / 6J mice sensitized with 2,6,10,14-tetramethyl-pentadecane (pristane) (n=10 per group). In all experiments, animals were assigned to treatment / control groups based on the urn randomization method. We tested for disease establishment by analyzing serum anti-Dsg3 titers (by standard ELISA on days 3 and 10) and skin blisters (assessed by blinded investigators on days 2, 5, and 10). Based on the ELISA data, time points for tissue harvest were determined to observe acantholysis (by H&E staining). Peak disease time can be around day 7; mice can show hair loss, weight loss, and blistering in hair follicles and oral mucosa as well as AK23 autoantibodies with physiological anti-Dsg3 IgG levels (300RU / ml to 400RU / ml) produced by AK23 cells associated with epidermal keratinocytes ( Figure 5 Panels A to D).

[0180] Active transfer model. The AK23 model has advantages, however, treatment can overcome the rapidly proliferating hybridoma cells. Therefore, as a second model, we used an active PV immunization model that closely mimics the clinical phenotype of human disease, with a lower frequency of autoreactive Dsg3-specific B cells similar to what occurs clinically, and ultimately with high serum polyclonal autoantibody levels. In this model, we developed an active polyclonal pemphigus mouse disease model by first immunizing Dsg3- / - mice (JAX-002911) with recombinant extracellular domains of mouse Dsg3, followed by transfer of splenocytes into RAG2- / - mice. The transferred cells typically contain T cells and B cells, which may include Dsg3-reactive cells. Similar to observations made in the literature, without wishing to be bound by theory, animals may have poor growth ( Figure 5 Panel E) and develop mucocutaneous erosions with suprabasal acantholysis and vesicles ( Figure 5 Panels F to H). To assess clinical indicators, we compared autoantibody levels to physiological levels in PV patients (300 RU / ml to 400 RU / ml) using ELISA. When Dsg3-reactive antibodies equal or exceed this level, which (without wishing to be bound by theory) may occur within 3 to 4 weeks, treatment is initiated. Adoptive transfer of cells from Dsg3+ / - animals immunized with Dsg3 was used as a control 38 (n=10 mice / group).

[0181] monitor

[0182] Side Effects: Animals treated intravenously via the tail vein and appropriate controls were as described herein. For each treatment from both disease models, ten mice were maintained for at least 6 months after treatment. Anti-Dsg3 levels were measured by ELISA every 2 to 3 weeks to test long-term remission. Mice were tested by blinded investigators to examine skin lesions to ensure no disease recurrence. Without wishing to be bound by theory, mice may remain in complete remission. Fc-mediated approaches may or may not show some relapses, as with rituximab, but without wishing to be bound by theory, may respond with re-treatment. In view of clinical translation, the minority of patients who fail to respond to Dsg3-Fc therapy may have the option of radiotherapeutic agents and / or BCR-T cell engager approaches.

[0183] Susceptibility to infection: To test whether our therapy suppresses the immune system as a whole, C57BL / 6 mice can be infected with active LCMV-C113. Animals can be injected with AK23 hybridoma 21 days after infection, after which our treatment strategy is implemented according to the experimental design described herein. The viral load of infected mice and control mice can be compared 30 days after injection. Alternatively, mice can be challenged orally with Listeria monocytogenes 40 or intravenously with LCMV infection on day 7 after our PV therapy. The microbial load in the liver and spleen will be examined 10 days after infection and compared with mice infected only. In both experiments, and not wishing to be bound by theory, there will be no difference in viral load.

[0184] The ability of Dsg3-Fc fusion proteins to mediate killing of anti-Dsg3 B cells was tested.

[0185] Non-limiting exemplary results. We have prepared both mouse and human Fc fusion proteins: mDsg3-EC1-3-IgG2a (mFc) and hDsg3-EC1-3-IgG1 (hFc). The Fc regions from human IgG1 and mouse IgG2a were selected due to their high Fc-mediated killing activity. The protein was engineered to have a FLAG tag, a sortase recognition motif, and a His6 tag at the C-terminus. FLAG (an 8 amino acid sequence (DYKDDDDK)) can be used for Western blot and flow cytometry analysis, and is subsequently used to analyze the metabolic fate of the construct when used in vivo. The His6 tag is used for purification, and the sortase tag is used to introduce modifications site-specifically. We use mammalian Expi293F cells to express the two constructs, purify via Ni-NTA affinity columns, and characterize using SDS-PAGE and Western blot analysis, which confirms the formation of the construct ( Figure 6 Panel A to Panel B). Gly3-Alexa647 sortase substrate was synthesized and used to site-specifically label the fusion protein with Alexa Fluor 647. The sortase reaction was performed by mixing the construct (50 μM), Gly3-Alexa647 substrate (500 μM) and sortase (5 μM) at 4°C for 1 hour. The Alexa647-labeled construct was purified via size exclusion column chromatography, and labeling was further confirmed by in-gel fluorescence scanning of the construct ( Figure 6 Panel B). To characterize the functionality of the constructs, we used Alexa647-labeled mDsg3-EC1-3-mFc to stain anti-mDsg3 AK23 hybridoma and anti-hDsg3F779 cells. Cells were stained with affinity and specificity (at low nM concentrations) ( Figure 6Panel C) shows that the patient-derived BCR on F779 cells cross-reacts with the mouse Dsg3 protein. Nalm-6 cells used as a control did not show any binding ( Figure 6 Panel C). Similar experiments were performed using hDsg3-EC1-3-IgG1 (hFc) labeled with Alexa647, showing that the construct binds to F779 cells and also stains mouse AK23 cells (with Figure 6 Panel B to Panel C are similar). To further characterize the constructs, we performed an ELISA assay by first coating a plate with AK23 Ab and another plate with P3F3 (anti-human Dsg3). The results further showed that the human and mouse constructs we prepared specifically bound to both antibodies ( Figure 6 Panel D). P3F3 antibody was produced in Expi293F cells following the manufacturer's protocol. AK23 antibody was purified from AK23 hybridoma culture medium. Following a similar approach, we will generate mouse and human Dsg3-EC1-4 and Dsg3-EC1-5 fused to human and mouse Fc and will fully characterize their binding.

[0186] Establishment of Fc-mediated killing assay in vitro: First, we confirmed that Dsg3-Fc fusion binds to the Fcγ receptor of mouse macrophages with low nM affinity through its Fc (IgG2a) Figure 6 Panel E); control Nalm6 cells remained unstained. To determine whether the fusion protein could cause Fc-mediated killing, F779 target cells or AK23 target cells co-cultured with mouse RAW264.7 macrophages were treated with mDsg3-mFc fusion protein. After 24 hours, the 10 nM dose caused 65% and 60% killing of F779 cells and AK23 cells, respectively, while there was no killing of Nalm6 control cells or hybridoma control cells. At the 48 hour time point, we observed 94% killing of F779 cells, while there was no change in control Nalm-6 cells ( Figure 7 ). AK23 hybridoma cells release anti-Dsg3 antibodies into the culture medium, which neutralize the construct, similar to the physiological situation in PV patients. Despite this, we still observed similar effective killing between AK23 cells and F779 cells at a dose of 10 nM, indicating that antibodies against Dsg3 have minimal negative impact on the killing efficacy of the fusion protein. The dose dependence of killing can be evaluated, as this will have implications for animal studies and clinical translation. Similar experiments can be performed using mouse bone marrow-derived macrophage-autoantibodies by standard ELISA. Moreover, at the time of PBMC collection, normal B lymphocyte counts can be demonstrated by CD19 and CD20.

[0187] Animal studies

[0188] Treatment: To test the in vivo efficacy of Dsg3-Fc treatment, the fusion protein can be injected intravenously on day 0, day 2, or day 5 after AK23 injection (model 1). These time points can help us identify the relationship between disease burden and treatment effectiveness, i.e., determine whether treatments are preventive and / or whether they can rescue severe disease phenotypes. Treatment proteins can be used at varying concentrations (5 mg / kg to 15 mg / kg in a final volume of 100 μl 46, 47, injected IV via the tail vein) to find optimal conditions. This range can be determined based on the antibody concentration used for B cell depletion in the autoimmune mouse model. For the active disease model (model 2), treatment will be performed on day 0, day 14, or day 21 after adoptive cell transfer in Rag2- / - mice, as previous studies have reported that circulating anti-Dsg3 IgG is present in the serum of recipient Rag2- / - mice as early as day 4, then increases rapidly and reaches a plateau around day 21. Non-invasive readouts such as anti-Dsg3 ELISA, weight loss and skin lesions / erosions (n=10 mice for treated and control groups) can be performed at various time points (4, 10, 17, 25 and 35 days after treatment). The trends obtained from these data can be used to establish peaks in control mice that did not receive treatment. Studies have established a peak between days 10 and 20. After the peak time point, skin biopsies can be obtained for immunofluorescence and histological staining of the mucosal barrier. In both Model 1 and Model 2, soluble anti-Dsg3 antibodies can partially neutralize the killing ability of our constructs. In such a case, we will use different amounts of the construct to find the optimal dose (highest killing with the lowest off-target rate). Controls: For negative controls, Dsg1-Fc and Dsg3 mutant Fc (without Fc functionality) will be used at the same concentration as the treated protein. In addition and as a positive control, we will explore using anti-CD20 IgG (clone SA271G2) at a concentration of 250 μg per animal, as it has been shown to effectively deplete B cells in mice 48 (this may be more effective in Model 2, as AK23 hybridoma cells may or may not be completely depleted with anti-CD20 antibodies). Readout: The readout for the Model 1 experiment will be bioluminescent imaging (IVIS) of AK23 hybridoma cells (because they are luciferase positive), which allows for sensitive longitudinal measurements of AK23 cells. In addition, for both Model 1 and Model 2, serum anti-Dsg3 titers measured on days 5 and 14 after the start of treatment, blinded studies of skin erosions, immunofluorescence of mucosal samples for detection of IgG deposition, and histological assessment of the mucosal barrier can be performed. B cell counts can also be performed to ensure that they remain within normal levels during treatment. Without wishing to be bound by theory, treatment causes clinical and histological regression of the disease.

[0189] Additional Research

[0190] In vitro studies: Protein engineering and expression, cloning and synthesis of sortase peptides are routine in the PI laboratory, and without wishing to be bound by theory, there are no difficulties in the generation and scale-up of protein expression and peptide synthesis. However, in cases where the protein expression yield is very low for a particular construct, we can explore different approaches to address this problem: 1) re-optimize the codons for expression, 2) use a different signal peptide sequence, 3) use other systems for protein expression instead of Expi293F cells, such as CHO cells or insect cells. Without wishing to be bound by theory, soluble polyclonal anti-Dsg3 antibodies partially but not completely neutralize the effects of our constructs. Therefore, we can assess the killing ability of our constructs against F779 cells, PVB28 cells and AK23 cells in the presence of polyclonal PV serum IgG. Additionally, we do not see this as a limitation in clinical practice, as dosing of these constructs can be patient-dependent and based on the level of circulating anti-Dsg3 titers, similar but not directly analogous to drugs such as omalizumab (IgG1k anti-human IgE, used based on IgE levels). Additionally, in a real-world setting, our therapeutics could be used concurrently with other drugs that reduce anti-Dsg3 titers. Additionally, it was found that monoclonal and polyclonal anti-Dsg3 IgG had no significant effect on the killing capacity of CAAR T cells specific for B cells producing Dsg3 autoantibodies. 16. To further increase the efficacy of this fusion protein, we have designed and successfully expressed Dsg3-Fc fused to IL-2, which (without wishing to be bound by theory) can engage more cells and enhance killing. We can also explore other cytokines (e.g., IL-15). However, these approaches may or may not have some side effects. For negative control experiments, in addition to cells lacking anti-Dsg3 antibody expression and as an alternative, we have designed and prepared a plasmid for synthesizing the Dsg1-fusion, which we can now also express and use. In vivo studies: Long-term monitoring and any potential side effects can be performed as described above. We can carefully address the dose dependence and how it correlates with the presence of anti-Dsg3 autoantibody titers (via ELISA). With the widespread use of biologics, anti-drug antibodies have been reported for a variety of agents ranging from anti-TNFa to rituximab. Major immune adverse events (such as immune complex deposition) have been theorized but have not yet been realized in clinical practice. In cases where the biologic binds directly to highly circulating antibodies, such as in the case of omalizumab, dosing patients at high IgE levels did not result in immune adverse events. Similarly, without wishing to be bound by theory, the presence of anti-Dsg3 IgG in serum will not result in any major immune adverse events, but this will be monitored.

[0191] The ability of Dsg3-anti-CD3 fusions to mediate killing of anti-Dsg3 B cells was examined.

[0192] Synthesis of Dsg3 fusions with anti-CD3e scFv. The NC Dsg3-anti-CD3e fusion expression plasmid was designed to contain cDNA for hDsg3-EC1-3 and OKT3 anti-CD3e scFv. The OKT3 clone has been used in the clinic as the anti-CD3 portion of a bispecific T cell engager; CD3e is found on all mature T lymphocytes. The construct was designed to have Dsg3 on the N-terminus and anti-CD3e on the C-terminus, similar to other bispecific T cell engagers; in addition, this structure ensures that the EC1 to EC3 domains will be available for recognition by Dsg3-reactive B cells. A flexible (G4S)3 spacer was included between the Dsg3 protein and the scFv protein, similar to other bispecific T cell engagers. Expi293F cells were used to express the protein.

[0193] CC fusion using click chemistry: Without wishing to be bound by theory, by using sortase, we can site-specifically install a click handle at the C-terminus of the Dsg3 protein and the anti-CD3e scFv protein, which can then allow us to "click" them together using azide-alkyne click chemistry. This will lead to the production of CC fusions that are impossible to make by traditional genetic methods. Such methods are site-specific, so the product can retain its functionality. To establish this method, we can synthesize an anti-CD 19 click to anti-CD3 scFv fusion, similar to blinatumomab, because we can use it as a positive control for killing assays. We used the same blinatumomab sequence for both scFvs (which consisted of the anti-CD3 OKT3 clone). We first expressed the anti-CD3e scFv equipped with a sortase recognition tag (LPETG) at its C-terminus by bacteria. The anti-CD19 scFv was prepared similarly. Next, the Gly3-alkyne sortase substrate and the Gly3-azide sortase substrate were synthesized. The anti-CD3 escFv was installed with an alkyne substrate, and the anti-CD19 scFv was installed with an azide substrate, both installed at their C-termini via sortase. The click-functionalized scFvs were purified via FPLC and then clicked together via copper-mediated azide-alkyne cycloaddition chemistry ( Figure 8 Panel A). The product was purified via FPLC and characterized using SDS-PAGE and flow cytometry analysis, which confirmed that the clicked CC fusion stained both Nalm6 cells and human T cells with strong affinity. We will also use this method to prepare CC fusions of Dsg3-anti-CD3e. 2. Sortase-mediated synthesis of NC fusions: When and in cases where the expression of genetically fused heterodimeric proteins proves difficult, the click chemistry approach is an alternative to traditional genetic fusions. However, to provide a second alternative and to prepare a more "natural" fusion, without wishing to be bound by theory, by sortase, we can prepare NC fusions of Dsg3-anti-CD3e without any prior modification of either protein, as follows: Taking advantage of the reversibility of the sortase reaction (and without wishing to be bound by theory), a triglycine molecule (GGG) can be used to catalyze the formation of a CN protein fusion: Protein A is engineered to have a "LPETG" motif at the C-terminus, and Protein B will be engineered to have "LPETGGG" at the N-terminus. Addition of the sortase and triglycine molecule can remove the "LPET" moiety from Protein B and convert it to "Gly3-B". The in situ generated Gly3-B protein can then be reacted with Protein A to form the fusion product "A-LPET-GGG-B" without involving click chemistry ( Figure 8Panel B). The reaction can be carried out in a dialysis box, allowing excess GGG catalyst to leave the reaction mixture, which will further the reaction towards the formation of a fusion product. To establish this method, we prepared such an "anti-CD19-anti-CD3 scFv fusion". The anti-CD19 scFv has a "LPETG" sortase tag at its C-terminus. We engineered the anti-CD3 scFv protein to have the following sequence: "MHis6-LPETGGG-anti-CD3 scFv" (proteins always start with M because the methionine codon (ATG) is used as the start codon; His6 is used to facilitate purification). Next, we mixed the anti-CD19 and anti-CD3 scFv, Gly3 with the sortase, and allowed the reaction to proceed overnight at 4°C. Product formation was confirmed via SDS-PAGE analysis, and the fusion protein was purified via FPLC size exclusion chromatography ( Figure 8 Panel C); the fusion was used to stain Nalm6 cells (CD19+) and Jurkat cells (CD3+). Flow cytometry results confirmed that the fusion stained the cells with high affinity ( Figure 8 Panel D). This strategy is an unpublished method that can be widely used in the industry to prepare CN protein fusions that are difficult to express as genetic fusions. No prior modification of either protein is required, except for the introduction of a sortase tag in the cDNA plasmid. This method was used to prepare Dsg3-anti-CD3 epsilon fusions.

[0194] Mouse and human Dsg3-EC1-3 ( Fig. 9 Panel A to Panel B). Next, we used sortase to install Alexa647 ( Fig. 9 Panel A). To characterize the product, we stained anti-Dsg3 cells (F779 cells and AK23 cells). mDsg3-EC1-3 labeled with Alexa647 can stain cells with high affinity and specificity ( Fig. 9 Panel C). Nalm6 cells used as a control did not show any staining. We will follow both the click and direct sort-labeling approaches to prepare and fully characterize Dsg3-anti-CD3 fusion (mouse and human) proteins. We have also prepared and characterized anti-mouse CD3e scFv (clone 2C1) 61 .

[0195] The killing efficacy of the constructs will be measured. Positive anti-Dsg3 cell lines (AK23, F779, and PVB-28) and negative cell lines (Nalm6 and unrelated hybridomas) will be co-cultured with fresh human CD8+ cytotoxic T cells (E:T ratios of 1:1, 5:1, and 10:1). The chimeric Dsg3-anti-CD3e fusion protein will be incubated at 37°C in a standard cell culture incubator. The fusion protein will be used at varying concentrations to find the optimal conditions (10 μg / mL to 1 ng / mL). As a second control, cells will be incubated with culture medium only, and no cell death difference is expected between anti-Dsg3 cells and control cells. Flow cytometry analysis will be used to perform a standard live-dead analysis of the cells. ELISpot assay will be used to assess the production of IFN-γ as an indicator of T cell activation. Characterize the efficacy of this approach on patient PBMCs in an in vitro assay: Similar to Aim 1, hDsg3-anti-hCD3e fusion protein can be added to human PBMC cultures obtained from PV patients; healthy PBMCs can be used as controls. No additional T cells are added to the mixture because (without wishing to be bound by theory) the patient's own T cells are directed and activated to kill targeted anti-Dsg3 B cells. Varying concentrations of the fusion can be used to find optimal conditions (10 μg / mL to 1 ng / mL). Killing efficacy can be analyzed 4 hours, 12 hours, and 24 hours after addition of the fusion (n=10 for each experiment); analysis can be performed similarly to the Fc approach.

[0196] Animal studies using the Dsg3-anti-CD3e approach. Recombinant proteins can be injected intravenously on day 0, day 2, or day 5 after AK23 cell injection (model 1) at varying concentrations (0.5 mg / kg to 1 mg / kg) similar to those used in the tumor treatment setting in a final volume of 100 μl to find optimal conditions. For the active disease model (model 2), recombinant proteins will be injected on day 0, day 14, or day 21 after adoptive cell transfer in Rag2- / - mice (as described above). As a negative control, Dsg1-anti-CD3e complexes can be used at the same concentration as the treatment protein. For readout (as described in Aim 1), cells can be isolated from skin biopsies of treated and untreated mice, along with luciferase (for model 1), immunofluorescence and histological imaging, and anti-Dsg3 ELISA titers. Normalized counts of CD3+ cells will be analyzed by flow cytometry analysis on days 5, 14, and 20 after treatment. There may be an increase in T cell counts in mice injected with Dsg3-anti-CD3e treatment, confirming that the recombinant protein can recruit T cells. Long-term monitoring and any potential side effects will be performed as described herein.

[0197] Additional Research

[0198] In vitro studies: The sortase reaction can be monitored via SDS-PAGE and / or mass spectrometry. Typically, once we obtain >90% of the protein labeled with the sortase substrate, the product can be purified via size exclusion chromatography. The azide-alkyne cycloaddition reaction is a well-characterized reaction that is widely used for bioconjugation of proteins with near-complete yields. The final fusion construct can be further characterized by mass spectrometry, SDS-PAGE, flow cytometry, and immunoblot analysis. The synthesis of various modified peptides is routine in the laboratory, and (without wishing to be bound by theory) there are no difficulties in the generation and scale-up of the synthesis of modified peptides. However, some proteins can become less soluble when hydrophobic substrates are added. In cases where this becomes a problem, we will include a very hydrophilic small polyethylene glycol (PEG) spacer between the Gly3 and alkyne functional groups (e.g., Gly3-PEG5-propargyl alkyne). In addition, in cases where the alkyne-azide click reaction does not result in high product yields for a given construct, we can use alternative click handles that form stable oxime products (such as more hydrophilic aldehyde and aminooxy click handles), and we have extensive experience with this. We have included a small PEG3 spacer between Gly3 and the alkyne or azide functional groups in the sortase substrate molecule. Without wishing to be bound by theory, the PEG spacer may result in higher stability of the construct; in cases where a given fusion has low stability or has low solubility, the PEG spacer size may be varied. In addition, we can analyze whether the size of the spacer affects the killing ability of the construct. We have shown that our mouse and human Dsg3-EC1-3 constructs (expressed by bacteria and then refolded) bind with high affinity (low nanomolar) to all anti-Dsg3 cells and antibodies we have available. In addition, it was shown that glycosylation of Dsg3 does not play a significant role in its binding to patient anti-Dsg3 antibodies. Therefore, we will continue to use our established methods to prepare Dsg3 constructs. We will continue our optimization efforts to increase the yield of gene fusion expression through the alternatives already discussed in Aim 1 (such as codon optimization, different signal sequences and different expression systems) as it may be more relevant when considering clinical translation. For the Fc constructs discussed in Aim 1, all proteins have been and will be expressed in mammalian Expi293F cells as glycosylation is critical for Fc functionality and we already have good expression yields for Fc constructs (approximately 1 mg per 100 ml of Expi293 cells). In vivo studies: Without wishing to be bound by theory, a side effect of anti-CD3 treatment may be the engagement of CD4 T cells (e.g., T follicular helper cells (Tfh)) with autoreactive B cells, which may lead to their expansion and thus exacerbation of the disease.Without wishing to be bound by theory, this would not occur because the bispecific T cell engagers used in the clinic are effective in recruiting CD8 cytotoxic T cells to kill target cells. Without wishing to be bound by theory, the frequency of CD8 T cell recruitment may be higher than the frequency of recruited Tfh cells; this is because most, if not all, of the CD8 T cells bearing any TCR may be recruited to kill autoreactive Dsg3 cells, whereas engagement of CD4 T cells (expressing an irrelevant TCR) with autoreactive B cells is not expected to result in B cell expansion; it is possible that engagement of only a few CD4 T cells reactive to peptide-MHC complexes derived from Dsg3 may result in expansion of autoreactive B cells. Furthermore, there are no reports of the development of autoimmunity in patients who have received bispecific T cell engagers (e.g., blinatumomab), and given the not insignificant incidence of different types of B cell-mediated autoimmune diseases, this observation suggests that the occurrence of such an event is unlikely. However, we will monitor this issue. The active immunization model of PV (model 2) may be an ideal model for studying this question, and this model will be carefully evaluated by monitoring anti-Dsg3 titers, the number of Dsg3 autoreactive B cells, and the number and phenotype of CD4 T cells (especially Tfh cells). Similar to the Fc-mediated approach, the effect of anti-Dsg3 antibodies on this therapeutic is unlikely to be clinically significant; in addition, in a real-world setting, our therapeutic may be used concurrently with other drugs that reduce anti-Dsg3 titers. However, this question can be monitored and evaluated.

[0199] Study on the ability of α-emission labeled Dsg3 to kill anti-Dsg3 B cells.

[0200] Radiolabeling of Desmoglein-3 Protein. Among the available isotopes, actinium-225 ( 225 Ac)(t1 / 2=9.9d) has been used clinically25,71. 225 Ac labeling of antibodies can be performed via the well-characterized DOTA chelator molecule. We have synthesized the Gly3-DOTA sortase substrate and the site-specifically modified mDsg3-EC1-3 protein with this substrate, characterized the product and confirmed that the protein is still functional with high binding affinity to anti-Dsg3 cells ( Fig.10 ). Next, use 225 Ac radioisotope will be used to install DOTA-labeled Dsg3. Radio-HPLC analysis will be used to determine product formation and radiochemical yield. Purified will be assessed by incubation in PBS and in human serum at 37°C. 225To ensure that the radiolabeling does not affect the functionality of desmoglein, positive anti-Dsg3 cells and negative cells will be isolated from 225 Ac-Dsg3 will be incubated together for 30 minutes. The cells will be washed 3 times and the radioactivity will be measured. We expect the anti-Dsg3 cells to be radioactive, while the negative cells may or may not have any radioactivity. This confirms that the radiolabeling process has not compromised the binding capacity of the Dsg3 protein.

[0201] The anti-Dsg3 cells established were used to measure the killing efficacy of the radiolabeled constructs. Positive anti-Dsg3 hybridoma cells and negative cells were cultured in round-bottom 48-well plates. The radiolabeled 225 Ac-Dsg3 protein will be added to the cells. Radiolabeled recombinant constructs will be used at varying concentrations to find the optimal conditions (10 μCi / mL to 1 nCi / mL). As a control, cells will be treated with the same amount of 225 Ac-DOTA (not conjugated to Dsg3) is incubated with it, and no anti-Dsg3 cells are expected to be killed. Incubation with radiolabeled Dsg3 or control isotope will be carried out for 20 minutes, after which any unbound reagent / isotope will be washed off (3x) to prevent nonspecific cell death caused by radiation. Analysis will be performed via flow cytometry and standard live-dead analysis 4 hours, 16 hours, 24 hours and 48 hours after incubation of cells and radiolabeled Dsg3.

[0202] In vitro assays to evaluate 225 Efficacy of Ac radiolabeled Dsg3 constructs on PBMCs from PV patients. Similar to Aims 1 and 2, 225 Ac radiolabeled Dsg3 constructs will be added to human PBMC cells (both healthy and patient samples) and the mixture will be incubated at 37°C in a standard cell culture incubator. Varying concentrations of the construct will be used to find the optimal conditions (10 mCi / mL to 1 nCi / mL). As a control, cells will be incubated with the same amount of 225Ac-DOTA is incubated together. Incubation with radiolabeled Dsg3 or control isotope will be performed for 20 minutes, after which any unbound reagent / isotope will be washed off (3x) to prevent nonspecific cell death caused by radiation. Analysis will be performed via ELISpot assay for antigen-specific and total IgG B cell depletion at 4 hours, 16 hours, 24 hours and 48 hours after incubation with radiolabeled Dsg3. We will measure the percentage reduction of autoreactive anti-Dsg3 IgG and total IgG levels. In addition, analysis will be performed via flow cytometry and standard live-dead analysis of nonspecific cells (including B cells and T cells), which will serve as internal standards for determination. Control, inclusion and exclusion criteria will be the same as those mentioned in Objectives 1 and 2. The expected results will confirm the targeted killing of Dsg3 autoreactive B cells.

[0203] Animal studies using radiotherapy methods. Radiolabeled recombinant protein was administered to AK23 cells 0, 2, or 5 days after injection (Model 1). 225 Ac-labeled Dsg3 construct (approximately 30 kBq activity and 50 μg Dsg3 per animal) 72 ) are injected intravenously. We will use 225 Ac-DOTA (chelator molecule) will serve as a control (same amount of activity (about 30 kBq), about 3.0 μg DOTA per animal). For readout, cells will be isolated from skin biopsies of treated and untreated mice and activity will be measured using a gamma counter, along with luciferase, immunofluorescence and histological imaging and anti-Dsg3 ELISA titers. Following the experimental strategy as explained in Aim 1, an active immunization model will be developed. 2 Similar experiments were performed. In vitro biodistribution studies were performed as we have described. 29、30 Animals will be euthanized at 2, 6, 24, and 48 hours after injection. Next, their major organs and tissues will be isolated and weighed, and their radioactivity will be measured along with the injection standards ( 225 Ac-DOTA as a control). The results will be analyzed and reported as the percentage of injected dose per gram of tissue (% ID / g). Measurement of the circulating half-life will be performed by collecting blood drops at multiple time points and then measuring their activity.

[0204] Additional Research

[0205] In vitro studies: We have extensive experience with radiolabeling proteins. Radiolabeling can affect the binding affinity of autoreactive antibodies to the Dsg3 protein. This is likely due to the high positive charge of the actinium cation (3+). In the event that radiolabeling affects the binding ability of the Dsg3 protein, we will synthesize the sortase substrate with a PEG spacer (e.g. Gly3-PEG5-DOTA). This should allow for an appropriate distance between the Ac cation (3+) and the Dsg3 protein. The synthesis of peptides is routine in our laboratory. We chose to use 225 -Ac isotope, not only because it is already used in the clinic, but also because it has unique benefits over other existing isotopes, such as limited range in tissues, good linear energy transfer, relatively short half-life (about 10 days), and multiple (4 net) alpha particles emitted with each decay. 225 In the case of actinium, we can use 213 -Bismuth as an alternative. In vivo studies: A problem with radiotherapeutic agents is nephrotoxicity. We will monitor nephrotoxicity and use methods such as attachment of polyethylene glycol (PEG), a biologically inert and hydrophilic polymer, to reduce renal uptake. We have shown that pegylation reduces renal uptake of radiolabeled antibody fragments (by a factor of >10) in preclinical studies. In addition, pegylation has been shown to be safe in the clinic as there are several approved pegylated protein therapeutics. We will use PEGs of different sizes (5kDa, 10kDa, and 20kDa) to evaluate the effect of pegylation on kidney clearance. Alternatively, we can co-inject mice with 150mg / kg succinylated gelatin, which has been shown to reduce renal uptake and nephrotoxicity. We can evaluate the effect of pegylation on renal clearance by using PET isotopes ( 64 Cu and 89 Zr, which have t of about 12.7 hours and about 3.3 days, respectively. 1 / 2 ) labeled constructs to study the pharmacokinetics and tissue biodistribution of the constructs in vivo, with which we have extensive experience. Whole body PET images will reveal not only the tissue biodistribution and kinetics, but also whether any of the constructs can potentially sequester in any organ, which in turn can cause organ damage. Therefore, PET imaging experiments will reveal what the potential side effects may be, if any. We do have extensive experience with PET imaging. In vitro autoradiography will also be performed to quantitatively measure tissue biodistribution with very high sensitivity. Similar to the previous two methods, the effects of anti-Dsg3 autoantibodies on this therapeutic agent will be carefully evaluated. 225The half-life of Ac is relatively short (about 10 days). However, it is recirculated due to complexation with autoantibodies and through FcRn. 225 In the case of an increased circulating half-life of Ac-Dsg3, thereby enhancing side effects on cells that can absorb the complex, clinically used serotonin with a very short half-life (about 45 minutes) can be used. 213 -Bi isotope. This should address the problem of side effects resulting from complex formation between radiolabeled Dsg3 and autoantibodies. In view of clinical translation, this approach could be an option for patients who have failed existing treatments, with potential future applications to be extended to other autoimmune blistering diseases, for example, in paraneoplastic or immunotherapy-induced autoimmune blistering diseases when the use of immunosuppression is associated with worse outcomes. 83 Additionally, similar to the Fc-mediated and bispecific T cell engager approaches, in a real-world setting, radiation therapy approaches could be used concurrently with other drugs that reduce anti-Dsg3 titers and / or saturate FcRn, such as IVIG.

[0206] Additional in vivo studies: The passive transfer model has been established in Rag2- / - mice32,34. We can establish this model in immunocompetent WT mice and optimize the number of hybridoma cells required for this model. Alternatively, the AK23 passive transfer model in Rag2- / - will receive WT C57BL / 6 splenocytes, which can be similar to immunocompetent hosts. In addition, for the proposed treatments, we will perform toxicology screening by using primary human cells and high-throughput membrane proteome arrays to identify any off-target cytotoxic interactions for each of the developed treatments. Without wishing to be bound by theory, constructs containing Dsg3 will not incorporate themselves into desmosomes in the skin because they require an intact structure on the cell surface, including the transmembrane domain for potential long-term stability. Furthermore, extensive studies of Dsg3-CAAR T cells in animal models did not show any accumulation of Dsg3-CAAR in animal skin, and similarly, when human skin was transplanted into mouse skin, no hDsg3-CAAR T cells were detected in the transplanted skin, indicating that the Dsg3 constructs are not expected to incorporate themselves into desmosomes. This will be investigated by histological analysis. We can determine whether existing anti-Dsg3 antibodies bind to the agent thereby affecting biodistribution or causing interaction with cells expressing the Dsg3 autoantibody Fc receptor. This will be investigated in both animal models and by extensive histological, PET and flow cytometric analysis. Without wishing to be bound by theory, this will not be a significant problem because the biologics we are developing will have a short circulating half-life and, unlike adoptive cell therapies such as CAAR T cell therapy, will not remain in the recipient (mouse or eventual patient); the half-life of the therapeutics developed can be in only a few hours for radiotherapeutics and anti-CD3 fusions, and in a few hours to potentially days or even weeks for Dsg3-Fc constructs (which can be recycled via FcRn). To test whether our treatment has any adverse effects on other immune cell compartments, PBMCs will be collected from mice that have received our proposed therapy, and the percentages of Th1, Th2, Th17, Treg, and CD8 T cells will be analyzed by flow cytometric analysis. Age and sex matched unmanipulated WT B6 mice will be used as controls. Without wishing to be bound by theory, there will be no differences in the percentages of immune cell populations, indicating that there are no adverse long-term effects of the treatment.

[0207] The methods used herein for targeting autoreactive B cells and our strategies for developing these therapeutics (site-specific installation of radioisotopes, synthesis of CC fusions and NC sortase-mediated fusions) are unique. Our strategy for preparing Dsg3-Fc is safe and can replace the use of rituximab. The other two methods provide alternative options for patients who fail to respond to available treatments. Therefore, the compositions and methods described herein may not only transform the treatment of PV, but also open up pathways for developing treatments for several autoantibody / immune complex-mediated diseases to known antigen targets, ranging from other autoimmune blistering diseases (e.g., bullous pemphigoid, mucous membrane pemphigoid, acquired bullous epidermolysis bullosa, linear IgA bullous dermatosis), lupus subtypes, scleroderma, Goodpasture's disease, Graves' disease to immune-mediated vasculitis. Therefore, we believe that the proposed therapeutics can be considered a breakthrough addition to the therapeutic toolbox for autoimmune diseases.

[0208] Example 3

[0209] Pemphigus vulgaris is a destructive B cell-mediated autoimmune disease. Autoantibodies targeting desmoglein 3 (Dsg3), a desmosomal protein that is essential for intercellular adhesion of the skin and mucosa, are responsible for the disease phenotype. Standard treatment includes immunosuppressive drugs that systemically suppress the immune system. We have developed a targeted immunotherapeutic approach that specifically and precisely targets and depletes only autoreactive B cells that recognize Dsg3. Our in vitro and in vivo experiments show that this approach causes effective and specific depletion of autoreactive B cells. We can use peripheral blood mononuclear cells (PBMCs) obtained from PV patients at different stages of the disease to determine the efficacy and specificity of this approach, and perform additional in vivo studies using mouse models of passive and active disease. We will perform studies in dogs that develop a disease with a pathogenesis and phenotype similar to that of humans. Without wishing to be bound by theory, this approach can be translated into a clinical setting. The technology developed herein may have broader applications to all autoantibody-driven diseases by targeting autoreactive cells without causing overall immunosuppression.

[0210] background

[0211] Pemphigus vulgaris (PV) is a fatal autoimmune blistering disease characterized by painful blistering and erosions of the skin and mucous membranes that limits activities of daily living (e.g., eating, drinking), has an impact on a person's overall health and is associated with significant morbidity and mortality. 1至3PV is caused by the production of autoantibodies against desmoglein 3 (Dsg3), with or without antibodies against Dsg1, leading to epithelial detachment (acantholysis). 2、4至6 There is a therapeutic need for the treatment of pemphigus. There is no cure for PV; treatment strategies rely heavily on systemic steroids and immunosuppressive drugs with multiple systemic side effects. 7至9 Although anti-CD20 antibodies (eg, rituximab) 3 First-line option for moderate to severe disease, but associated with off-target immunosuppression (including blunted humoral responses to vaccines), with current real-life impacts and increased risk of infection (although lower than with traditional immunosuppressants) 10、11 and a high risk of recurrence after treatment 10至12 Currently in clinical trials, neonatal Fc receptor and Bruton's tyrosine kinase inhibitors cannot circumvent off-target immunosuppression. Early cell-based therapies (such as autologous polyclonal regulatory T cells13 and chimeric autoantigen receptor (CAAR) T cells) have been 14 ) cannot be globally immunosuppressive in cases where they are proven to be effective. However, cell-based therapies must be personalized, with specific requirements for manufacturing, storage, and transportation, which may not be feasible in resource-poor areas. Relapses in PV are often due to the expansion of the same autoreactive cells that were not exhausted during initial treatment. 2 Without wishing to be bound by theory, complete depletion of autoreactive B cells would provide a cure. Herein, we describe a treatment that targets specific autoreactive B cells using the autoantigen itself (Dsg3) and the commonly used Fc-mediated killing. This approach would selectively target autoreactive pathogenic cells without affecting overall immune function.

[0212] Compared to other autoimmune blistering diseases, pemphigus vulgaris affects a younger healthy group of patients (i.e., young / middle-aged adults, averaging 40 to 60 years old). Current existing treatment strategies are limited to immunosuppressive drugs, such as systemic steroids, mycophenolate mofetil, azathioprine, and rituximab, which carry with them the risk of infection, a higher risk of malignancy in the long term, and a blunted response to new vaccinations, with current real-life implications. The disease can be brought into remission with cycles of intensive immunosuppression, but the risk of relapse is as high as 80%. 10 Research shows that patients with pemphigus have a similar risk of post-traumatic stress as those following a cancer diagnosis, and both conditions can be life-threatening if they recur frequently. 16Patients with this disease group need targeted therapies that eliminate autoreactive cells without affecting their overall health and immune function. Clinicians treating these diseases have only a limited arsenal of therapies available, all of which carry a lot of toxicity, short-term and long-term adverse health effects, including life-threatening infections. From the perspective of insurance payers, targeted therapies can reduce overall overall health care costs by reducing the risk of infection in the near term, the risk of long-term malignancies, and reducing the number of visits, adjuvant therapies, and hospitalizations. This targeted non-immunosuppressive therapy may be attractive to patients, clinicians, and insurance payers alike.

[0213] The clinical effects of therapeutic agents are visible to the human eye, and there are commercially available serum tests for monitoring relapses. The disease prevalence in the United States is estimated to be 5.2 cases per 100,000 adults. 15 Patients may relapse during their lifetime, requiring repeated treatment. There is a higher incidence in people of Jewish descent (approximately 4 and 10 times the average) 15 , 17 Existing treatments (i.e., prednisone, mycophenolate mofetil, azathioprine, rituximab) and upcoming treatments (e.g., neonatal Fc receptor antagonists, Burton's tyrosine kinase inhibitors) are immunosuppressive or difficult to scale to global markets (e.g., CAART). Our approach is based on common shared self-antigens that can be manufactured without the need for personalization.

[0214] Non-limiting exemplary products / solutions

[0215] The treatment described herein can be used in an outpatient setting in a similar manner to rituximab (which can be given in an outpatient infusion center). The treatment will be used in the initial phase of treatment and in the event of a relapse. The disease population will be patients with mucosal dominant pemphigus vulgaris, with a clear goal of expanding to other autoimmune blistering diseases in the future, such as pemphigus foliaceus in the next step (where the major autoantigen is Dsg1). The treatment can replace the current standard of care rituximab (anti-CD20) because it is selective and does not have off-target effects / overall immunosuppression from the complete depletion of the B cell pool by rituximab. The antigen-Fc (Dsg3-Fc) fusion protein will effectively and specifically kill cells that recognize Dsg3. The Dsg3 portion of the construct will bind to the anti-Dsg3 BCR of autoreactive pathogenic B cells, and the Fc domain will induce Fc-mediated killing of cells that recognize Dsg3 by recruiting phagocytic cells and natural killer (NK) cells ( Fig.12Panel A). We have engineered and prepared mouse Dsg3 and human Dsg3 constructs fused to mouse IgG2a and human IgG1 Fc domains, respectively, to achieve maximum Fc-mediated cytotoxicity. We have shown that treatment is able to target and mediate killing of autoreactive B cells in both in vitro and in vivo studies.

[0216] Non-limiting exemplary data

[0217] We have prepared both mouse and human Fc fusion proteins: mDsg3-mIgG2a (mFc) and hDsg3-hIgG1 (hFc). We used the extracellular domains 1 to 3 (EC1 to 3) of the Dsg3 protein because it can be the immunogenic and pathogenic part ( Fig.13 ) 18 Human IgG1 and mouse IgG2a were selected due to their high Fc-mediated killing activity 19至21 . The protein was engineered to have a FLAG tag, sortase recognition motifs 22, 23, and a His6 tag at the C-terminus. FLAG, an 8 amino acid sequence (DYKDDDDK), can be used for western blot and flow cytometry analysis, and subsequently for analysis of the metabolic fate of the construct when used in vivo. The His6 tag is used for purification, and the sortase tag is used to site-specifically introduce modifications, such as attachment of a fluorophore. To characterize the functionality of the construct, we used Alexa647-mDsg3-mFc against the mDsg3AK23 hybridoma 24 and anti-hDsg3 F779 cells 14 (B lymphoma cell line (Nalm6) engineered with a patient-derived pathogenic anti-Dsg3 antibody) was stained. Cells were stained with high affinity and specificity (at low nM concentrations) ( Fig.12 Panel B), indicating that the patient-derived BCR on F779 cells cross-reacts with the mouse Dsg3 protein. Nalm-6 cells used as a control did not show any binding. Similar experiments were performed using hDsg3-hFc labeled with Alexa647, which confirmed that the construct strongly bound to F779 cells ( Fig.12 Panel B) and also stained mouse AK23 cells (with Fig.12 (Similar to panel B).

[0218] First, we confirmed that the Dsg3-Fc fusion binds to the Fc-g receptor on mouse macrophages through its Fc (IgG2a) with low nM affinity; control Nalm6 cells remained unstained. To determine whether the fusion protein could cause Fc-mediated killing, F779 target cells or AK23 target cells co-cultured with mouse RAW264.7 macrophages were treated with mDsg3-mFc fusion protein. After 24 hours, the 10 nM dose caused 65% and 60% killing of F779 cells and AK23 cells, respectively, with no killing of Nalm6 control cells or hybridoma control cells. At the 48 hour time point, we observed an impressive 94% killing of F779 cells, with no change in control Nalm-6 cells. AK23 hybridoma cells release anti-Dsg3 antibodies into the culture medium, which neutralize the construct, similar to the physiological situation in PV patients. Nevertheless, we still observed similar effective killing between AK23 cells and F779 cells at the 10 nM dose, indicating that antibodies against Dsg3 will have minimal impact on the killing efficacy of the fusion protein.

[0219] To establish the in vivo efficacy of the Dsg3-Fc construct, NSG (NOD-scid-γ) mice were pretreated with 600 mg / kg IVIG (to block nonspecific killing via FcγR) for 2 days prior to intravenous (iv) injection of luciferase-positive F779 cells (1 million) into the tail vein ( Fig.12 Panel C). On day 4 after F779 injection, 10x10 6 All mice were injected iv with Rag2- / - splenocytes, followed by intraperitoneal (ip) injection of 30 μg of fusion protein to the treatment group and ip injection of PBS to the control group (n=5 for each cohort). During the duration of the study, mDsg3-mFc was injected 5 times per week to ensure sufficient drug availability in the circulation. Disease progression was monitored by bioluminescent imaging and mouse body scoring. At BSC<2, PBMCs were collected via submandibular bleeding and animals were euthanized. The results showed that the control group had an average survival of 26 days, while the treatment group had a survival of 57 days. ( Fig.12 Panel D). Flow cytometric analysis of PBMCs from both groups showed nearly 100% antigen loss in the treated group ( Fig.12Panel E), shows that treatment is effective in mediating the exhaustion of antigen-positive F779 cells. It is worth noting that F779 cells are malignant and therefore rapidly proliferate. This is not the case in the clinic where pathogenic B cells have normal proliferation capacity. In addition, antigen loss is not a problem in patients: if the autoantigen is lost on pathogenic B cells, it will no longer be pathogenic. The lower dose that we can process is repeated to determine the lower limit of the dose required for a complete response.

[0220] Non-limiting exemplary strategies

[0221] The ability of Dsg3-Fc fusion proteins to mediate killing of anti-Dsg3 B cells was further tested in different mouse models of disease.

[0222] Passive transfer model. In this model, we developed a passive monoclonal pemphigus mouse disease model by implanting an established hybridoma cell line (AK23; already available) that induces pemphigus. 24、25 We will inject approximately 1 million AK23 hybridoma cells (which secrete anti-Dsg3 antibodies that cause a pemphigus phenotype) into NSG mice 24、25 In all experiments, animals will be assigned to treatment / control groups based on urn randomization. We will test for the establishment of disease by analyzing serum anti-Dsg3 titers (by standard ELISA on days 3 and 10) and skin blisters (assessed by a blinded investigator on days 2, 5, and 10). Based on the ELISA data, time points for tissue harvest will be determined to observe acantholysis (by H&E staining). Peak disease time is expected to be around day 7 24 ; We expected mice to show hair loss 24 , weight loss, and blistering in hair follicles and oral mucosa, as well as AK23 autoantibodies produced by AK23 cells associated with epidermal keratinocytes with physiological anti-Dsg3 IgG levels (300RU / ml to 400RU / ml) 26 .

[0223] Active transfer model. The AK23 model has advantages such as easy readout, however, processing can overcome the rapidly proliferating hybridoma cells. Therefore, as a second model, we will use an active PV immunization model that mimics the clinical phenotype of human disease, with a lower frequency of autoreactive Dsg3-specific B cells similar to what occurs clinically, and ultimately with high serum polyclonal autoantibody levels. In this model, we can develop an active polyclonal pemphigus mouse disease model by first immunizing Dsg3- / - mice with a recombinant extracellular domain of mouse Dsg3 (JAX-002911), after which splenocytes are transferred into RAG2- / - mice. 27、28 The transferred cells will contain T cells and B cells, which will include Dsg3 reactive cells. Similar to the observations made in the literature 27至29 , we expect animals to have poor growth and develop mucocutaneous erosions with suprabasal acantholysis and blisters. To assess clinical indicators, using ELISA, we will compare autoantibody levels with physiological levels in PV patients (300RU / ml to 400RU / m1) 26 When Dsg3-reactive antibodies equal or exceed this level, it is expected to occur within 3 to 4 weeks. 26、30 , treatment will be started. Adoptive transfer of cells from Dsg3+ / - animals immunized with Dsg3 will serve as controls 29 (n=10 mice / group).

[0224] To test the ability of antigen-Fc fusion proteins to mediate depletion of autoreactive B cells in dogs. Dogs, cats, and horses develop pemphigus with a pathogenesis similar to that of humans 31至37 Pemphigus is the most common autoimmune skin disease diagnosed in veterinary medicine, for which no cure exists and the prognosis remains poor. 31至37 Common autoantigens in canine pemphigus are Dsg3 (pemphigoid vulgaris) and Dsc1 (desmoglein-1; pemphigus foliaceus (PF)). 31、38至41 .

[0225] Because pemphigus in canines develops due to autoreactivity against desmosomal proteins and has a similar phenotype to humans, canine models can be used as a bridge between preclinical and human trials. To further assess the power of our targeted therapy and to set the stage for clinical translation, we will use our pre-tested approach in mice to treat dogs diagnosed with pemphigus. We will prepare similar constructs using canine Dsg3 and Dsg1 fused to canine IgG1 equivalent to human IgG1. 42The production of such proteins is now easy in our laboratory, and we anticipate no obstacles in making large quantities of these proteins. Improvement of lesions and circulating autoantibody titers during the first three months of treatment will be carefully assessed.

[0226] Successful completion can set the stage of clinical transformation for the method. Compositions and methods described herein can not only transform the treatment of pemphigus, but also open the way for developing the treatment for several autoantibodies / immune complex mediated diseases to known antigen targets, the range of these diseases is from other autoimmune blistering diseases (for example, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, acquired bullous epidermolysis, linear IgA bullous dermatosis), lupus subtype, psoriasis, scleroderma, Goodpasture's disease, Graves' disease to immune-mediated vasculitis. As an alternative, we have prepared the fusion of antigen-anti-CD3 antibody (Dsg3 is fused to anti-CD3 scFv antibody) so that T cells engage with targeted cells, similar to the bispecific T cell conjugate therapeutic agent available in the clinic. Although we are developing targeted therapy for pemphigus, compositions and methods described herein can be used for the treatment toolbox for autoimmune diseases.

[0227] References cited in this example

[0228] 1.Regezi JA, Sciubba J, Jordan RC. Oral pathology: clinical pathologiccorrelations. Elsevier Health Sciences; 2016.

[0229] 2. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zilikens D, Payne AS, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. PMCID: PMC5901732

[0230] 3. Murrell DF, S,Joly P,Marinovic B,Hashimoto T,Diaz LA,Sinha AA,Payne AS,Daneshpazhooh M,Eming R,Jonkman MF,Mimouni D,Borradori L,Kim SC,Yamagami J,Lehman JS,Saleh MA,Culton DA,Czernik A,Zone JJ,Fivenson D,Ujiie H,Wozniak K,Akman- A,Bernard P,Korman NJ,Caux F,Drenovska K,Prost-Squarcioni C,Vassileva S,Feldman RJ,Cardones AR,Bauer J,Ioannides D,Jedlickova H,Palisson F,Patsatsi A,Uzun Yayli S,Zillikens D,Amagai M,HertlM,Schmidt E,Aoki V,Grando SA,Shimizu H,Baum S,Cianchini G,Feliciani C,IranzoP,MascaróJM,Kowalewski C,Hall R,Groves R,Harman KE,Marinkovich MP,MaverakisE,Werth VP.Diagnosis and management of pemphigus:Recommendations of aninternational panel of experts.J Am Acad Dermatol.2020March:82(3):575-585.el.PMCID:PMC7313440

[0231] 4.MaskedJM, A,Liu Z,Ding X,Swartz SJ,Fairley JA,DiazLA.Mechanisms of acantholysis in pemphigus vulgaris:role of IgG valence.ClinImmunol Immunopathol.1997Oct:85(1):90-96.PMID:9325074

[0232] 5.Anhalt GJ,Labib RS,Voorhees JJ,Beals TF,Diaz LA.Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with thedisease Med.1982 / 5 / 20:306(20):1189-1196.PMID:7040962

[0233] 6.Furue M,Kadono T.Pemphigus,a pathomechanism ofcantholysis.Australian J Dermatol.2017Aug 2017:58(3):171-173.PMID:28211055

[0234] 7.Ahmed AR,Moy R.Death in pemphigus.J Am Acad Dermatol.1982August:7(2):221-228.PMID:7130483

[0235] 8.Tavakolpour S,Mahmoudi H,Balighi K,Abedini R,DaneshpazhoohM.Sixteen-year history of rituximab therapy for 1085pemphigusvulgarispatients:A systematic review.Int Immunopharmacol.2018Jan:54:131-138.PMID:29132070

[0236] 9. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard M-A, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P, French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. May 20, 2017; 389(10083): 2031-2040. PMID: 28342637

[0237] 10. Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus. JAMA Dermatol. December 1, 2019; 155(12): 1404.

[0238] 11.Wang HH,Liu CW,Li YC,Huang YC.Efficacy of rituximab for pemphigus:a systematic review andmeta-analysis of different regimens.Acta DermVenereol.2015 / 11 / 95(8):928-932.PMID:25881672

[0239] 12.Mahmoudi H,Balighi K,Tavakolpour S,Daneshpazhooh M.Unexpected worsening of pemphigus vulgaris afterrituximab:A report of three cases.IntImmunopharmacol.2019Jun:71:40-42.PMID:30877872

[0240] 13.Esensten JH,Muller YD,Bluestone JA,Tang Q.Regulatory T-cell therapy for autoimmune and autoinflammatory diseases:The next frontier.JAllergy Clin Immunol.2018 / 12 / 142(6):1710-1718.PMID:30367909

[0241] 14.Ellebrecht CT,Bhoj VG,Nace A,Choi EJ,Mao X,Cho MJ,Di Zenzo G,Lanzavecchia A,Seykora JT,Cotsarelis G,Milone MC,Payne AS.Reengineeringchimeric antigen receptor T cells for targeted therapy of autoimmune disease.Science.2016Jul8:353(6295):179-184.PMCID:PMC5343513

[0242] 15.Wertenteil S,Garg A,Strunk A,Alloo A.Prevalence Estimates forPemphigus in the United States:A Sex-and Age-Adjusted Population Analysis.JAMA Dermatol.2019Feb 1:155(5):627-629.PMCID:PMC6506879

[0243] 16.Wei EX,Li SJ,Mostaghimi A.Br J Dermatol.2020April:182(4):1044-1045.PMID:31545508

[0244] 17.Vodo D,Sarig O,Sprecher E.The Genetics of Pemphigus Vulgaris.FrontMed.2018Aug 14:5:2

[0245] 18.Ohyama B,Nishifuji K,Chan PT,Kawaguchi A,Yamashita T,Ishii N,Hamada T,Dainichi T,Koga H,Tsuruta D,Amagai M,Hashimoto T.Epitope spreadingis rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules.J Invest Dermatol.2012April:132(4):1158-1168.PMID:22277941

[0246] 19.Bruhns P.Properties of mouse and human IgG receptors and their contribution to disease models.Blood.20126 / 14 / 119(24):5640-5649.PMID:22535666

[0247] 20. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. PMCID: PMC4202688

[0248] 21. Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. May 5, 2020;13(1):45. PMCID: PMC7201658

[0249] 22. Cong M, Tavakolpour S, Berland L, H, Andreiuk B, Rakhshandehroo T, Uslu S, Mishra S, Clark L, Rashidian M. Direct N- or C-Terminal Protein Labeling Via a Sortase-Mediated Swapping Approach. Bioconjug Chem. November 17, 2021;32(11):2397-2406. PMID: 34748323

[0250] 23. Guimaraes CP, Witte MD, Theile CS, Bozkurt G, Kundrat L, Blom AEM, Ploegh HL. Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions. Nat Protoc. September 2013;8(9):1787-1799. PMID: 23989673

[0251] 24. Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T, Koyasu S, Nishikawa T, Amagai M. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol. February 15, 2003; 170(4): 2170 - 2178. PMID: 12574390

[0252] 25. Shimizu A, Ishiko A, Ota T, Saito H, Oka H, Tsunoda K, Amagai M, Nishikawa T. In vivo ultrastructural localization of the desmoglein 3 adhesive interface to the desmosome mid-line. J Invest Dermatol. May 2005; 124(5): 984 - 989. PMID: 15854040

[0253] 26. Schmidt E, C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, W, Hashimoto T, E - B, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. May 2010; 19(5): 458 - 463. PMID: 20163452

[0254] 27.Takae Y,Nishikawa T,Amagai M.Pemphigus mouse model as a tool toevaluate various immunosuppressive therapies.Exp Dermatol.2009March:18(3):252-260.PMID:18643850

[0255] 28.Aoki-Ota M,Tsunoda K,Ota T,Iwasaki T,Koyasu S,Amagai M,NishikawaT.A mouse model of pemphigus vulgaris by adoptive transfer of naivesplenocytes from desmoglein 3knockout mice.Br J. Dermatol.2004Aug:151(2):346-354.PMID:15327541

[0256] 29.Amagai M,Tsunoda K,Suzuki H,Nishifuji K,Koyasu S,Nishikawa T.Useof autoantigen-knockout mice in developing an active autoimmune disease modelfor pemphigus.J Clin Invest.2000March:105(5):625-631.PMCID:PMC292455

[0257] 30.Lee J,Lundgren DK,Mao X,Manfredo-Vieira S,Nunez-Cruz S,WilliamsEF,Assenmacher CA,Radaelli E,Oh S,Wang B,Ellebrecht CT,Fraietta JA,MiloneMC,Payne AS.Antigen-specific B cell depletion for precision therapy ofmucosal pemphigus vulgaris.J Clin Invest

[0258] 31. Tham HL, Linder KE, Olivry T. Deep pemphigus (pemphigus vulgaris, pemphigus vegetans and paraneoplastic pemphigus) in dogs, cats and horses: a comprehensive review. BMC Vet Res. December 2020; 16(1): 457.

[0259] 32. Mueller RS, Krebs I, Power HT, Fieseler KV. Pemphigus foliaceus in 91 dogs. J Am Anim Hosp Assoc. June 2006; 42(3): 189 - 196. PMID: 16611930

[0260] 33. Levy BJ, Mamo LB, Bizikova P. Detection of circulating anti - keratinocyte autoantibodies in feline pemphigus foliaceus. Vet Dermatol. October 2020; 31(5): 378 - e100. PMID: 32372490

[0261] 34. Preziosi DE. Feline Pemphigus Foliaceus. Vet Clin North Am Small Anim Pract. January 2019; 49(1): 95 - 104. PMID: 30227972

[0262] 35. Vandenabeele SIJ, White SD, Affolter VK, Kass PH, Ihrke PJ. Pemphigus foliaceus in the horse: a retrospective study of 20 cases. Vet Dermatol. December 2004; 15(6): 381 - 388. PMID: 15585014

[0263] 36.Zabel S,Mueller RS,Fieseler KV,Bettenay SV,Littlewood JD,WagnerR.Review of 15 cases of pemphigus foliaceus in horses.Vet Rec.2005Oct.22:157(17):505-509.PMID:16244232

[0264] 37.Goodale E.Foliaceous pemphigus.Can Vet J.2019March:60(3):311-313.PMCID:PMC6380263

[0265] 38.Olivry T,LaVoy A,Dunston SM,Brown RS,Lennon EM,Warren SJ,PrisayanhP,Müller EJ,Suter MM,Dean GA.Desmoglein-1is a minor autoantigen in dogs withpemphigus foliaceus.Vet Immunol Immunopathol.2006April15:110(3-4):245-255.PMID:16293316

[0266] 39.Bosch-Amate X,Iranzo P,Ivars M,MascaróGaly JM, A.Anti-Desmocollin Autoantibodies in Autoimmune Blistering Diseases.FrontImmunol.20219 / 10 / 12:740820.

[0267] 40.Bizikova P,Dean GA,Hashimoto T,Olivry T.Cloning and establishmentof canine desmocollin-1 as a major autoantigen in canine pemphigusfoliaceus.Vet Immunol Immunopathol.2012Oct 15:149(3-4):197-207.PMID:22884397

[0268] 41.Bizikova P,Linder KE,Olivry T.Immunomapping of desmosomal andnondesmosomal adhesion molecules in healthy canine footpad,haired skin andbuccal mucosal epithelia:comparison with canine pemphigus foliaceus serum immunoglobulin G staining patterns.Vet Dermatol.2011April:22(2):132-142.PMID:20738839

[0269] 42.Miyakawa S,Nomura Y,Sakamoto T,Yamaguchi Y,Kato K,Yamazaki S,Nakamura Y.Structural and molecular basis for hyperspecificity of human immunoglobulin aptamer RNA G.RNA.2008Jun:14(6):1154-1163.PMCID:PMC2390795

[0270] Example 4

[0271] mDsg3(EC13)-mFc(SEQ ID NO.1):

[0272]

[0273] hDsg3(EC13)-hFc(SEQ ID NO.2):

[0274]

[0275]

[0276] mDsg3(EC14)-mFc(SEQ ID NO.3) .

[0277]

[0278] hDsg3(EC 14)-hFc(SEQ ID NO.4) .

[0279]

[0280]

[0281] hDsg3(EC1-5)-hFc(SEQ ID NO.29)

[0282]

[0283] mDsg3(EC1-5)-mFc(SEQ ID NO.30)

[0284]

[0285]

[0286] hDsg1(EC1-4)-hFc(SEQ ID NO.31)

[0287]

[0288] mDsg1(EC1-4)-mFc(SEQ ID NO.32)

[0289]

[0290]

[0291] Human Dsg3 amino acid sequence (SEQ ID NO.5)

[0292]

[0293] Human Dsg1 amino acid sequence, isoform 1 (SEQ ID NO.6)

[0294]

[0295] Human Dsg1 amino acid sequence, isoform 2 (SEQ ID NO. 7)

[0296]

[0297] Example 5

[0298] Pemphigus vulgaris (PV)

[0299] -A destructive, chronic autoimmune disease that can be characterized by painful blistering of the skin and mucous membranes

[0300] -Can be life-threatening, with a mortality rate of about 5% to 15%. Without treatment, 8 out of 10 people die within a year

[0301] - U.S. prevalence: 30,000 to 40,000 cases; WW incidence: 1 to 10 cases per million people

[0302] - Usually not inherited and is triggered later by environmental factors

[0303] - Caused by the production of self-Abs against desmoglein 3 (Dsg3) presented on B cells

[0304] -Dsg3 is a calcium-binding transmembrane glycoprotein component of desmosomes in vertebrate epithelial cells

[0305] -Desmosomes are cell-cell junctions between epithelial, cardiac, and certain other cell types

[0306] - No cure

[0307] -Treatment strategy

[0308] - Systemic steroid use and / or immunosuppressive medications

[0309] -Anti-CD20 antibody (eg, rituximab) as a first-line option (targets all B cells)

[0310] - Off-target immunosuppressive effects, including increased risk of infection

[0311] -High risk of recurrence after treatment

[0312] - Depletion of B cells presenting anti-Dsg3:

[0313] - Caballetta Bio: Potential treatment based on chimeric autoantibody receptor T cells (CAAR-T) (IND approved)

[0314] - New strategies need to be added

[0315] Selective Depletion of Anti-Dsg3-Ab Presenting B Cells: Two Non-Limiting Exemplary Methods

[0316] A) "Fc-mediated ″

[0317] - Similar to rituximab, but now selective for Dsg3-B cells (safer / less side effects)

[0318] - Circumventing technical challenges / costs of CAAR-T (autologous cell therapy)

[0319] B) "BCR-effector cell engagers, including BCR-T cell engagers"

[0320] -Selectivity

[0321] - General - Autoantibodies / immune complex-mediated diseases against known antigenic targets

[0322] -Bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, linear IgA bullous dermatosis

[0323] - Lupus subtypes, scleroderma, Goodpasture's disease, Graves' disease

[0324] - Demonstrated in vitro binding of Dsg3-Fc fusion to mouse Fcγ receptors of mouse macrophages and 94% killing of target B cells (at 10 nM) within 48 hours

[0325] - Developed cell lines for production of mouse protein constructs to work on in vivo models

[0326] - We could show in vitro effects on peripheral blood mononuclear cells (PBMCs) from PV patients with autoreactive B cells against the Dsg3 protein (different disease stages)

[0327] Non-Limiting Examples of the Subject Matter Described Herein

[0328] -Fc-Dsg3 fusion construct sequence

[0329] -Processing of PV

[0330] Example 6

[0331] Non-limiting exemplary methods for attaching a therapeutic moiety, an imaging moiety, a capture moiety, or a combination thereof

[0332] In certain embodiments, the sortase technology can be used to site-specifically attach any biomolecule of interest at the C-terminus of a protein. In certain clinical embodiments, biomolecules of interest can also be attached non-specifically, for example, via the reaction of maleimide with free cysteine ​​or the reaction of NHS reactive groups with free amines of lysine side chains.

[0333] Certain embodiments may include multiple antigens on a single fusion protein. Embodiments include a knob-hole Fc. Under one embodiment, the antigen is placed on the hole, and the second antigen is placed on the knob. Such embodiments allow for the inclusion of two major antigens in one drug. By way of example, an embodiment may include a Dsg3-knob and a Dsg1-hole, or vice versa. Embodiments may include a specific extracellular (EC) domain of Dsg1 or Dsg3, for example, as an antigen included in these therapeutics. Such embodiments may be used in treatments for patients with pemphigus.

[0334] Various embodiments may be used in the treatment of autoimmune disorders.

[0335] Exemplary autoimmune disorders are provided in U.S. Pat. No. 7,332,168, which is hereby incorporated by reference in its entirety. Non-limiting examples of autoimmune disorders (and exemplary autoantigens suitable for use in certain therapeutic constructs) are provided below:

[0336] Paraneoplastic pemphigus (primarily IgG Abs against thrombolysins (involucrin, parathrombolysin, desmoplakin I, desmoplakin II, exothrombolysin, plectin, BP230), cadherins (Dsg3, Dsg1, Dsc1, Dsc2, Dsc3), α2-macroglobulin-like molecules)

[0337] IgA pemphigus: IgA against Dsg1, Dsg3, Dsc1, Dsc2, Dsc3

[0338] Pemphigus vegetative: IgG against Dsg3, Dsg1, Dsc3

[0339] Pemphigus erythematosus: IgG Dsg1

[0340] Pemphigus herpetiformis: IgG Dsg1, Dsg3, Dsc1, Dsc3

[0341] Drug-induced pemphigus: IgG Dsg1, Dsg3

[0342] Bullous pemphigoid: Anti-IgG against BP180 (NC16A domain), BP230

[0343] Lichen planus pemphigoid: IgG against BP180 (NC 16A) domain, BP230

[0344] Pemphigoid gestationis: Anti-IgG against BP180 (NC16A domain; 90% of cases), BP230 (less prevalent)

[0345] Linear IgA dermatosis: IgA targeting the BP180NC16A / LABD97 / LAD-1 domain and BP 230

[0346] Mucous membrane pemphigoid: IgG / IgA against BP180 [NC16A domain / C-terminal epitope], laminin 332, BP230, α6β4 integrin, and collagen VII

[0347] Anti-laminin gamma 1 / p200 Pemphigoid: IgG against laminin gamma 1 (p200)

[0348] Epidermolysis bullosa acquisita: IgG against type VII collagen

[0349] Dermatitis herpetiformis: IgA / G against epidermal transglutaminase, tissue transglutaminase, endomysium, and deamidated prolamins

[0350] Myasthenia gravis

[0351] Graves' disease

[0352] Immune thrombocytopenic purpura

[0353] Psoriasis

[0354] Vitiligo

[0355] Systemic lupus erythematosus

[0356] Type 1 diabetes

[0357] Rheumatoid arthritis

[0358] Multiple sclerosis

[0359] Crohn's disease

[0360] Ulcerative colitis

[0361] Addison's disease

[0362] Sjögren's syndrome

[0363] Hashimoto's thyroiditis

[0364] Autoimmune vasculitis

[0365] Pernicious anemia

[0366] Celiac disease

[0367] Ankylosing spondylitis

[0368] Behcet syndrome

[0369] Congenital adrenal hyperplasia

[0370] Goodpasture's syndrome

[0371] Hereditary hemochromatosis

[0372] Idiopathic membranous glomerulonephritis

[0373] Narcolepsy

[0374] Sarcoidosis

[0375] Autoimmune kidney diseases, e.g., see the 124 autoantigens described in Zhang W, Rho Jh, Roehrl MW, Roehrl MH, Wang JY (2019) A repertoire of 124 potential autoantigens for autoimmune kidney diseases identified by dermatan sulfate affinity enrichment of kidney tissue proteins. PLoS ONE 14(6), which is hereby incorporated by reference in its entirety.

[0376] Example 7

[0377] Background and significance. Pemphigus vulgaris (PV) is a devastating autoimmune disease characterized by painful blistering of the skin and mucous membranes. 1至4 Desmoglein, part of the cadherin family, is the major cellular glue between keratinocytes in stratified epithelia. Autoantibodies against desmoglein molecules inhibit their adhesive function, causing a loss of cell-cell adhesion known as acantholysis. 5、6 In addition, autoantibody interference in cell-cell adhesion triggers cellular signaling pathways that enhance pathological autoimmune responses and contribute to acantholysis. 2、3、7 Mucosal-predominant PV is caused by the production of autoantibodies against desmoglein-3 (Dsg3), resulting in painful mucosal erosions. 8、2、9 ( Fig.14 Oral mucosal erosions are particularly painful and troublesome for patients, causing difficulty in eating and drinking. Mucosal erosions can also occur in other mucosal services, including the nasal mucosa, vaginal mucosa, perianal mucosa, laryngeal mucosa / esophageal mucosa, urogenital mucosa, and conjunctival mucosa ( Fig.14 There is no cure for PV; treatment strategies typically include systemic steroids and immunosuppressive drugs. 10至22 Anti-Dsg3 antibodies from autoreactive B cells are the main driver of mucosal-dominant PV 23、24 A direct role for pathogenic autoantibodies in pemphigus has been established, and monovalent autoantibodies have been shown to be sufficient to cause the disease. 8、25、26。 Although anti-CD20 antibodies (eg, rituximab) have become the first-line option for moderate to severe disease 11、4、27至30, but are associated with off-target immunosuppressive effects, including increased risk of infection (although lower than with conventional immunosuppressants), depletion of B cells, blunted humoral responses to vaccination or new infections for 6 or more months, and a high risk of relapse after treatment. 29、31至34 Treatment options include neonatal Fc receptor antagonists 35、36、 Blocking antibodies against B cell activating factor receptor (BAFF-R) 37 and Bruton's tyrosine kinase inhibitors (BTKi) 38、39 , some of which are currently not in clinical trials to circumvent off-target immunosuppression that blunts overall humoral immunity and carries a high risk of severe hypogammaglobulinemia, particularly in the case of neonatal Fc receptor antagonists 40 Additionally, early animal studies of BTKi showed efficacy but not complete cure against canine pemphigus foliaceus (a superficial variant of pemphigus in dogs driven by anti-desmoglein and anti-desmoglein autoantibodies); BTKi was not able to completely suppress autoantibody production in all canines, which is key to disease remission and cure. 39 Relapses in PV may be due to expansion of the same autoreactive cells that were not exhausted during initial treatment. 41至43 Therefore, complete depletion of autoreactive B cells could provide a cure. Early cell-based therapies (such as autologous polyclonal regulatory T cells) 44 and chimeric autoantigen receptor (CAAR) T cells 45 ) cannot be globally immunosuppressive in the cases where they are proven to be effective. However, cell-based therapies can be personalized for individual patients and have specific requirements for manufacturing, storage and transportation, which may not be feasible in all hospitals and clinics treating this disease group. Targeting the ICOS molecule (a co-stimulatory receptor expressed on T cells) (which affects the activity of T follicular helper cells that play a key role in the development of anti-Dsg3 pathogenic B cells) via anti-ICOS antibodies has shown results in delaying PV progression in animal models 46 ; however, this is a less direct way to target anti-Dsg3 antibody production than targeting anti-Dsg3 B cells themselves, and without wishing to be bound by theory, may only delay disease progression and may have a negative impact on the production of other protective antibodies. The development of targeted therapies that precisely deplete autoreactive cells while retaining protective immunity is an unmet need and will save many patients.

[0378] Dsg3 and Dsg1 have different expression patterns in skin and mucosa 1Dsg3 is expressed by the mucosa and in deeper layers of adult skin; in mucosal-dominant PV, Dsg1 and cadherins are unable to compensate for the loss of Dsg3 function in the mucosa. Anti-desmoglein autoantibodies play a pathogenic role in inducing loss of adhesion between keratinocytes and the formation of blisters and erosions. Experimental models have shown that Dsg3 and Dsg1 autoantibodies are directly pathogenic. 24、25、47 Anti-Dsg1 and anti-Dsg3 autoantibody levels may correlate with disease severity 48 Perifocal autoreactive B lymphocytes and T lymphocytes that work together to produce autoreactive antibodies are cellular players in the pathogenesis of the disease 49 ; Relapses may be associated with the return of autoreactive T and B cells that work together to cause the disease phenotype. Remissions are induced by reducing or depleting autoreactive antibodies that target desmoglein. Relapses are higher in patients in whom autoreactive B cells are not completely depleted. 50 Therefore, complete targeted depletion of autoreactive B cells that recognize desmoglein, the direct effector cells of the disease phenotype, is key to treating this group of autoantibody-driven diseases; autoreactive T cells alone (without autoreactive B cells) may not be able to induce the disease phenotype, as suppression of autoreactive B cells is critical to maintain remission. 43、51 .

[0379] We can address this problem by leveraging protein engineering techniques and generating new tools to precisely target and deplete pathogenic B cells without affecting the overall B cell pool. We can characterize mucosal-dominant PVs driven by anti-Dsg3 autoreactive B cells. In a mechanism similar to existing therapeutic monoclonal antibodies, including rituximab, 29 Without wishing to be bound by theory, Dsg3 protein fused to the Fc portion of an antibody can effectively and specifically mediate killing of autoreactive B cells that recognize Dsg3. The Dsg3 portion of the construct binds to the anti-Dsg3 B cell receptor (BCR) of the autoreactive B cells. The Fc portion then induces Fc-mediated killing of pathogenic B cells that recognize Dsg3 by recruiting phagocytic cells and natural killer (NK) cells. Fig.15Panel A). We have created murine and human Dsg3-Fc fusions and demonstrated that these constructs bind to their targets with specificity and affinity. In addition, our data demonstrate that the engineered proteins mediate in vitro and in vivo killing of established Dsg3-specific B cells with efficacy (complete responses observed in in vivo animal models). As an alternative approach, we can use Dsg3 protein fused to anti-CD3e scFv to direct and engage T cells to kill pathogenic B cells that recognize Dsg3 in a mechanism similar to existing bispecific T cell engager therapeutics in tumor therapy ( Fig.15 Small Figure B) 52、55 .

[0380] Without wishing to be bound by theory, the compositions and methods described herein may provide a platform for treatment not only for mucosal-predominant PV, other variants of pemphigus, but also for antibody-driven autoimmune diseases with known antigens.

[0381] There is no cure for pemphigus, and treatment is overall immunosuppressive. The Fc-mediated approach described herein (as well as our alternative T-cell-mediated approach) is unique in that it allows for precise targeting and depletion of Dsg3 autoreactive pathogenic B cells without affecting normal B cells. The data presented herein suggest that the compositions and methods described herein may not only transform the treatment of mucosal-dominant PV, but also open avenues for developing treatments for autoantibody / immune complex-mediated diseases with known antigenic targets, ranging from other autoimmune blistering diseases (e.g., mucocutaneous pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquired, linear IgA bullous dermatosis), lupus subtypes, scleroderma, Goodpasture's disease, Graves' disease to immune-mediated vasculitis. We believe that the proposed therapeutic agent may be considered a breakthrough addition to the therapeutic toolbox for autoimmune diseases.

[0382] Biological activity can be established using standardized in vitro assays. Extensive in vitro biodistribution and metabolic fate analysis can be performed. For each group of experiments, at least about 10 mice per group can be used to enable statistical analysis and illustrate inherent animal-to-animal variability. Where applicable, unpaired Student's 2-tail t-tests with significance level α <= 0.05 can be used to perform statistical analysis. Survival analysis can be performed using the log-rank (Mantel-Cox) test. Animals can be age-matched in each experiment. The experiment can include male and female mice to illustrate gender differences in response to therapeutic agents. Therapeutic studies in animals can be performed in a double-blind manner to ensure that observer bias is avoided. Non-commercial biological preparations and chemicals can be verified.

[0383] Site-specific modification of proteins. Sortase, a bacterial transpeptidase, can be used to modify proteins at the C-terminus (Figure 16, panel A) 54、55 The enzyme has a short recognition sequence (LPETG) that cleaves between T and G to form an intermediate thioester, allowing resolution by nucleophilic reaction with Gly3-containing substrates. The reaction can provide near quantitative yields and can be rapid, robust, and reproducible. We have used sortase to install functional groups on proteins, such as fluorophores, polymers, and radioisotopes. 56至61 Sortase-mediated site-specific labeling ensures that the binding ability of the protein is not impaired after labeling, and therefore, here we will use the sortase technology to modify the protein.

[0384] Immunogenicity of the Dsg3 extracellular domain. Studies of PV patients have shown that 91%, 71%, 51%, 19% and 12% of patients have autoantibodies against the extracellular domains EC1, EC2, EC3, EC4 and EC5, respectively ( Fig.13 ) 62 To establish this approach, we can use Dsg3-EC1-3, as it covers the majority of physiological anti-Dsg3 antibodies in PV patients, and its generation is not as complex as the full-sized EC1-5 construct. In addition, non-limiting exemplary results (below) show similar killing of autoreactive B cells independent of the targeted extracellular domain. Once established, we will prepare EC1-4 and 1-5 constructs, which may be more relevant when considering clinical translation, and to cover the full spectrum of anti-Dsg3 reactive pathogenic B cells.

[0385] Anti-Dsg3 cell lines and antibodies. We can use three cell lines and four anti-Dsg3 antibodies: 1) AK23 hybridoma cells, which produce anti-mouse Dsg3 antibody 63 that induces PV in mice. The AK23 antibody recognizes the EC1 domain and cross-reacts with human Dsg3-EC1; 2 and 3) Nalm-6F779 and Nalm-6 PVB28 cancer cell lines. Nalm-6 is a B-cell precursor leukemia cell line, and F779 and PVB28 are Nalm-6 cells engineered to express patient-derived anti-Dsg3 antibodies that recognize the Dsg3-EC1 and Dsg3-EC2 domains, respectively. 45 In addition, we have obtained plasmids targeting four anti-human Dsg3 antibodies (P3F3, P1F5, P5D4, and P5G6) identified from PV patients. 64 The P3F3 antibody is an IgG1 antibody that specifically binds to the human Dsg3-EC1 domain and induces strong acantholysis when added to human keratinocytes 64The P1F5 antibody, the P5D4 antibody, and the P5G6 antibody bind to the Dsg3-EC2 domain, the Dsg3-EC4 domain, and the Dsg3-EC1 domain, respectively, and together induce strong acantholysis 64 The combined monoclonal antibodies caused higher keratinocyte dissociation than any of them alone.

[0386] Dsg3-Fc fusion proteins were developed to target and mediate killing of anti-Dsg3 autoreactive B cells in an in vitro setting.

[0387] Development and characterization of mDsg3-mFc and hDsg3-hFc constructs. As discussed herein, to establish this approach, we developed the Dsg3-EC1-3 domain. Thus, we have produced both mouse and human Fc fusion proteins: mDsg3-EC1-3-IgG2a and hDsg3-EC1-3-IgG1 (from now on referred to as mDsg3-mFc and hDsg3-hFc). Human IgG1 and mouse IgG2a were selected due to their high Fc-mediated killing activity. 65至67. The protein was engineered to have a FLAG tag, a sortase recognition motif, and a His6 tag at the C-terminus (Fig. 16, panel A). FLAG (an 8 amino acid sequence (DYKDDDDK)) can be used for Western blot and flow cytometry analysis, and is subsequently used to analyze the metabolic fate and pharmacokinetics of the construct when used in vivo. The His6 tag is used for purification, and the sortase tag (LPETG) is used to introduce modifications site-specifically. We prepared plasmids for the two constructs in accordance with the established cloning technology, and confirmed the final sequence via Sanger sequencing. Then, we used mammalian HEK293 cells to express the two constructs, purified via Ni-NTA affinity columns, and characterized using SDS-PAGE and Western blot analysis, which confirmed the formation of the construct (Fig. 16, panel A to panel B). Gly3-Alexa647 sortase substrate was synthesized and used to site-specifically label the fusion protein with AlexaFluor647. The sortase reaction was performed by mixing the construct (50 μM), Gly3-Alexa647 substrate (500 μM) and sortase (5 μM) at 4 ° C for 1 hour. The construct labeled with Alexa647 was purified via size exclusion column chromatography, and the installation of the fluorophore was further confirmed by in-gel fluorescence scanning of the construct (Figure 16, panel B). In order to characterize the functionality of the construct, we used mDsg3-mFc labeled with Alexa647 to stain against mDsg3 AK23 hybridoma and anti-hDsg3 F779 and PVB28 cells. The cells were stained with large affinity and specificity (at a concentration of 10 nM) (Figure 16, panel C), indicating that the patient-derived BCR on F779 cells and PVB28 cells cross-reacted with the mouse Dsg3 protein. Nalm-6 cells used as a control did not show any binding, confirming the specificity of the construct (Figure 16, panel C). Similar experiments were performed using Alexa647 labeled hDsg3-hFc fusion protein, which confirmed its strong binding to F779 cells and PVB28 cells and also stained mouse AK23 cells, indicating that the AK23 anti-mouse Dsg3 antibody cross-reacts with the human Dsg3 protein (Figure 16, panel C). It is noteworthy that human Dsg3 is similar to mouse Dsg3 (86% sequence homology). 68 Functionally rescues Dsg3 deficiency in mice 69. To further analyze the constructs, we measured the EC50 values ​​of the mDsg3-mFc construct and the hDsg3-hFc construct by using different concentrations of Alexa647-labeled proteins. The results showed that hDsg3-hFc and mDsg3-mFc bound to F779 cells with an EC50 of 1.8±0.8nM and 2.3±0.9nM, respectively (Figure 16, panels D to E). To further characterize the constructs, we performed an ELISA assay by first coating a plate with AK23 antibody and another plate with P3F3 antibody (anti-human Dsg3). 64 , and then analyzed the binding of the constructs to the coated plates. The results further confirmed that the human and mouse constructs we prepared specifically bound to both anti-Dsg3 antibodies, but not to the control plate (Figure 16 panel F). The P3F3 antibody was prepared in Expi293F cells following the manufacturer's protocol. The AK23 antibody was purified from AK23 hybridoma culture media using a protein-G affinity column. Following a similar approach, we can generate mouse and human Dsg3-EC1-4 and Dsg3-EC1-5 fused to mouse IgG2a and human IgG1 Fc, and will characterize them similarly.

[0388] An Fc-mediated in vitro killing assay was established. First, we confirmed that the mDsg3-mFc construct binds to the Fcγ receptor of mouse macrophages through its Fc portion (IgG2a) with low nM affinity (Figure 16, Panel G); EC50 value of 2.3±0.8 nM); control Nalm6 cells remained unstained. To determine whether the fusion protein can cause Fc-mediated killing, F779 target cells co-cultured with mouse RAW264.7 macrophages (10:1 effector:target ratio) were treated with the mDsg3-mFc fusion protein. As low as 1 nM of the construct was able to mediate effective killing of F779 target cells (approximately 60% and approximately 80% killing after 24 hours and 48 hours, respectively, while there was no killing of Nalm6 control cells; Fig.17 Similar experiments were performed using PVB28 as target cells (which bind to EC2); the results showed similarly effective killing of target cells, indicating that treatment can mediate killing of different autoreactive cells regardless of the targeted epitope on Dsg3 ( Fig.17 The experiment was repeated with different doses of mDsg3-mFc (1 nM, 10 nM, and 100 nM) to investigate the effect of treatment concentration and any potential nonspecific killing that may occur at higher treatment concentrations. The results showed high killing rates of targeted cells (approximately 90% killing) at 10 nM and 100 nM without nonspecific killing against Dsg3-negative Nalm6 cells, indicating that the treatment remained highly effective and specific at the higher concentration range ( Fig.17We performed similar experiments using RAW264.7 macrophages as effector cells and F779 and PVB28 as target cells, but this time used the hDsg3-hFc construct (mouse Fcγ-receptors (FcγRs) are known to recognize human Fc; however, human FcRs do not recognize mouse Fc). 65 The results showed highly effective and specific killing similar to that of the mDsg3-mFc experiment described above ( Fig.17 We then repeated the experiment with a similar setup, but this time using THP1 cells. 70 (a widely used and established human monocytic cell line derived from AML patients) were used as effector cells, and the hDsg3-hFc construct was used as treatment. The results showed effective killing of target cells without killing of control anti-Dsg3 negative Nalm-6 cells ( Fig.17 We used a range of doses (0 nM, 1 nM, 10 nM and 100 nM) of hDsg3-hFc constructs for treatment ( Fig.17 ) were performed killing assays, and effective killing efficacy was observed for all concentrations tested, indicating that the treatment was effective at low concentrations and remained highly specific at high concentrations.

[0389] A potential question is whether the presence of anti-Dsg3 autoantibodies (as they occur in PV patients) can block the binding of the treatment to target cells and thus reduce or neutralize the treatment efficacy. To investigate this question, we first used the well-established AK23 hybridoma cells that release anti-Dsg3 antibodies into the culture medium. The AK23 antibodies recognize the EC1 domain on Dsg3, as discussed above, and can therefore potentially neutralize the treatment. The experiments were performed following the same setup as above. The results showed very effective killing of AK23 cells (with Raw cells or THP1 cells as effector cells, and with mDsg3-mFc or hDsg3-hFc as treatment), similar to what we observed for F779 cells and PVB28 cells ( Fig.17 ). To perform a more systematic analysis of the effect of the presence of anti-Dsg3 autoantibodies, we repeated the killing assay using AK23 cells and F779 cells as target cells, Raw cells as effector cells, 10 nM of mDsg3-Fc or hDsg3-Fc as treatment and following the same settings as above (10:1 effector:target ratio); however, this time we added a range of known amounts of AK23 antibodies to the mixture to assess whether the presence of anti-Dsg3 antibodies could affect the killing efficacy. Surprisingly, we observed no changes in the killing efficacy in any of the conditions tested (a range of 100 pM to 500 nM AK23 antibodies was tested; see Fig.18; the first two columns in each group are 24 hour assessments, and the next two columns are 48 hours). We repeated the assay using all four different cells (Nalm-6 as control, and then AK23, F779 and PVB28 as target cells), and this time used THP-1 cells as effector cells in the presence of 100 nM AK23 antibody and used different doses of hDsg3-hFc as treatment (0 nM, 1 nM, 10 nM and 100 nM). Surprisingly and similar to above, no blocking was observed, and effective killing was obtained under all conditions tested ( Fig.18 ). This suggests that the presence of autoantibodies against Dsg3 may have minimal negative impact on the killing efficacy of the Dsg3-Fc fusion protein.

[0390] To further evaluate this potential problem, and to characterize how the presence of polyclonal anti-Dsg3 antibodies may affect the efficacy of this approach, we have prepared four different patient-derived anti-Dsg3 antibodies P3F3 and P5G6 (binding to Dsg3-EC1), P1F5 (binding to Dsg3-EC 2), and P5D4 (binding to Dsg3-EC4). We have already prepared the P3F3 antibody, and production of the other three antibodies is ongoing. In the presence of a mixture of these five antibodies, we will repeat the killing assays against AK23 cells, F779 cells, and PVB28 cells (AK23, P3F3, P5D4, P5G6, P1F5) at a concentration range similar to the one we have done above. In addition, we will perform assays in which we will use a mixture of target cells (AK23, F779, PVB28) in the presence of a mixture of anti-Dsg3 antibodies to closely mimic physiological conditions. Without wishing to be bound by theory, treatment may continue targeted killing of polyclonal pathogenic B cells in the presence of polyclonal autoantibodies.

[0391] In summary, the in vitro data demonstrate that the Dsg3-Fc construct can efficiently and specifically mediate killing against Dsg3+ target cells even in the presence of anti-Dsg3 autoantibodies.

[0392] Patient PBMCs were used to characterize the efficacy of the human construct (hDsg3-hFc) in an in vitro assay. Without wishing to be bound by theory, we can characterize the efficacy of this method in killing pathogenic B cells without affecting normal B cells in the presence of polyclonal anti-Dsg3 IgG present in the patient's blood. We will obtain PBMCs 71 with confirmed autoreactive B cells against the Dsg3 protein from PV patients (at least n=10). PBMCs obtained from anti-Dsg3 positive patients at different disease stages (including: 1) treatment naive, and 2) disease relapse) will be cultured in round-bottom 48-well plates (n=10 for each group). hDsg3-hFc fusion protein (1 nM and 10 nM) will be added to the cells after incubation at 37°C in a standard cell culture incubator. No additional phagocytic cells will be added to the mixture because we expect that the patient's own phagocytic cells and NK cells present in the PBMCs will be able to kill the targeted anti-Dsg3+ pathogenic B cells. One and two days after incubation of cells and treatment (hDsg3-hFc), ELISpot assays will be performed to assess antigen specificity and total IgG B cell depletion. The results will show a reduction in the percentage of autoreactive anti-Dsg3 IgG compared to total IgG levels (total IgG levels are expected to be unaffected; therefore, used as a control). Analysis will be performed via flow cytometry and standard live-dead analysis (including B cells and T cells, which will serve as internal standards for the assay). In addition to using antibodies to gate for CD3+ cells, CD4+ cells, CD8+ cells, and CD20+ cells, we will also use fluorophore-labeled hDsg3 constructs (hDsg3-Alexa647) to stain PBMCs. hDsg3 protein (without Fc) is already available. We prepared hDsg3 protein (EC1-3) following a similar protocol to that used to prepare the described protein (standard cloning, expression, purification, and site-specific labeling via sortase to install Alexa647). This will allow gating of anti-Dsg3+ B cells present in the PBMCs of PV patients. Flow cytometric analysis before and after the assay, which includes staining with Alexa647-labeled Dsg3 protein, will show how effectively the anti-Dsg3 cells are targeted and killed. As a second control, healthy PBMCs will be used with the same settings to further confirm the observed results (here, we expect no changes). PBMCs of PV patients will be collected from patients who meet the following inclusion / exclusion criteria: Inclusion criteria: 1) PV proven by biopsy; 2) circulating anti-Dsg3 IgG autoantibodies by standard ELISA; 3) normal B lymphocyte counts demonstrated by CD19 and CD20 at the time of PBMC collection. Exclusion criteria: 1) Patients with known hematogenous malignancies (including B-cell and T-cell lymphomas / leukemias).Treatment within the previous 12 months and at the time of PBMC collection will be recorded, including any treatment that may affect PBMC levels or function. Without wishing to be bound by theory, pathogenic B cells in the patient's PBMCs may be effectively and specifically killed without affecting normal B cells.

[0393] We have prepared >150 mg of mDsg3-EC1-3-mFc, >150 mg of hDsg3-EC1-3-hFc, >200 mg of mDsg3-EC1-3, and >200 mg of hDsg3-EC1-3, which exceeds the amount required for the proposed experiments, and more can be prepared as needed. We will similarly prepare constructs containing mouse and human Dsg3-EC1-4-Fc and Dsg3-EC1-5-Fc. In the event that the protein expression yield is very low for a particular construct, we can explore different approaches to solve the problem, including but not limited to: 1) re-optimizing the nucleotide codons for expression, 2) using different signal peptide sequences, and / or 3) using other systems for protein expression instead of HEK293 cells, such as CHO cells, Expi293F cells, or insect cells.

[0394] Regarding the presence and neutralization of autoantibodies, the results indicate that the presence of autoantibodies (as they occur in the physiological conditions of PV patients) does not (or at least not completely) neutralize the process. Without wishing to be bound by theory, this is due to the dynamic and reversible nature of antigen-antibody interactions, which is in contrast to the irreversible process of killing target cells via effector cells. Furthermore, the clustering that occurs between effector cells and target cells (which occurs by bridging several Dsg3-Fc molecules of these two cells) may be stronger in affinity than the interaction of autoantibodies with Dsg3-Fc molecules, thereby driving the killing process forward even in the presence of autoantibodies. Importantly, antibodies can bind to different epitopes on the Dsg3 protein; therefore, many antibodies will have non-overlapping epitopes. Thus, even when autoantibodies bind to the Dsg3-Fc treatment constructs, the complex (antibody bound to Dsg3-Fc) can still bind to anti-Dsg3 BCRs (on the surface of pathogenic B cells) with non-overlapping epitopes and thus bridge the effector to the target cell facilitating cluster formation between the two cells and thus mediating killing of the target cell. Thus, given the many potential epitopes on the Dsg3 protein and the dynamic nature of the interaction, the likelihood that the Dsg3-Fc constructs will reach all pathogenic clones of the anti-Dsg3 BCR is still statistically high. Furthermore, and importantly, we do not view this as a limitation in clinical practice, as dosing of these constructs can be patient dependent, potentially based on the level of circulating anti-Dsg3 titers, similar to but not directly similar to drugs such as omalizumab (IgG1k anti-human IgE, used based on IgE levels). Additionally, in a real world setting, this therapeutic could be used concurrently with other drugs that reduce anti-Dsg3 titers, such as IVIG. 72至76 Another approach used in the clinic to reduce circulating anti-Dsg3 autoantibodies is plasma exchange and immunoadsorption, which can reduce the titer of circulating autoantibodies and is often used for patients with severe pemphigus. 77至80 Therefore, there are multiple ways to address this (potential) issue, and we will continue to assess this carefully as we proceed with our experiments and as discussed above. In addition, it was reassuring to find that monoclonal and polyclonal anti-Dsg3 IgG had no significant effect on the in vivo killing capacity of CAAR T cells specific for B cells producing Dsg3 autoantibodies. 45 . Therefore, not only the data, but also the efficacy of anti-Dsg3 CAR T cells suggest that circulating anti-Dsg3 antibodies do not block the effects of treatment. Another example (although not directly analogous to the current proposal) is the efficacy of B cell maturation antigen (BCMA) CAR T cells in multiple myeloma patients, most of whom have high levels of soluble BCMA antigen in the circulation due to shedding caused by γ-secretase.81 ; However and despite the presence of high levels of soluble BCMA in the circulation, patients receiving BCMACAR T cells have shown significant responses, indicating that BCMACAR T cells can effectively kill BCMA+ multiple myeloma cells even in the presence of soluble BCMA with specificity and efficacy. In a word, these observations show that the presence of soluble antigens (or autoantibodies) does not impair the activity of effector cells killing target cells. This may be due to the dynamic nature of the interaction, non-overlapping epitopes and the clustering effect between effector cells and target cells, as discussed above.

[0395] To further increase the efficacy of the Fc-mediated approach, we have designed and successfully expressed Dsg3-Fc fused to IL-2, which can engage more cells and enhance killing. In the context of this increased efficacy, we can also explore other cytokines (e.g., IL-15). For negative control experiments, in addition to cells lacking anti-Dsg3 antibody expression and as an alternative, we have designed and prepared a plasmid for synthesizing Dsg1-Fc fusions, which we can also express and use.

[0396] We were able to generate similar constructs for the Dsg1 protein. Dsg1 and Dsg3 are expressed throughout the squamous layer of the mucosa, however, Dsg3 is expressed at higher levels than Dsg1 1、3、23 . In the skin, although Dsg1 is expressed throughout the epidermis, it is more concentrated in the superficial layers. In contrast to Dsg1, Dsg3 is more concentratedly expressed in the lower part of the epidermis, including in the basal and parabasal layers, and to a lesser extent in the superficial layers. As a result of these different expression patterns in the skin and mucosa: i) Dsg3 appears as the major pathogenic antigen in patients with the mucosal-predominant type of pemphigus vulgaris, who develop deep erosions in their mucosa with no or minimal skin involvement (because Dsg1 can compensate for this in the skin); all mucosal-predominant PV patients have high levels of anti-Dsg3 IgG autoantibodies 3、23; ii) patients with high levels of anti-Dsg3 and anti-Dsg1 IgG autoantibodies develop the mucocutaneous type of pemphigus vulgaris and show deep erosions in the mucosa and skin; and iii) patients with pemphigus foliaceus (PF) have only high levels of anti-Dsg1 autoreactive antibodies and show only superficial skin blisters without mucosal involvement, indicating that Dsg1 is the major pathogenic autoantigen in PF. We can develop and characterize Dsg3-Fc fusion proteins that can be used to treat the mucocutaneous active type of PV. We can also prepare similar constructs against Dsg1. Without wishing to be bound by theory, patients with mucocutaneous PV can be treated with a mixture of Dsg3-Fc and Dsg1-Fc, and patients with PF can be treated with Dsg1-Fc. In addition, we can generate Dsg3-Dsg1-Fc knob-in-hole structures 82 (Dsg3-knob+Dsg1-hole), which allows heterodimerization of CH3 in the Fc part and can therefore target both Dsg1 and Dsg3 autoreactive pathogenic B cells.

[0397] In additional studies, we have generated Dsg3-EC1-3 fused to an anti-CD3e single-chain Fv (scFv) antibody fragment that can direct and enable T cells to target and kill pathogenic autoreactive B cells ( Fig.15 Panel B); this approach can bypass potential FcR saturation and provide an alternative if pathogenic B cells are resistant to killing via Fc-mediated approaches. For example, some patients show resistance to rituximab due to genetic polymorphisms, which results in reduced antibody-dependent cellular cytotoxicity 83至85 Without wishing to be bound by theory, the Dsg3-anti-CD3e construct will establish molecular clustering and formation of an immunological synapse between the target anti-Dsg3 B cells and T cells, which will thus lead to activation of the T cells. 52、53 And specifically kills targeted anti-Dsg3 B cells, leaving other B cells intact 52、53、86至88 Unlike in oncology applications, cytokine release syndrome is not expected in the treatment of autoimmune diseases, given that the load of autoreactive B cells is much lower than that against malignant clones. Therefore, the NC Dsg3-anti-CD3e fusion plasmid was designed to contain the cDNA for hDsg3-EC1-3 and the OKT3 anti-CD3e scFv. The OKT3 clone has been used in the clinic as the anti-CD3e part of a bispecific T cell engager 89, and therefore we chose to use this clone; notably, CD3e is found on all mature T lymphocytes. The construct was designed to have Dsg3 on the N-terminus and an anti-CD3e scFv on the C-terminus, similar to other bispecific T cell engagers; in addition, this structure will ensure that the most pathogenic Dsg3-EC1 and EC2 domains will be available for recognition by Dsg3-reactive B cells. A flexible (G4S)3 spacer / linker was included between the Dsg3 protein and the scFv protein, similar to other bispecific T cell engagers. The protein was expressed using HEK293 cells, purified via Ni-NTA beads and size exclusion chromatography, and further characterized by SDS-PAGE, anti-FLAG Western blot, and flow cytometric analysis. Flow cytometric analysis showed that the fusion protein bound to established anti-Dsg3 B cells and CD3+ Jurkat cells (human T cells) with high specificity and affinity, but not to control Nalm-6 cells ( Fig.19 ). We have produced >10 mg of protein and will produce more on demand.

[0398] The efficacy of Dsg3-Fc fusion proteins to target and mediate killing of anti-Dsg3 autoreactive B cells in vivo was tested.

[0399] In some embodiments, the Dsg3-Fc construct can mediate the expression of circulating anti-Dsg3 + Targeted depletion of autoreactive B cells. In some embodiments, the presence of autoantibodies does not affect targeted depletion.

[0400] To test the in vivo efficacy of Dsg3-Fc fusion proteins for specific targeting and depletion of circulating anti-Dsg3+ B cells, PVB-28 malignant cells expressing anti-DSG were implanted into immunodeficient NOD-scidγ (NSG) mice. NSG mice lack mature T cells, B cells, and NK cells, show reduced dendritic cell function and defective macrophage activity, and are therefore widely used to implant a wide range of human cells for preclinical studies. Therefore, luciferase-positive PVB28 cells (1x10 6) were injected intravenously (iv) via the tail vein to NSG mice. Mice were pretreated with 16 mg / kg IVIG (intraperitoneal (ip) injection) on days -3, -2, and -1 prior to PBV28 cell administration to block nonspecific killing via FcγR (i.e., to enhance engraftment of PVB28 cells). The treated group was treated with mDsg3-mFc, starting on day 4, ip injections 3 times a week for two weeks and then once a week. The control group received isotype IgG2a. The autoantibody group received a mixture of AK23, AK19, and AK18 (150 μg; anti-Dsg antibodies from hybridomas), starting the day before treatment of all mice (treated and control) (i.e., on day 3), twice a week for two weeks. Disease progression was monitored by bioluminescence imaging (BLI).

[0401] Fig. 20 Panel A shows BLI imaging, which demonstrates slower signal enhancement in treated recipient mice even in the presence of the antibody. Fig. 20 Panel B shows that the survival rate in both treatment recipient groups was significantly higher compared to the control group (P value = 0.0023). In addition, the median survival for the autoantibody + treatment (AutoAb + Tx) group was 38 days, which was higher than the treatment group (median survival = 35 days; P value = 0.048). Fig. 20 Panel C shows flow cytometric analysis at endpoint and demonstrates complete depletion of PBV28 cells in the bone marrow of treated recipient mice (data represent n=5 for each group).

[0402] Animal studies in PV mouse models. The efficacy of this approach will be tested in two PV mouse models:

[0403] Passive transfer model. In this model, we can develop a passive monoclonal pemphigus mouse model by injecting AK23 antibody 91 , which is known to cause the development of blisters in both the skin and mucous membranes 26 ; This mouse model recapitulates the main features described in PV patients 26. Therefore, an experiment with the same setup as above can be performed, the only difference being that the animals will be pre-injected with 200 μg of AK23 antibody 3 times per week, starting 2 days before the start of treatment and during the duration of treatment. This ensures that the mice will have a constant high amount of anti-Dsg3 autoantibodies in circulation during the duration of treatment. The goal of this experiment is to characterize the effect of the presence of pathogenic anti-Dsg3 autoantibodies in circulation on the efficacy of the treatment. The readout will be the same BLI analysis and survival as above. Once established, we can repeat the same experiment, however, this time we can inject polyclonal pathogenic B cells (a mixture of F779 and PVB28) and polyclonal anti-Dsg3 autoantibodies (a mixture of AK23 antibodies, P1F5 antibodies, P3F3 antibodies, P5G6 antibodies, and P5D4 antibodies; 200 μg total antibodies per injection, 40 μg of each antibody). This can show that the treatment will remain effective even in the presence of polyclonal autoantibodies and polyclonal pathogenic Dsg3-reactive B cells. This setup can be similar to the physiological situation in PV patients. We can test for disease establishment by analyzing serum anti-Dsg3 titers (by standard ELISA) and skin blistering (assessed by a blinded investigator) three times a week after injection of pathogenic antibodies. Without wishing to be bound by theory, mice can exhibit hair loss, weight loss, and blistering in hair follicles and oral mucosa as well as autoantibodies that bind to epidermal keratinocytes ( Fig.21 Thumbnail A to Thumbnail D) 91、48 Similar to above, BLI imaging can be used to monitor the killing efficacy of treatment. Two groups of controls can be used: mice that will not receive treatment (negative controls) and mice that will receive treatment but not autoantibodies (positive controls; in this setting, we have shown treatment results that approach complete responses).

[0404] Active transfer model. Passive disease models have advantages; however, treatment should overcome rapidly proliferating malignant cells, which may not be the case in PV patients. Therefore, as a second model, we can use an active PV immunization model that closely mimics the clinical phenotype of human disease, with a lower frequency of autoreactive Dsg3-specific B cells similar to what occurs clinically, and ultimately with high serum polyclonal anti-Dsg3 autoantibody levels. In this model, we can develop an active polyclonal pemphigus mouse disease model by first immunizing Dsg3- / - mice (JAX-002911) with a recombinant extracellular domain of mouse Dsg3 (already generated and available), followed by transferring splenocytes into RAG2- / - mice 95至97 The transferred cells will contain B cells (and T cells), which may include pathogenic Dsg3-reactive B cells. Similar to observations made in the literature 95、96、98 Without wishing to be bound by theory, animals may have poor growth ( Fig.21 Panel E) and develop mucocutaneous erosions with suprabasal acantholysis and vesicles ( Fig.21 Panels F to H). To assess clinical parameters, we compared autoantibody levels with physiological levels in PV patients (300RU / ml to 400RU / ml) using ELISA. 48 When Dsg3-reactive antibodies equal or exceed this level (this can occur within 3 to 4 weeks) 42、48 Treatment can be initiated using the same settings as discussed above (200 μg of mDsg3-mFc per mouse, 3 times per week for two weeks). Adoptive transfer of cells from Dsg3+ / - animals immunized with Dsg3 can be used as controls 98 (at least n=10 mice per group).

[0405] The efficacy of this method can be further assessed by serum anti-Dsg3 titers measured at days 5 and 14 after the start of treatment, blinded studies of skin erosions, immunofluorescence of mucosal samples for detection of IgG deposition, histological assessment of the mucosal barrier, and quantification of histopathology. B cell counts can also be performed to ensure that they remain within normal levels during treatment. Without wishing to be bound by theory, treatment can result in clinical and histological regression of the disease, an expected outcome.

[0406] To further ensure the safety of the treatment and that there will be no off-target cytotoxic interactions, we can perform toxicology screening using primary human cells and high-throughput membrane proteome arrays. Without wishing to be bound by theory, BCR engagement-induced endocytosis may occur with our therapeutics, for example, with "antigens" (such as Dsg3-Fc) that only engage the anti-Dsg3 BCR and do not co-engage other receptors, thereby inducing a low rate of endocytosis. 99 . In addition, in vitro and in vivo data support that engagement of Dsg3-Fc with anti-Dsg3 BCRs results in targeted, almost complete killing of autoreactive B cells that recognize Dsg3; therefore, based on current evidence, it cannot be clinically significant in the context of anti-BCR engagement-induced endocytosis and degradation occurring. In addition, by definition, antibodies generated by autoreactive B cells that recognize Dsg3 (the target of our therapeutic) inherently target our therapeutic (Dsg3-Fc); therefore, we are less concerned about the generation of "neutralizing antibodies" as seen with other therapeutics that reduce their efficacy (such as rituximab or anti-TNF-α) and as discussed in detail above; in particular, see our discussion of how non-overlapping epitopes can actively help overcome the neutralization problem).

[0407] In active disease models, anti-Dsg3 levels can be measured weekly by ELISA to test long-term remission. Mice can be tested by blinded investigators to examine skin lesions to ensure that there is no disease recurrence. Fc-mediated methods can show relapses, as with rituximab, but without wishing to be bound by theory, they may respond to re-treatment. Interestingly, some studies have shown that the majority of patients treated with multiple cycles of rituximab for several years show long-term remission. 100 However, because rituximab depletes the patient's entire B cell pool and repeated infusions can cause delayed repopulation of B cells, it carries a risk of infection and can eliminate humoral responses to new infections or vaccinations. The targeted nature of the Dsg3-Fc approach developed here allows it to be used as a continuous treatment over multiple cycles without worrying about any major side effects. For example, after the first course of treatment is over and when the patient is in remission, they can be re-injected once every three months (or even more frequently) for a year or even longer. In a mechanism similar to continuous and multiple cycles of rituximab treatment, this ensures that all Dsg3 pathogenic B cells will be depleted. Since the Dsg3-Fc approach does not affect the normal B cell pool, without wishing to be bound by theory, using it multiple times over several months in patients will not face major problems and will therefore allow long-term remission; this is an advantage over anti-CD20 biologics. Therefore, as proposed here, the complete targeted depletion of autoreactive B cells can cause long-lasting to lasting remission.

[0408] We can study the dose dependence of the treatment and how its effectiveness correlates with the presence of anti-Dsg3 autoantibody titers (via ELISA). With the widespread use of biologics, studies have reported responses against a range of 101 Rituximab 102、103 Anti-drug antibodies to multiple agents. Significant immune adverse events (such as immune complex deposition) have been theorized 104 In cases where the biologic is bound to highly circulating antibodies, such as in the case of omalizumab, dosing patients with high IgE levels has not resulted in immune adverse events. 105 Similarly, the presence of anti-Dsg3 antibodies in the serum did not cause any major immune adverse events; this can be monitored as discussed herein. For active PV model experiments and as a positive control, we can explore using anti-CD20 IgG (clone SA271G2; 250 μg per animal), as it has been shown to effectively deplete B cells in mice. 106 .

[0409] As an alternative to the injection of pathogenic antibodies for the passive transfer PV model (Model 1), we can inject only luciferase-positive AK23 cells into NSG mice. 45 , because the cells produce pathogenic anti-Dsg3 antibodies (which are known to cause disease) 45 The readout will be BLI, the same as discussed in this article.

[0410] To verify that Dsg3-Fc treatment does not suppress the immune system as a whole, active LCMV-Cl13 (2 × 10 6 PFU, iv) to infect animals with active PV treated with Dsg3-Fc (Model 2). C57BL / 6 will be used as a positive control. Plaque assays can be used to compare viral loads in the liver and blood of infected mice 30 days after injection 107至109 Alternatively, for acute infection after treatment, Listeria monocytogenes (10 4 CFU to 10 5 CFU) orally challenged mice with LCMV Armstrong (2×10 5 PFU) intraperitoneally challenged mice 110至112 The microbial load in the liver and spleen can be examined 10 days after infection and compared to mice infected only. In both experiments, without wishing to be bound by theory, there will not be any differences in viral load.

[0411] The BCR-T cell engager approach (Dsg3 fused to anti-CD3) may be an alternative approach, as discussed herein. To achieve this, we have prepared and characterized Dsg3-anti-CD3e fusion proteins, as discussed herein. A clinical problem with this type of molecule is that (due to their small size) they sometimes have less than optimal in vivo pharmacokinetic properties. 113 (short half-life, t 1 / 2 About 0.6 hours). To address this issue, we can develop a bispecific antibody construct with the Dsg3 extracellular domain on one arm and an anti-CD3 scFv on the other arm. We can use a knob-in-hole approach to attach two different targeting agents to one antibody structure, while using the LALA mutation to ensure no macrophage recruitment. 114 This structure ensures high pharmacokinetic properties (due to the Fc region) as well as better expression, stability and clinical applicability.

[0412] For the in vivo experiments performed as discussed herein, we have used both male and female mice, and no differences between sexes were observed in either control or treatment groups (e.g., a total of n=27 NSG mice have been used for in vivo studies, 8 males and 19 females, which were randomly assigned to each experiment); regardless of sex, control mice showed increased BLI signals and had to be euthanized at approximately day 30, whereas treated mice showed approximately 100% antigen loss at the endpoint, or showed a complete response and remained healthy with no detectable BLI signal (for PVB28 experiments) ( Fig. 20 A to C). We will continue to use both sexes in our experiments and will monitor any differences we may observe, especially for the active PV model.

[0413] Methods. Cloning, protein production and characterization, Western blot, flow cytometry and ELISA analysis, and animal BLI imaging were performed following standard laboratory methods. In vitro and in vivo efficacy evaluation experiments were performed as described above. For details related to the development of PV passive and active models, see the vertebrate section.

[0414] References cited in this example

[0415] 1. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions inpemphigus foliaceus and vulgaris. J Clin Invest. 1999 Feb 15; 103(4): 461-468.

[0416] 2. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zilikens D, Payne AS, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017 May 11;3:17026. PMCID: PMC5901732

[0417] 3. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. The Lancet. 2019 September; 394(10201): 882-894.

[0418] 4. Murrell DF, S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA, Payne AS, Daneshpazhooh M, Eming R, Jonkman MF, Mimouni D, Borradori L, Kim S-C, Yamagami J, Lehman JS, Saleh MA, Culton DA, Czernik A, Zone JJ, Fivenson D, Ujiie H, Wozniak K, Akman- A, Bernard P, Korman NJ, Caux F, Drenovska K, Prost-Squarcioni C, Vassileva S, Feldman RJ, Cardones AR, Bauer J, Ioannides D, Jedlickova H, Palisson F, Patsatsi A, Uzun S, Yayli S, Zillikens D, Amagai M, Hertl M, Schmidt E, Aoki V, Grando SA, Shimizu H, Baum S, Cianchini G, Feliciani C, Iranzo P, Mascaró JM, Kowalewski C, Hall R, Groves R, Harman KE, Marinkovich MP, Maverakis E, Werth VP. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. March 2020;82(3):575-585.e1. PMCID: PMC7313440

[0419] 5.Koch PJ,Walsh MJ,Schmelz M,Goldschmidt MD,Zimbelmann R,FrankeWW.Identification of desmoglein,a constitutive desmosomal glycoprotein,as a member of the cadherin family of eell adhesion molecules.EurJ Cell Biol.1990Oct:53(1):1-12.PMID:1706270

[0420] 6.Amagai M,Klaus-Kovtun V,Stanley JR.Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris,a disease of celladhesion.Cell.1991 / 11 / 29:67(5):869-877.PMID:1720352

[0421] 7.Sajda T,Sinha AA.Autoantibody Signaling in Pemphigus Vulgaris:Development of an Integrated Model.Front Immunol.2018:9:692.PMCID:PMC5932349

[0422] 8.MaskedJM, A,Liu Z,Ding X,Swartz SJ,Fairley JA,DiazLA.Mechanisms of acantholysis in pemphigus vulgaris:role of IgG valence.ClinImmunol Immunopathol.1997Oct:85(1):90-96.PMID:9325074

[0423] 9.Furue M,Kadono T.Pemphigus,a pathomechanism ofacantholysis.Australian J Dermatol.2017Aug 2017:58(3):171-173.PMID:28211055

[0424] 10.Murrell DF,Dick S,Ahmed AR,Amagai M,Barnadas MA,Borradori L,Bystryn JC,Cianchini G,Diaz L,Fivenson D,Hall R,Harman KE,Hashimoto T,HertlM,Hunzelmann N,Iranzo P,Joly P,Jonkman MF,Kitajima Y,Korman NJ,Martin LK,Mimouni D,Pandya AG,Payne AS,Rubenstein D,Shimizu H,Sinha AA,Sirois D,Zillikens D,Werth VP.Consensus statement on disease definitions,endpoints,and therapeutic response for pemphigus.J Am Acad Dermatol.2008 / 6 / 58(6):1043-1046.PMCID:PMC2829665

[0425] 11.Joly P,Maho-Vaillant M,Prost-Squarcioni C,Hebert V,Houivet E,CalboS,Caillot F,Golinski ML,Labeille B,Picard-Dahan C,Paul C,Richard MA,BouazizJD,Duvert-Lehembre Bemard P,Caux F,Alexandre M,Ingen-Housz-Oro S,Vabres P,Delaporte E,Quereux G,Dupuy A,Debarbieux S,Avenel-Audran M,D′Incan M,BedaneC,Beneton N,Jullien D,Dupin N,Misery L,Machet L,Beylot-Barry M,Dereure O,Sassolas B,Vermeulin T,Benichou J,Musette P,First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus(Ritux 3):prospective,multicenter,parallel-group,open-label randomized trial.Lancet.20175 / 20:389(10083):2031-2040.PMID:28342637

[0426] 12.Committee for Guidelines for the Management of Pemphigus Disease,Amagai M,Tanikawa A,Shimizu T,Hashimoto T,Ikeda S,Kurosawa M,Niizeki H,AoyamaY,Iwatsuki K,Kitaj ima Y.Japanese guidelines for the management ofpemphigus.J Dermatol.2014Jun:41(6):471-486.PMID:24909210

[0427] 13.Hertl M,Jedlickova H,Karpati S,Marinovic B,Uzun S,Yayli S,MimouniD,Borradori L,Feliciani C,Ioannides D,Joly P,Kowalewski C,Zambruno G,Zillikens D,Jonkman MF.Pemphigus.S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum(EDF).J Eur Acad DermatolVenereo1.2015March:29(3):405-414.PMID:25338479

[0428] 14.Atzmony L,Hodak E,Gdalevich M,Rosenbaum O,Mimouni D.Treatment ofpemphigus vulgaris and pemphigus foliaceus:a systematic review and meta-analysis.Am J Clin Dermatol.2014Oct:15(6):503-515.PMID:25403548

[0429] 15.Werth VP.Treatment of pemphigus vulgaris with brief,high-doseintravenous glucocorticoids.Arch Dermatol.1996 / 12 / 132(12):1435-1439.PMID:8961871

[0430] 16. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-dose intravenous "pulse" methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med. July 2002; 31(6): 339-344. PMID: 12201245

[0431] 17. Almugairen N, Hospital V, Bedane C, Duvert-Lehembre S, Picard D, Tronquoy A-F, Houivet E, D′incan M, Joly P. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. October 2013; 69(4): 583-588. PMID: 23850258

[0432] 18. Beissert S, Werfel T, Frieling U, M, Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N, Meurer M, Gollnick H, Ruzicka T, Pillekamp H, Junghanns V, Luger TA. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. November 2006; 142(11): 1447-1454. PMID: 17116835

[0433] 19. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi SZ, Seirafi H, Nazemi M-JT, Mortazavi H, Mirshams-Shahshahani M. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. October 2007; 57(4): 622-628. PMID: 17583373

[0434] 20. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. August 2010; 130(8): 2041-2048. PMID∶20410913

[0435] 21. Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. July 2012; 26(7): 855-860. PMID: 21752101

[0436] 22.Chams-Davatchi C,Mortazavizadeh A,Daneshpazhooh M,Davatchi F,Balighi K,Esmaili N,Akhyani M,Hallaji Z,Seirafi H,Mortazavi H.Randomizeddouble blind trial of prednisolone and J Eur Acad DermatolVenereol.2013October 27(10)∶1285-1292.PMID:23062214

[0437] 23.Amagai M,Tsunoda K,Zillikens D,Nagai T,Nishikawa T.The clinical phenotype of pemphigus: anti-desmoglein autoantibody profile.

[0438] 24.Anhalt GJ,Labib RS,Voorhees JJ,Beals TF,Diaz LA.Induction ofpemphigus in neonatal mice by passive transfer of IgG from patients with thedisease.N Engl J Med.1982 / 5 / 20:306(20):1189-1196.PMID:7040962

[0439] 25.Rock B,Labib RS,Diaz LA.Monovalent Fab′immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human diseasein neonatal Balb / c mice.J Clin Invest.January 1990:85(1):296-299.PMCID:PMC296418

[0440] 26.Schulze K,Galichet A,Sayar BS,Scothern A,Howald D,Zymann H,SiffertM,Zenhausern D,Bolli R,Koch PJ,Garrod D,Suter MM,Müller EJ.An Adult PassiveTransfer Mouse Model to Study Desmoglein 3Signaling in Pemphigus Vulgaris.Journal of Investigative Dermatology.2012February:132(2):346-355.

[0441] 27.Joly P,Mouquet H,Roujeau JC,D′Incan M,Gilbert D,Jacquot S,GougeonM-L,Bedane C,Muller R,Dreno B,Doutre MS,Delaporte E,Pauwels C,Franck N,CauxF,Picard C,Tancrede-Bohin E,Bernard P,Tron F,Hertl M,Musette PA Single cycles of rituximab for the treatment of severe pemphigus Med.2007August9:357(6):545-552.PMID:17687130

[0442] 28. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. July 2011; 7(4): 529 - 541. PMID: 21790294

[0443] 29. Wang H-H, Liu C-W, Li Y-C, Huang Y-C. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. November 2015; 95(8): 928 - 932. PMID: 25881672

[0444] 30. Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. September 2012; 148(9): 1031 - 1036. PMCID: PMC3658473

[0445] 31. Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, von Wussow P, Hertl M, Zillikens D, Freivogel K, T, Schmidt E. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. October 2012; 10(10): 727 - 732. PMID: 22577946

[0446] 32.Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, I,HaasJ,Unger L,Lovric S,Haubitz M,Fischer-Betz R,Chehab G,Rubbert-Roth A,SpeckerC,Weinerth J,Holle J,Müller-Ladner U, R, Fiehn C, Burgwinkel P, Budde K, H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, VeelkenR, Ziemann U, Strutz F, von Wussow P, Meier FMP, Hunzelmann N, Schmidt Energy Energy R A.Eming R.Hertl M.Stadler R.Schwarz-Eywill M.Wassenberg S.Fleck M.Metzler C.Zettl U.Westphal J.Heitmann S.Herzog AL.Wiendl H.Jakob W.F. K, T,GRAID investigators.Safety and clinical outcomes ofrituximab therapy in patients with different autoimmune diseases:experiencefrom a national registry(GRAID).

[0447] 33.Kushner CJ,Wang S,Tovanabutra N,Tsai DE,Werth VP,Payne AS.FactorsAssociated With Complete Remission After Rituximab Therapy for Pemphigus.JAMADermatol.

[0448] 34.Mahmoudi H,Balighi K,Tavakolpour S,Daneshpazhooh M.Unexpected worsening of pemphigus vulgaris after rituximab:A report of three cases.IntImmunopharmacol.2019Jun:71:40-42.PMID:30877872

[0449] 35.Goebeler M,Bata- Z,De Simone C,Didona B,Remenyik E,Reznichenko N,Stoevesandt J,Ward ES,Parys W,de Haard H,Dupuy P,Verheesen P,Schmidt E,Joly P,ARGX-113-1701 Investigator StudyGroup.Treatment of pemphigusvulgaris and foliaceus with efgartigimod,a neonatal Fc receptor inhibitor:a phase II multicenter,open-label feasibility trial.Br J Dermatol.2021 / 10 / 5 / PMID:34608631

[0450] 36. Werth VP, Culton DA, Coneha JSS, Graydon JS, Blumberg LJ, Okawa J, Pyzik M, Blumberg RS, Hall RP. Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. J Invest Dermato1. December 2021;141(12):2858-2865.e4. PMID: 34126109

[0451] 37. Izumi K, Bieber K, Ludwig RJ. Current Clinical Trials in Pemphigus and Pemphigoid. Front Immuno]. 2019;10:978. PMCID: PMC6509547

[0452] 38. Goodale EC, White SD, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, Jordan TJM, Emery CB, Outerbridge CA. Open trial of Bruton′s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. Vet Dermatol. October 2020;31(5):410-e110. PMID: 32803903

[0453] 39. Goodale EC, Varjonen KE, Outerbridge CA, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, White SD. Efficacy of a Bruton′s Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. Vet Dermatol. August 2020; 31(4): 291-e71. PMID: 31899567

[0454] 40. Peter H-H, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, Jolles S. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J Allergy Clin Immunol. September 2020; 146(3): 479-491.e5. PMCID: PMC7471860

[0455] 41. Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR. Persistenee of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. March 2015; 135(3): 742-749. PMCID: PMC4294994

[0456] 42.Lee J,Lundgren DK,Mao X,Manfredo-Vieira S,Nunez-Cruz S,WilliamsEF,Assenmacher CA,Radaelli E,Oh S,Wang B,Ellebrecht CT,Fraietta JA,MiloneMC,Payne AS.Antigen-specific B cell depletion for precision therapy ofmucosal pemphigus vulgaris.J Clin Invest

[0457] 43.Colliou N,Picard D,Caillot F,Calbo S,Le Corre S,Lim A,Lemercier B,Mauff B,Maho-Vaillant M,Jacquot S,Bedane C,Bernard P,Caux F,Prost C,Delaporte E,Doutre MS,Dreno B,Franck N,Ingen-Housz-Oro S,Chosidow O,PauwelsC,Picard C,Roujeau JC,Sigal M,Tancrede-Bohin E,Templier I,Eming R,Hertl M,D′Incan M,Joly P,Musette P.Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.Sci Transl Med

[0458] 44.Esensten JH,Muller YD,Bluestone JA,Tang Q.Regulatory T-cell therapy for autoimmune and autoinflammatory diseases:The next frontier.JAllergy Clin Immunol.2018 / 12 / 142(6):1710-1718.PMID:30367909

[0459] 45.Ellebrecht CT,Bhoj VG,Nace A,Choi EJ,Mao X,Cho MJ,Di Zenzo G,Lanzavecchia A,Seykora JT,Cotsarelis G,Milone MC,Payne AS.Reengineeringchimeric antigen receptor T cells for targeted therapy of autoimmune disease.Science.2016Jul8:353(6295):179-184.PMCID:PMC5343513

[0460] 46.Kim AR,Han D,Choi JY,Seok J,Kim SE,Seo SH,Takahashi H,Amagai M,Park SH,Kim SC,Shin EC,Kim JH.Targeting inducible costimulator expressed in CXCR5+PD-l+TH cells suppresses progression of pemphigus vulgaris.JAllergy Clin Immunol.146(5):1070-1079.e8.PMID:32311391

[0461] 47.Hashimoto K, Shafran KM, Webber PS, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. J Exp Med. January 1, 1983; 157(1): 259 - 272. PMCID: PMC2186905

[0462] 48.Schmidt E, C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, W, Hashimoto T, E - B, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies tO desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. May 2010; 19(5): 458 - 463. PMID: 20163452

[0463] 49.Yuan H, Zhou S, Liu Z, Cong W, Fei X, Zeng W, Zhu H, Xu R, Wang Y, Zheng J, Pan M. Pivotal Role of Lesional and Perilesional T / B Lymphocytes in Pemphigus Pathogenesis. J Invest Dermatol. November 2017; 137(11): 2362 - 2370. PMID: 28647348

[0464] 50. Albers LN, Liu Y, Bo N, Swerlick RA, Feldman RJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. December 2017; 77(6): 1074 - 1082. PMID: 28927663

[0465] 51. Mouquet H, Musette P, Gougeon M - L, Jacquot S, Lemercier B, Lim A, Gilbert D, Dutot I, Roujeau JC, D′Incan M, Bedane C, Tron F, Joly P. B - cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. December 2008; 128(12): 2859 - 2869. PMID: 18563177

[0466] 52. Huehls AM, Coupet TA, Sentman CL. Bispecific T - cell engagers for cancer immunotherapy. Immunol Cell Biol. March 2015; 93(3): 290 - 296. PMCID: PMC4445461

[0467] 53. Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and Clinical Development of Bispecific T - cell Engaging Antibodies for Cancer Treatment. Clin Pharmacol Ther. May 2017; 101(5): 634 - 645. PMCID: PMC5763312

[0468] 54.Mazmanian SK,Liu G,Ton-That H,Schneewind O.Staphylococcus aureusSortase,an Enzyme that Anchors Surface Proteins to the Cell Wall.Science.1999 / 7 / 30 / 285(5428):760-763.

[0469] 55.Dorr BM,Ham HO,An C,Chaikof EL,Liu DR.Reprogramming thespecificity of sortase enzymes.Proe Natl Acad Sci USA.20149 / 16 / 111(37):13343-13348.

[0470] 56.Rashidian M,Keliher EJ,Bilate AM,Duarte JN,Wojtkiewicz GR,JacobsenJT,Cragnolini J,Swee LK,Victora GD,Weissleder R,Ploegh HL.Noninvasive imagingof immune responses.Proc Natl Acad Sci USA.2015 May 12:112(19):6146-6151.PMCID:PMC4434737

[0471] 57.Rashidian M,Keliher E,Dougan M,Juras PK,Cavallari M,WojtkiewiczGR,Jacobsen J,Edens JG,Tas JMG,Victora G,Weissleder R,Ploegh H.The use of(18)F-2-fluorodeoxyglucose(FDG)to label antibody fragments for immuno-PET ofpancreatic cancer.ACS Cent Sci.2015Jun 24:1(3):142-147.PMCID:PMC4778250

[0472] 58. Rashidian M, Wang L, Edens JG, Jacobsen JT, Hossain I, Wang Q, Victora GD, Vasdev N, Ploegh H, Liang SH. Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics. Angew Chem Int Ed Engl. January 11, 2016; 55(2): 528-533. PMCID: PMC4718774

[0473] 59. Ingram JR, Dougan M, Rashidian M, Knoll M, Keliher EJ, Garrett S, Garforth S, Blomberg OS, Espinosa C, Bhan A, Almo SC, Weissleder R, Lodish H, Dougan SK, Ploegh HL. PD-L1 is an activation-independent marker of brown adipocytes. Nat Commun. September 21, 2017; 8(1): 647. PMCID: PMC5608754

[0474] 60. Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, Grotenbreg GM, Bhan A, Weinberg RA, Ploegh HL. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. August 7, 2017; 214(8): 2243-2255. PMCID: PMC5551571

[0475] 61. Cong M, Tavakolpour S, Berland L, H,Andreiuk B,Rakhshandehroo T,Uslu S,Mishra S,Clark L,Rashidian M.Direct N-or C-TerminalProtein Labeling Via a Sortase-Mediated Swapping Approach.Bioconjug Chem.2021November 17:32(11):2397-2406.PMID:34748323

[0476] 62.Ohyama B,Nishifuj i K,Chan PT,Kawaguchi A,Yamashita T,Ishii N,Hamada T,Dainichi T,Koga H,Tsuruta D,Amagai M,Hashimoto T.Epitope spreadingis rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules.J Invest Dermatol.2012April:132(4):1158-1168.PMID:22277941

[0477] 63.Tsunoda K,Ota T,Aoki M,Yamada T,Nagai T,Nakagawa T,Koyasu S,Nishikawa T,Amagai M.Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface ofdesmoglein 3.JImmunol.2003February15:170(4):2170-2178.PMID:12574390

[0478] 64.Cho A,Caldara AL,Ran NA,Menne Z,Kauffman RC,Affer M,Llovet A,Norwood C,Scanlan A,Mantus G,Bradley B,Zimmer S,Schmidt T,Hertl M,Payne AS,Feldman R,Kowalczyk AP,Wrammert J.Single-Cell Analysis Suggests that OngoingAffinity Maturation Drives the Emergence of Pemphigus Vulgaris AutoimmuneDisease.Cell Rep.2019Jul23:28(4):909-922.e6.PMCID:PMC6684256

[0479] 65.Bruhns P.Properties of mouse and human IgG receptors and their contribution to disease models.Blood.20126 / 14 / 119(24):5640-5649.PMID:22535666

[0480] 66.Vidarsson G,Dekkers G,Rispens T.IgG subclasses and allotypes:from structure to effector functions.Front Immunol.2014:5:520.PMCID:PMC4202688

[0481] 67.Yu J,Song Y,Tian W.How to select IgG subclasses in developing anti-tumor therapeutic antibodies.J Hematol Oncol

[0482] 68. Ishikawa H, Li K, Tamai K, Sawamura D, Uitto J. Cloning of the mouse desmoglein 3 gene (Dsg3): interspecies conservation within the cadherin superfamily. Exp Dermatol. August 2000; 9(4): 229 - 239. PMID: 10949543

[0483] 69. Culton DA, McCray SK, Park M, Roberts JC, Li N, Zedek DC, Anhalt GJ, Cowley DO, Liu Z, Diaz LA. Mucosal pemphigus vulgaris anti - Dsg3 IgG is pathogenic to the oral mucosa of humanized Dsg3 mice. J Inivest Derinatol. June 2015; 135(6): 1590 - 1597. PMCID: PMC4430403

[0484] 70. Bosshart H, Heinzelmann M. THP - 1 cells as a model for human monocytes. Ann Transl Med. November 2016; 4(21): 438. PMCID: PMC5124613

[0485] 71. Pollmann R, Walter E, Schmidt T, Waschke J, Hertl M, C, Eming R. Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris. Front Immunol. 2019; 10: 1375. PMCID: PMC6587433

[0486] 72.Amagai M,Ikeda S,Shimizu H,Iizuka H,Hanada K,Aiba S,Kaneko F,IzakiS,Tamaki K,Ikezawa Z,Takigawa M,Seishima M,Tanaka T,Miyachi Y,Katayama I,Horiguchi Y,Miyagawa S,Furukawa F,Iwatsuki K,Hide M,Tokura Y,Furue M,Hashimoto T,Ihn H,FujiwaraS,Nishikawa T,Ogawa H,Kitajima Y,Hashimoto K,Pemphigus Study Group.A randomized double-blind trial of intravenous immunoglobulin for pemphigus.J Am Acad Dermatol.2009 Apr:60(4):595-603.PMID:19293008

[0487] 73.Li N,Zhao M,Hilario-Vargas J,Prisayanh P,Warren S,Diaz LA,Roopenian DC,Liu Z.Complete FcRn dependence of intravenous Ig therapy for inautoimmune skin blistering diseases.J Clin Invest.2005Dec115(12):3440-3450.PMCID:PMC 1280965

[0488] 74.Paquin Proulx D,Aubin E,Lemieux R,Bazin R.Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins(IVIg).

[0489] 75.Baker K,Rath T,Pyzik M,Blumberg RS.The Role of FcRn in Antigen Presentation.Front Immunol.2014:5:408.PMCID:PMC4145246

[0490] 76.Nimmerjahn F,Ravetch JV.The anti-inflammatory activity of IgG:theintravenous IgG paradox.J Exp Med.2007January22:204(1):11-15.PMCID:PMC2118416

[0491] 77.Mazzi G,Raiheri A,Zanolli FA,Da Ponte C,De Roia D,Santarossa L,Guerra R,Orazi BM.Plasmapheresis therapy in pemphigus vulgaris and bullouspemphigoid.Transfus Apher Sci.2003Feb:28(1):13-18.PMID:12620264

[0492] J Am AcadDermatol.2000 / 12 / 43(6):1058-1064.PMID:11100023.78.Tumer MS,Sutton D,Sauder DN

[0493] 79. Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, Zillikens D, Schmidt E. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine / mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. January 2012; 166(1): 154 - 160. PMID: 21910700

[0494] 80. Behzad M, C, Kneisel A, M, Hoyer J, Hertl M, Eming R. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol. April 2012; 166(4): 844 - 852. PMID: 22092243

[0495] 81. Laurent SA, Hoffmann FS, Kuhn P-H, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister H-W, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. June 11, 2015; 6: 7333. PMCID: PMC4490565

[0496] 82. Ridgway JB, Presta LG, Carter P. "Knobs-into-holes" engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. July 1996; 9(7): 617 - 621. PMID: 8844834

[0497] 83. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. September 1, 1997; 100(5): 1059 - 1070. PMCID: PMC508280

[0498] 84. Dall′Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. July 1, 2004; 64(13): 4664 - 4669. PMID: 15231679

[0499] [ PMC free article ] [ PubMed ] 85.Anolik JH,Campbell D,Felgar RE,Young F,Sanz I,Rosenblatt J,LooneyRJ erythematosus.ArthritisRheum.2003Feb:48(2):455-459.PMID:12571855

[0500] 86.Kantarjian H,Stein A, N,Fielding AK,Schuh AC,Ribera JM,Wei A,Dombret H,FoàR,Bassan R,Arslan O,Sanz MA,Bergeron J,Demirkan F,Lech-Maranda E,Rambaldi A,Thomas X,Horst HA,Brüggemann M,Klapper W,W00d BL,Fleishman A,Nagorsen D,Holland C,Zimmerman Z,Topp MS.Blinatumomab versusChemotherapy forAdvanced Acute Lymphoblastic Leukemia.N Engl J. Med.2017March2:376(9):836-847.PMCID:PMC5881572

[0501] 87. Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg S. CD3xPDL1 bispecific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget. August 29, 2017; 8(35):57964-57980. PMCID: PMC5601626

[0502] 88. Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors. Clin Caneer Res. May 1, 2018; 24(9):2128-2137. PMID: 29437789

[0503] 89. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. August 8, 1985; 313(6):337-342. PMID: 2861567

[0504] 90.Kujawski M,Li L,Bhattacharya S,Wong P,Lee WH,Williams L,Li H,CheaJ,Poku K,Bowles N,Vaidehi N,Yazaki P,Shively JE.Generation of dual specificbivalent BiTEs(dbBIspecific). T-cell engaging antibodies)for cellular immunotherapy.BMC Caneer.20199 / 5 / 19(1):882.PMCID:PMC6727398

[0505] 91.Tsunoda K,Ota T,Aoki M,Yamada T,Nagai T,Nakagawa T,Koyasu S,Nishikawa T,Amagai M.Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface ofdesmoglein 3.JImmunol.2003February15:170(4):2170-2178.PMID:12574390

[0506] 92.Boggon TJ,Murray J,Chappuis-Flament S,Wong E,Gumbiner BM,ShapiroL.C-cadherin ectodomain structure and implicatiohs for cell adhesionmechanisms.Science.2002March17:296(5571):1308-1313.PMID:11964443

[0507] 93.Harrison OJ,Brasch J,Lasso G,Katsamba PS,Ahlsen G,Honig B,ShapiroL.Structural basis of adhesive bonding by desmocollins and desmogleins.ProcNatl Acad Sci USA.20166 / 28:113(26):7160-7165.

[0508] 94.Cho MJ,Lo ASY,Mao X,Nagler AR,Ellebrecht CT,Mukherjee EM,HammersCM,Choi EJ,Sharma PM,Uduman M,Li H,Rux AH,Farber SA,Rubin CB,Kleinstein SH,Sachais BS,Posner MR,Cavacini LA,Payne AS.Shared VH1-46gene usage bypemphigus vulgaris autoantibodies indicates common humoral immune responsesamong patients.Nat Commun.20146 / 19:5:4167.PMCID:PMC4120239

[0509] 95.Takae Y,Nishikawa T,Amagai M.Pemphigus mouse model as a tool toevaluate various immunosuppressive therapies.Exp Dermatol.2009March:18(3):252-260.PMID:18643850

[0510] 96.Aoki-Ota M,Tsunoda K,Ota T,Iwasaki T,Koyasu S,Amagai M,NishikawaT.A mouse model of pemphigus vulgaris by adoptive transfer of naivesplenocytes from desmoglein 3knockout mice.Br J. Dermatol.2004Aug:151(2):346-354.PMID:15327541

[0511] 97.Lotti R,Athens CG,Marconi A,Di Rocco G,Reggiani Bonetti L,ZanoccoMarani T.Pincelli C.Development of a Desmocollin-3Active Mouse ModelRecapitulating Human Atypical Pemphigus.Front Immunol.2019:10:1387.PMCID:PMC6593104

[0512] 98.Amagai M,Tsunoda K,Suzuki H,Nishifuji K,Koyasu S,Nishikawa T.Useof autoantigeh-knockout mice in developing an active autoimmune disease modelfor pemphigus.J Clin Invest.2000March:105(5):625-631.PMCID:PMC292455

[0513] 99.Courtney AH,Bennett NR,Zwick DB,Hudon J,Kiessling LL.Synthetic antigens reveal dynamics of BCR endocytosis during inhibitory signaling.ACSChem Biol.2014January17:9(1):202-210.PMCID:PMC3947029

[0514] 100.Shimanovich I,Baumann T,Schmidt E,Zillikens D,Hammers CM.Long-term outcomes of rituximab therapy in pemphigus.J Eur Acad DermatolVenereol.2020Dec:34(12):2884-2889.PMID:32367562

[0515] 101.Bito T,Nishikawa R,Hatakeyama M,Kikusawa A,Kanki H,Nagai H,Sarayama Y,Ikeda T,Yoshizaki H,Seto H,Adachi A,Horikawa T,Oka M,NishigoriC.Influence of neutralizing antibodies to Br J Dermatok.April 2014:170(4):922-929.PMID:24329764

[0516] 102.Schmidt E,Hennig K,Mengede C,Zillikens D,KrommingaA.Immunogenicity of rituximab in patients with severe pemphigus.ClinImmunol.2009 / 9 / 132(3):334-341.PMID:19502112

[0517] 103.Boyer-Suavet S,Andreani M,Lateb M,Savenkoff B,Brglez V,BenzakenS,Bernard G,Nachman PH,Esnault V,Seitz-Polski B.Neutralizing Anti-RituximabAntibodies and Relapse in Membranous Nephropathy Treated With Rituximab.FrontImmuno1.2019:10:3069.PMCID:PMC6

[0518] 104.Krishna M,Nadler SG.Immunogenicity to Biotherapeutics-The Role ofAnti-drug Immune Complexes.Front Immuno1.2016:7:21.PMCID:PMC4735944

[0519] 105. Maselli DJ, Singh H, Diaz J, Peters JI. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU / mL: a retrospective study. Ann Allergy Asthma Immunol. June 2013;110(6):457 - 461. PMID: 23706716

[0520] 106. Bongard N, Le-Trilling VTK, Malyshkina A, Rückborn M, Wohlgemuth K, Wensing I, Windmann S, Dittmer U, Trilling M, Bayer W. Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection. PLoS Pathog. September 2019;15(9):e1008043. PMCID: PMC6786657

[0521] 107. Korns Johnson D, Homann D. Accelerated and improved quantification of lymphocytic choriomeningitis virus (LCMV) titers by flow cytometry. PLoS One. 2012;7(5):e37337. PMCID: PMC3355137

[0522] 108.Yamada DH,Elsaesser H,Lux A,Timmerman JM,Morrison SL,de la TorreJC,Nimmerjahn F,Brooks DG.Suppression of Fcγ receptor-mediated antibody effector function during persistent viral infection.Immunity.February 17, 2015:42(2):379-390.PMCID:PMC4334737

[0523] 109.PratumchaiI,Zak J,Huang Z,Min B,Oldstone MBA,Teijaro JR.B cell-derived IL-27promotes control of persistent LCMV infection.Proc Natl Acad SciU S A.2022Jan 18:119(3)e2116741119.PMCID:PMC8784116

[0524] 110.Shen H,Whitmire JK,Fan X,Shedlock DJ,Kaech SM,Ahmed RA Specificrole of B cells in the generation of CD8 T cell memory by recombinantListeria monocytogenes.J Immunol.2003February1:170(3):1443-1451.PMID:12538706

[0525] 111.Lee CC,Kung JT.Marginal zone B cell is a major source of Il-10in Listeria monocytogenes susceptibility.J Immunol

[0526] 112. Misumi I, Whitmire JK. B cell depletion curtails CD4+T cell memory and reduces protection against disseminating virus infection. J Immunol. 2014 February 15; 192(4): 1597-1608. PMCID: PMC3925510

[0527] 113.Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, -Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusiohs with tunedFcRn affinity. Commun Biol. 2021 Mar 8;4(1):310. PMCID: PMC7940400

[0528] 114. Saxena A. Wu D. Advances in Therapeutic Fc Engineering-Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol. 2016; 7: 580. PMCID: PMC5149539

[0529] Example 8

[0530] Animal models of pemphigus disease in mice are known (discussed herein). In experiments, therapeutic agents disclosed herein have been administered to these mice to determine their effects on disease in mice (e.g., Example 7). Data from these experiments indicate that the therapeutic agents are effective. Additional studies like this are described in this Example.

[0531] Fig. 22Panels A to D demonstrate efficacy in immunocompetent mice (even in the presence of autoantibodies) and that treatment does not cause cytokine storms or toxicity. The plan for injecting mice with treatment (mDsg3-EC14-mFc) and / or autoantibody cocktails (AK23, AK19, AK18) is shown in Panel A. In Panels B and C, it is shown that treated recipient mice with or without autoantibodies continue to gain normal weight without observing toxicity (n=6 for each group; 3 males and 3 females). Panel D shows an ELISA analysis that demonstrates that there is no cytokine storm in any of the three groups that received only treatment, or received only autoantibodies, or received both autoantibodies and treatment (using ELISA MAX TM Standard Set Mouse (BioLegend). Serum from 6 mice that did not receive anything was used as a healthy control in each sex. Samples from 3 mice that received 2 mg / kg of lipopolysaccharide (LPS) were used to simulate cytokine storm in each sex. Unpaired t-test was used to test for significant differences between groups. (ns, P>0.05; *, P≤0.05; **, P≤0.01; ***, P≤0.001; ****, P≤0.0001).

[0532] Fig.23 Panels A to E show that treatment (mDsg3-EC1-4-mFc) inhibits the pathogenic effects of the AK23 antibody. All animals received AK23 (12 mg / kg; subcutaneous); the AK23+ treated cohort received mDsg3-mFc (15 mg / kg, ip) 1 hour later. Panels A and B show the AK23 group, which exhibited significant hair loss by tape stripping performed after 72 hours (Panel A) and showed a severe PV phenotype (i.e., hair loss and mucosal erosions (not shown)) on day 5 (Panel B); however, the "AK23+ treated" group was similar to control healthy mice (Panels A and B); data represent n=3 for each cohort. Panel C shows that the AK23 cohort showed weight loss; however, weight gain was normal in mice that received AK23 and treatment. Panel D shows an ELISA analysis of IL6 performed on serum collected at 72 hours and demonstrates high levels of the cytokine in the AK23 cohort, but similar to healthy controls in the "AK23+ treated" group. Panel E shows a survival analysis of the experiment. All AK23 mice developed severe PV and had to be euthanized within 7 days. All treated mice appeared normal and were alive (n=3 for each cohort).

[0533] *****

[0534] Equivalent

[0535] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of the present invention.

Claims

1. A fusion protein comprising: an extracellular (EC) domain or a portion of the EC domain of desmoglein 3 (Dsg3) or an EC domain or a portion of the EC domain of desmoglein 1 (Dsg1); and an isolated immunoglobulin Fc region or a fragment thereof. 2 . The fusion protein according to claim 1 , wherein the fusion protein comprises any one of SEQ ID NOs: 1 to 4 or a fragment thereof. 3 . The fusion protein according to claim 1 , comprising an amino acid sequence that is at least 80% identical to SEQ ID Nos: 1 to 4 or 29 to 32. 4 .

4. The fusion protein of claim 1, wherein the fusion protein targets one or more B cells. 5 . The fusion protein of claim 4 , wherein the B cells comprise autoreactive anti-Dsg3 B cells or autoreactive anti-Dsg1 B cells. The fusion protein of claim 1 , wherein the Fc region comprises an amino acid sequence that is at least 80% identical to the Fc region in SEQ ID NOs: 1 to 4 or 29 to 32.

7. The fusion protein of claim 1, wherein the Fc region comprises an IgG Fc region. 8 . The fusion protein according to claim 1 , wherein the EC domain comprises any one or more of the various sequence identifiers (SEQ ID NOs. 8 to 28) provided in FIG. 13 . 9 . The fusion protein according to claim 8 , wherein the EC domain comprises EC1, EC2, EC4, EC5 or a combination thereof.

10. The fusion protein of claim 1, further comprising a therapeutic moiety, an imaging moiety, a capture moiety, or a combination thereof.

11. The fusion protein of claim 10, wherein the capture moiety comprises a hydrophilic protein, a bacterial transpeptidase, a GST tag, a His tag, polyethylene glycol (PEG), or a combination thereof.

12. The fusion protein of claim 10, wherein the imaging moiety comprises a fluorophore, a radioisotope, or a combination thereof.

13. The fusion protein of claim 10, wherein the therapeutic moiety comprises a cytokine, a toxin, a radiotherapeutic agent, a T cell engaging moiety, a natural killer cell engaging moiety, or a combination thereof.

14. The fusion protein of claim 13, wherein the therapeutic moiety comprises IL-2, IL-15, or a molecule having IL-1 activity. 15 . A pharmaceutical composition comprising the fusion protein according to any one of claims 1 to 14 and a pharmaceutically acceptable carrier.

16. A method of depleting autoreactive anti-Dsg3 or anti-Dsg1 B cells, the method comprising administering to a subject a therapeutically effective amount of the fusion protein of any one of claims 1 to 14.

17. The method of claim 16, wherein the effective amount is positively correlated with the level of circulating anti-Dsg3 or anti-Dsg1 antibodies in the subject.

18. A method for treating an autoimmune disease, the method comprising administering a therapeutically effective amount of the fusion protein according to any one of claims 1 to 14 to a subject, wherein the subject is suffering from the autoimmune disease.

19. The method of claim 18, wherein the disease is selected from the group consisting of autoimmune blistering disease, lupus, scleroderma, Goodpasture's disease, Graves' disease, and immune-mediated vasculitis.

20. The method of claim 19, wherein the autoimmune blistering disease comprises pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, or linear IgA bullous dermatosis.

21. The method of claim 18, wherein the therapeutically effective amount of the fusion protein or the pharmaceutical composition eliminates or disables autoreactive B cells in the subject.

22. The method of claim 18, wherein the method is effective in the presence of autoantibodies reactive with the fusion protein or the fusion protein in the pharmaceutical composition.

23. A nucleic acid encoding the fusion protein according to any one of claims 1 to 14.

24. A vector comprising a nucleic acid encoding the fusion protein according to any one of claims 1 to 14.

25. A cell comprising a vector encoding the fusion protein according to any one of claims 1 to 14.

26. A fusion protein, comprising: Autoreactive antigens; and The Fc portion of an antibody or an antibody that binds to effector cells.

27. The fusion protein of claim 26, wherein the autoreactive antigen comprises a molecule or a fragment of a molecule from the group consisting of desmoplakin, involucrin, parathrombolysin, plectin, bullous pemphigoid antigen 1, keratogranulin, microtubule-actin cross-linking factor, exothrombolysin, and cadherin.

28. The fusion protein of claim 27, wherein the autoreactive antigen comprises the extracellular (EC) domain of the molecule or a B cell epitope thereof.

29. The fusion protein of claim 28, wherein the EC domain or a B cell epitope thereof is selected from the group of desmosomal cadherins consisting of: Desmoglein-1 (Dsg1), Desmoglein-2 (Dsg2), Desmoglein-3 (Dsg3), Desmoglein-4 (Dsg4), Desmoglein-1 (Dsc1), Desmoglein-2 (Dsc2) and Desmoglein-3 (Dsc3).

30. The fusion protein of claim 28, wherein the EC domain or B cell epitope thereof comprises all or part of the following: EC1, EC2, EC3, EC4, EC5, and combinations thereof.

31. The fusion protein of claim 26, wherein the autoreactive antigen binds to a B cell receptor (BCR) of an autoreactive B cell.

32. The fusion protein of claim 31, wherein the autoreactive B cells are from an animal suffering from an autoimmune disease.

33. The fusion protein of claim 32, wherein the autoimmune disease is characterized by the production of autoantibodies in the animal.

34. The fusion protein of claim 32, wherein the autoimmune disease comprises autoimmune blistering disease, lupus, scleroderma, Goodpasture's disease, Graves' disease, or an immune-mediated vasculitis.

35. The fusion protein of claim 34, wherein the autoimmune blistering disease is selected from the group consisting of pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, linear IgA bullous dermatosis, pemphigus foliaceus, intraepidermal neutrophilic IgA dermatosis, and paraneoplastic pemphigus.

36. The fusion protein of claim 32, wherein the autoimmune disease is present in a human, dog, cat, or horse.

37. The fusion protein of claim 26, wherein the Fc portion of the antibody is capable of binding to a cell having an Fc receptor (FcR).

38. The fusion protein of claim 37, wherein the FcR comprises an Fc-gamma receptor (FcγR), an Fc-alpha receptor (FcαR), or an Fc-epsilon receptor (FcεR).

39. The fusion protein of claim 38, wherein the FcγR comprises FcγRI, FcγRII or FcγRIII.

40. The fusion protein of claim 37, wherein the FcR is present on a B cell, a follicular dendritic cell, a natural killer cell, a macrophage, a neutrophil, an eosinophil, a basophil, a platelet, or a mast cell.

41. The fusion protein of claim 37, wherein the FcR is present on a natural killer cell or a macrophage.

42. The fusion protein of claim 26, wherein the Fc portion of the antibody comprises an amino acid sequence that is at least 80% identical to the Fc portion of SEQ ID NOs: 1 to 4 or 29 to 32.

43. The fusion protein of claim 26, wherein the antibody that binds to the effector cell binds to a T cell.

44. The fusion protein of claim 43, wherein the antibody that binds to the T cell comprises an anti-CD3 antibody.

45. The fusion protein of claim 44, wherein the anti-CD3 antibody comprises a single chain variable fragment (scFv).

46. ​​The fusion protein of claim 26, wherein the effector cells comprise T cells.

47. The fusion protein of claim 26, further comprising a cytokine.

48. The fusion protein of claim 47, wherein the cytokine comprises IL-2, IL-15, or a molecule having IL-1 activity.

49. A fusion protein, comprising: an autoreactive B cell epitope from the extracellular portion of desmoglein or desmoglein; and The Fc portion of an antibody capable of binding to an Fc-gamma receptor (FcγR), an Fc-alpha receptor (FcαR), or an Fc-epsilon receptor (FcεR).

50. The fusion protein of claim 49, wherein the autoreactive B cell epitope comprises the N-terminus of the fusion protein and the Fc portion comprises the C-terminus of the fusion protein.

51. The fusion protein of claim 49, further comprising an amino acid spacer linking the autoreactive B cell epitope and the Fc portion.

52. The fusion protein of claim 49, wherein the fusion protein comprises at least two B cell epitopes from the extracellular portion of desmoglein or desmoglein.

53. The fusion protein of claim 52, wherein the fusion protein comprises: A first polypeptide having a first self-reactive antigen and a first C from an antibody heavy chain H 3 domains; and A second polypeptide having a second self-reactive antigen and a second C from an antibody heavy chain H 3 domains; The first polypeptide and the second polypeptide are connected by a disulfide bond.

54. The fusion protein of claim 53, wherein the first CH3 domain and the second CH3 domain are configured to preferentially heterodimerize.

55. The fusion protein of claim 54, wherein complementary modifications to amino acids in the first CH3 domain and the second CH3 domain provide preferential dimerization.

56. The fusion protein of claim 54, wherein the first CH3 domain and the second CH3 domain are modified using a knob-and-hole arrangement.

57. A fusion protein, comprising: an autoreactive B cell epitope from the extracellular portion of desmoglein or desmoglein; and Antibodies that bind to effector cells.

58. The fusion protein of claim 57, wherein the effector cells comprise T cells.

59. The fusion protein of claim 57, wherein the antibody comprises an anti-CD3 antibody.

60. The fusion protein of claim 57, wherein the antibody comprises an anti-CD8 (cytotoxic T cell) or an anti-CD4 (helper T cell) antibody.

61. The fusion protein of claim 57, wherein the antibodies comprise antibodies specific for macrophages (eg, CD14, CD40, CD11b, CD64, CD68) or natural killer (NK) cells (CD56).

62. The fusion protein of claim 57, wherein the autoreactive B cell epitope comprises the N-terminus of the fusion protein and the antibody comprises the C-terminus of the fusion protein.

63. The fusion protein of claim 57, further comprising an amino acid spacer linking the autoreactive B cell epitope and the antibody.

64. The fusion protein of claim 63, wherein the amino acid spacer comprises about 2 to about 40 amino acids.

65. The fusion protein of claim 64, wherein the amino acid spacer is a flexible amino acid spacer.

66. The fusion protein of claim 65, wherein the flexible amino acid spacer comprises a Gly residue and a Ser residue.

67. The fusion protein of claim 65, wherein the flexible amino acid spacer comprises (Gly-Gly-Gly-Gly-Ser) n .

68. The fusion protein of claim 65, wherein the flexible amino acid spacer comprises (Gly-Gly-Gly-Gly-Ser)3.

69. The fusion protein of claim 57, wherein the autoreactive B cell epitope and the antibody are linked by a C—C bond made using copper-mediated azide-alkyne cycloaddition chemistry (Fig. 8A).

70. The fusion protein of claim 57, wherein the autoreactive B cell epitope and the antibody are linked by a NC bond made using a sortase (Figure 8B).

71. The fusion protein of claim 70, wherein the autoreactive B cell epitope and the antibody are linked by the amino acid sequence Leu-Pro-Glu-Thr-Gly-Gly-Gly.

72. The fusion protein of claim 57, wherein the fusion protein comprises at least two B cell epitopes from the extracellular portion of desmoglein or desmoglein.

73. A method for linking a first polypeptide to a second polypeptide, the method comprising: The C-terminus of the first polypeptide is modified to include the amino acid sequence Leu-Pro-Glu-Thr-Gly; The N-terminus of the second polypeptide is modified to comprise the amino acid sequence Leu-Pro-Glu-Thr-Gly-Gly-Gly; and The modified first polypeptide and the modified second polypeptide are reacted in the presence of triglycine (Gly-Gly-Gly) and sortase, so that the first modified polypeptide and the second modified polypeptide are linked through the amino acid sequence Leu-Pro-Glu-Thr-Gly-Gly-Gly.

74. An Fc-mediated therapeutic agent for treating autoimmune blistering disease, the Fc-mediated therapeutic agent comprising: A first polypeptide comprising a first self-reactive antigen and a heavy chain from an antibody that is capable of preferentially binding to a second C H The first C of 3-domain heterodimerization H 3 domains; and a second polypeptide comprising a second self-reactive antigen and a heavy chain of an antibody that preferentially binds to the first C H The second C H 3 domains; wherein a disulfide bond covalently attaches the first polypeptide and the second polypeptide.

75. The Fc-mediated therapeutic agent of claim 74, wherein the first C H 3 domains and the second C H The complementary amino acids in the 3 domain were modified using a knob-in-hole strategy.

76. The Fc-mediated therapeutic agent of claim 74, wherein said first C H 3 domains and the first C H 3 domain dimerization compared with the second C H 3 domain and the second C H Compared with the dimerization of the first C H 3 domains and the second C H The 3 domains preferentially dimerize.

77. A pharmaceutical composition comprising the Fc-mediated therapeutic agent according to any one of claims 74 to 76 and a pharmaceutically acceptable carrier.

78. A method of depleting autoreactive B cells, the method comprising administering to a subject a therapeutically effective amount of an Fc-mediated therapeutic agent according to any one of claims 74 to 76.

79. A fusion protein, comprising: Allergens, parts of said allergens or molecules that mimic said allergens; and The Fc portion of an antibody or an antibody that binds to effector cells.

80. The fusion protein of claim 79, wherein the allergen, a portion of the allergen, or a molecule that mimics the allergen comprises a protein, a polypeptide, or a peptide.

81. The fusion protein of claim 79, wherein the allergen, a portion of the allergen, or a molecule that mimics the allergen is from a drug, food, insect, latex, mold, animal, or plant.

82. The fusion protein of claim 79, wherein the allergen, a portion of the allergen, or a molecule that mimics the allergen is capable of binding to a B cell receptor (BCR) of a B cell that produces or will produce IgE.

83. The fusion protein of claim 82, wherein the B cells are from an animal with an allergy.

84. The fusion protein of claim 83, wherein the allergy is a type I hypersensitivity reaction.

85. The fusion protein of claim 79, wherein the Fc portion of the antibody is capable of binding to a cell having an Fc receptor (FcR).

86. The fusion protein of claim 79, wherein the antibody that binds to the effector cell is capable of binding to a T cell.

87. The fusion protein of claim 86, wherein the antibody capable of binding to a T cell comprises an anti-CD3 antibody.